[
  {
    "id": "20251020-055501-976653da",
    "createdAt": "2025-10-20T05:55:01.553Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/19/2025, 11:55:00 PM"
    },
    "articles": [
      {
        "id": 557,
        "title": "1-(2,5-Dimethoxybenzyl) piperazine",
        "slug": "1-2-5-dimethoxybenzyl-piperazine"
      }
    ],
    "markdown": "# 1-(2,5-Dimethoxybenzyl) piperazine · #557\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-  \"index-category\": \"\"\n+  \"index-category\": \"Hidden\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-201514-b1ba5d82",
    "createdAt": "2025-10-19T20:15:14.114Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/19/2025, 2:15:12 PM"
    },
    "articles": [
      {
        "id": 163,
        "title": "Mitragynine Pseudoindoxyl",
        "slug": "mitragynine-pseudoindoxyl"
      },
      {
        "id": 161,
        "title": "Hexen",
        "slug": "hexen"
      },
      {
        "id": 56,
        "title": "Oxycodone",
        "slug": "oxycodone"
      },
      {
        "id": 67,
        "title": "Phenobarbital",
        "slug": "phenobarbital"
      },
      {
        "id": 68,
        "title": "Triazolam",
        "slug": "triazolam"
      },
      {
        "id": 66,
        "title": "Hydrocodone",
        "slug": "hydrocodone"
      },
      {
        "id": 71,
        "title": "Mirogabalin",
        "slug": "mirogabalin"
      },
      {
        "id": 81,
        "title": "Remifentanil",
        "slug": "remifentanil"
      },
      {
        "id": 89,
        "title": "Heroin",
        "slug": "heroin"
      },
      {
        "id": 90,
        "title": "Oxazepam",
        "slug": "oxazepam"
      },
      {
        "id": 91,
        "title": "Alprazolam",
        "slug": "alprazolam"
      },
      {
        "id": 97,
        "title": "Fentanyl",
        "slug": "fentanyl"
      },
      {
        "id": 103,
        "title": "Clobromazolam",
        "slug": "clobromazolam"
      },
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 586,
        "title": "Acrylfentanyl",
        "slug": "acrylfentanyl"
      },
      {
        "id": 125,
        "title": "Midazolam",
        "slug": "midazolam"
      },
      {
        "id": 126,
        "title": "Etizolam",
        "slug": "etizolam"
      },
      {
        "id": 128,
        "title": "Diclazepam",
        "slug": "diclazepam"
      },
      {
        "id": 132,
        "title": "Brotizolam",
        "slug": "brotizolam"
      },
      {
        "id": 142,
        "title": "Flutoprazepam",
        "slug": "flutoprazepam"
      },
      {
        "id": 151,
        "title": "Hydromorphone",
        "slug": "hydromorphone"
      },
      {
        "id": 166,
        "title": "Morphine",
        "slug": "morphine"
      },
      {
        "id": 170,
        "title": "Nimetazepam",
        "slug": "nimetazepam"
      },
      {
        "id": 153,
        "title": "Gamma-hydroxybutyric acid",
        "slug": "gamma-hydroxybutyric-acid"
      },
      {
        "id": 171,
        "title": "Temazepam",
        "slug": "temazepam"
      },
      {
        "id": 175,
        "title": "Gabapentin",
        "slug": "gabapentin"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 177,
        "title": "Methaqualone",
        "slug": "methaqualone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 190,
        "title": "Benzphetamine",
        "slug": "benzphetamine"
      },
      {
        "id": 206,
        "title": "Kratom",
        "slug": "kratom"
      },
      {
        "id": 217,
        "title": "Chloral Hydrate",
        "slug": "chloral-hydrate"
      },
      {
        "id": 221,
        "title": "Flurazepam",
        "slug": "flurazepam"
      },
      {
        "id": 347,
        "title": "DPP-26",
        "slug": "dpp-26"
      },
      {
        "id": 245,
        "title": "Desomorphine",
        "slug": "desomorphine"
      },
      {
        "id": 249,
        "title": "Butylone",
        "slug": "butylone"
      },
      {
        "id": 255,
        "title": "Halazepam",
        "slug": "halazepam"
      },
      {
        "id": 366,
        "title": "SR-14968",
        "slug": "sr-14968"
      },
      {
        "id": 364,
        "title": "Spirochlorphine",
        "slug": "spirochlorphine"
      },
      {
        "id": 365,
        "title": "Lofentanil",
        "slug": "lofentanil"
      },
      {
        "id": 45,
        "title": "O-DSMT",
        "slug": "o-dsmt"
      },
      {
        "id": 283,
        "title": "MD-PiHP",
        "slug": "md-pihp"
      },
      {
        "id": 291,
        "title": "MDMA",
        "slug": "mdma"
      },
      {
        "id": 130,
        "title": "Pregabalin",
        "slug": "pregabalin"
      },
      {
        "id": 134,
        "title": "Flunitrazepam",
        "slug": "flunitrazepam"
      },
      {
        "id": 294,
        "title": "Bromantane",
        "slug": "bromantane"
      },
      {
        "id": 304,
        "title": "DHC",
        "slug": "dhc"
      },
      {
        "id": 305,
        "title": "Thiopental",
        "slug": "thiopental"
      },
      {
        "id": 309,
        "title": "MD-PHP",
        "slug": "md-php"
      },
      {
        "id": 314,
        "title": "Methadone",
        "slug": "methadone"
      },
      {
        "id": 313,
        "title": "6-MAM",
        "slug": "6-mam"
      },
      {
        "id": 318,
        "title": "Melatonin",
        "slug": "melatonin"
      },
      {
        "id": 319,
        "title": "Pronitazene",
        "slug": "pronitazene"
      },
      {
        "id": 322,
        "title": "SL-164",
        "slug": "sl-164"
      },
      {
        "id": 324,
        "title": "Cychlorphine",
        "slug": "cychlorphine"
      },
      {
        "id": 344,
        "title": "SR-17018",
        "slug": "sr-17018"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      },
      {
        "id": 357,
        "title": "Isotonitazepyne",
        "slug": "isotonitazepyne"
      },
      {
        "id": 360,
        "title": "Bezitramide",
        "slug": "bezitramide"
      },
      {
        "id": 374,
        "title": "Lean",
        "slug": "lean"
      },
      {
        "id": 421,
        "title": "MGM-15",
        "slug": "mgm-15"
      },
      {
        "id": 408,
        "title": "Mitragynine",
        "slug": "mitragynine"
      },
      {
        "id": 358,
        "title": "NDP",
        "slug": "ndp"
      },
      {
        "id": 416,
        "title": "IC-26",
        "slug": "ic-26"
      },
      {
        "id": 417,
        "title": "Avizafone",
        "slug": "avizafone"
      },
      {
        "id": 418,
        "title": "Isotonitazene",
        "slug": "isotonitazene"
      },
      {
        "id": 423,
        "title": "7-OH",
        "slug": "7-oh"
      },
      {
        "id": 443,
        "title": "Fluminorex",
        "slug": "fluminorex"
      },
      {
        "id": 455,
        "title": "Fluclotizolam",
        "slug": "fluclotizolam"
      },
      {
        "id": 459,
        "title": "Flupirtine",
        "slug": "flupirtine"
      },
      {
        "id": 460,
        "title": "Scopolamine",
        "slug": "scopolamine"
      },
      {
        "id": 462,
        "title": "Ethylbromazolam",
        "slug": "ethylbromazolam"
      },
      {
        "id": 463,
        "title": "Nifoxipam",
        "slug": "nifoxipam"
      },
      {
        "id": 474,
        "title": "Bromonordiazepam",
        "slug": "bromonordiazepam"
      },
      {
        "id": 475,
        "title": "Agmatine Sulfate",
        "slug": "agmatine-sulfate"
      },
      {
        "id": 484,
        "title": "Imodium",
        "slug": "imodium"
      },
      {
        "id": 489,
        "title": "D2PM",
        "slug": "d2pm"
      },
      {
        "id": 520,
        "title": "4-Methoxybutyrfentanyl",
        "slug": "4-methoxybutyrfentanyl"
      },
      {
        "id": 547,
        "title": "Monotropa uniflora",
        "slug": "monotropa-uniflora"
      },
      {
        "id": 549,
        "title": "Tapentadol",
        "slug": "tapentadol"
      },
      {
        "id": 551,
        "title": "Desmethylflunitrazepam",
        "slug": "desmethylflunitrazepam"
      },
      {
        "id": 598,
        "title": "Butorphanol",
        "slug": "butorphanol"
      },
      {
        "id": 603,
        "title": "Acetyldihydrocodeine",
        "slug": "acetyldihydrocodeine"
      },
      {
        "id": 604,
        "title": "Acetildenafil",
        "slug": "acetildenafil"
      },
      {
        "id": 612,
        "title": "Beta-meprodine",
        "slug": "beta-meprodine"
      },
      {
        "id": 615,
        "title": "Amobarbital",
        "slug": "amobarbital"
      },
      {
        "id": 174,
        "title": "Carisoprodol",
        "slug": "carisoprodol"
      },
      {
        "id": 671,
        "title": "Pentobarbital",
        "slug": "pentobarbital"
      },
      {
        "id": 672,
        "title": "Secobarbital",
        "slug": "secobarbital"
      }
    ],
    "markdown": "# Mitragynine Pseudoindoxyl · #163\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Hexen · #161\n\n-    \"psychoactive_class\": \"Stimulant; Euphoriant\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Oxycodone · #56\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Euphoriant; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Phenobarbital · #67\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Anticonvulsant; Anxiolytic; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anticonvulsant; Anxiolytic; Muscle Relaxant; GABAergic\",\n\n# Triazolam · #68\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Anxiolytic; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anxiolytic; GABAergic; Muscle Relaxant\",\n\n# Hydrocodone · #66\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Euphoriant; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Mirogabalin · #71\n\n-    \"psychoactive_class\": \"Anticonvulsant; Analgesic\",\n+    \"psychoactive_class\": \"Anticonvulsant\",\n\n# Remifentanil · #81\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Anesthetic; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Heroin · #89\n\n-    \"psychoactive_class\": \"Opioid; Euphoriant; Analgesic; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Oxazepam · #90\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; GABAergic; Muscle Relaxant\",\n\n# Alprazolam · #91\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; Muscle Relaxant; GABAergic; Anticonvulsant\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Muscle Relaxant; GABAergic; Anticonvulsant\",\n\n# Fentanyl · #97\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Clobromazolam · #103\n\n-    \"psychoactive_class\": \"Sedative; Anxiolytic; Hypnotic; Depressant; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Sedative; Anxiolytic; Depressant; GABAergic; Muscle Relaxant\",\n\n# Gaboxadol · #242\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; GABAergic; Hallucinogen; Deliriant; Oneirogen\",\n+    \"psychoactive_class\": \"Depressant; Sedative; GABAergic; Hallucinogen; Deliriant; Oneirogen\",\n\n# Acrylfentanyl · #586\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Midazolam · #125\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; GABAergic; Anticonvulsant; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; GABAergic; Anticonvulsant; Muscle Relaxant\",\n\n# Etizolam · #126\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Muscle Relaxant; GABAergic\",\n\n# Diclazepam · #128\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; Muscle Relaxant; Anticonvulsant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Muscle Relaxant; Anticonvulsant; GABAergic\",\n\n# Brotizolam · #132\n\n-    \"psychoactive_class\": \"Sedative; Hypnotic; Anxiolytic; Anticonvulsant; Muscle Relaxant; GABAergic; Depressant\",\n+    \"psychoactive_class\": \"Sedative; Anxiolytic; Anticonvulsant; Muscle Relaxant; GABAergic; Depressant\",\n\n# Flutoprazepam · #142\n\n-    \"psychoactive_class\": \"Hypnotic; Sedative; Anxiolytic; Depressant; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Sedative; Anxiolytic; Depressant; Muscle Relaxant; GABAergic\",\n\n# Hydromorphone · #151\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Morphine · #166\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Nimetazepam · #170\n\n-    \"psychoactive_class\": \"Depressant; Hypnotic; Sedative; Anxiolytic; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anxiolytic; GABAergic; Muscle Relaxant\",\n\n# Gamma-hydroxybutyric acid · #153\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Anesthetic\",\n+    \"psychoactive_class\": \"Depressant; Sedative\",\n\n# Temazepam · #171\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Anxiolytic; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anxiolytic; GABAergic; Muscle Relaxant\",\n\n# Gabapentin · #175\n\n-    \"psychoactive_class\": \"Anticonvulsant; Anxiolytic; Sedative; Analgesic; GABAergic; Muscle Relaxant; Depressant\",\n+    \"psychoactive_class\": \"Anticonvulsant; Anxiolytic; Sedative; GABAergic; Muscle Relaxant; Depressant\",\n\n# Zopiclone · #176\n\n-    \"psychoactive_class\": \"Sedative; Hypnotic; Depressant\",\n+    \"psychoactive_class\": \"Sedative; Depressant\",\n\n# Methaqualone · #177\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Anxiolytic; Muscle Relaxant; GABAergic; Euphoriant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anxiolytic; Muscle Relaxant; GABAergic\",\n\n# Zaleplon · #179\n\n-    \"psychoactive_class\": \"Sedative; Hypnotic; Depressant\",\n+    \"psychoactive_class\": \"Sedative; Depressant\",\n\n# Zolpidem · #183\n\n-    \"psychoactive_class\": \"Sedative; Hypnotic; Depressant\",\n+    \"psychoactive_class\": \"Sedative; Depressant\",\n\n# Benzphetamine · #190\n\n-    \"psychoactive_class\": \"Stimulant; Euphoriant\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Kratom · #206\n\n-    \"psychoactive_class\": \"Opioid; Stimulant; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Stimulant; Depressant\",\n\n# Chloral Hydrate · #217\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Sedative; GABAergic\",\n\n# Flurazepam · #221\n\n-    \"psychoactive_class\": \"Hypnotic; Sedative; Anxiolytic; Depressant; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Sedative; Anxiolytic; Depressant; Muscle Relaxant; GABAergic\",\n\n# DPP-26 · #347\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Desomorphine · #245\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Butylone · #249\n\n-    \"psychoactive_class\": \"Stimulant; Entactogen; Euphoriant\",\n+    \"psychoactive_class\": \"Stimulant; Entactogen\",\n\n# Halazepam · #255\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Muscle Relaxant; GABAergic\",\n\n# SR-14968 · #366\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Spirochlorphine · #364\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Lofentanil · #365\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Anesthetic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# O-DSMT · #45\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Anxiolytic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Anxiolytic; Depressant\",\n\n# MD-PiHP · #283\n\n-    \"psychoactive_class\": \"Stimulant; Euphoriant\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# MDMA · #291\n\n-    \"psychoactive_class\": \"Entactogen; Euphoriant; Stimulant; Psychedelic (mild); Hallucinogen\",\n+    \"psychoactive_class\": \"Entactogen; Stimulant; Psychedelic (mild); Hallucinogen\",\n\n# Pregabalin · #130\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Anticonvulsant; Sedative; Euphoriant\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Anticonvulsant; Sedative\",\n\n# Flunitrazepam · #134\n\n-    \"psychoactive_class\": \"Hypnotic; Sedative; Anxiolytic; Depressant; Euphoriant; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Sedative; Anxiolytic; Depressant; GABAergic; Muscle Relaxant\",\n\n# Bromantane · #294\n\n-    \"psychoactive_class\": \"Stimulant; Anxiolytic; Nootropic; Euphoriant (mild)\",\n+    \"psychoactive_class\": \"Stimulant; Anxiolytic; Nootropic\",\n\n# DHC · #304\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Thiopental · #305\n\n-    \"psychoactive_class\": \"Depressant; anesthetic; sedative; hypnotic\",\n+    \"psychoactive_class\": \"Depressant; sedative\",\n\n# MD-PHP · #309\n\n-    \"psychoactive_class\": \"Stimulant; Euphoriant; Entactogen (mild)\",\n+    \"psychoactive_class\": \"Stimulant; Entactogen (mild)\",\n\n# Methadone · #314\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# 6-MAM · #313\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Melatonin · #318\n\n-    \"psychoactive_class\": \"Hypnotic; Sedative; Oneirogen; Hormone Modulator; Hallucinogen; Depressant\",\n+    \"psychoactive_class\": \"Sedative; Oneirogen; Hormone Modulator; Hallucinogen; Depressant\",\n\n# Pronitazene · #319\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# SL-164 · #322\n\n-    \"psychoactive_class\": \"Sedative; Hypnotic; Depressant\",\n+    \"psychoactive_class\": \"Sedative; Depressant\",\n\n# Cychlorphine · #324\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Hypnotic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# SR-17018 · #344\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# MDA · #62\n\n-    \"psychoactive_class\": \"Entactogen; Psychedelic; Stimulant; Euphoriant; Hallucinogen\",\n+    \"psychoactive_class\": \"Entactogen; Psychedelic; Stimulant; Hallucinogen\",\n\n# Isotonitazepyne · #357\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Bezitramide · #360\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Lean · #374\n\n-    \"psychoactive_class\": \"Opioid; Depressant; Sedative; Analgesic; Euphoriant\",\n+    \"psychoactive_class\": \"Opioid; Depressant; Sedative\",\n\n# MGM-15 · #421\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Mitragynine · #408\n\n-    \"psychoactive_class\": \"Stimulant; Opioid; Analgesic; Antidepressant; Anxiolytic; Depressant\",\n+    \"psychoactive_class\": \"Stimulant; Opioid; Antidepressant; Anxiolytic; Depressant\",\n\n# NDP · #358\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# IC-26 · #416\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Avizafone · #417\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; GABAergic\",\n\n# Isotonitazene · #418\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# 7-OH · #423\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Fluminorex · #443\n\n-    \"psychoactive_class\": \"Stimulant; Euphoriant\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Fluclotizolam · #455\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Anxiolytic; Hypnotic; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anxiolytic; Muscle Relaxant; GABAergic\",\n\n# Flupirtine · #459\n\n-    \"psychoactive_class\": \"Analgesic\",\n+    \"psychoactive_class\": \"\",\n\n# Scopolamine · #460\n\n-    \"psychoactive_class\": \"Deliriant; Sedative; Hypnotic; Hallucinogen; Depressant\",\n+    \"psychoactive_class\": \"Deliriant; Sedative; Hallucinogen; Depressant\",\n\n# Ethylbromazolam · #462\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; Muscle Relaxant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Muscle Relaxant; GABAergic\",\n\n# Nifoxipam · #463\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; GABAergic; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; GABAergic; Muscle Relaxant\",\n\n# Bromonordiazepam · #474\n\n-    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic; Muscle Relaxant; Anticonvulsant; GABAergic\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Muscle Relaxant; Anticonvulsant; GABAergic\",\n\n# Agmatine Sulfate · #475\n\n-    \"psychoactive_class\": \"Nootropic; Anxiolytic; Antidepressant; Analgesic\",\n+    \"psychoactive_class\": \"Nootropic; Anxiolytic; Antidepressant\",\n\n# Imodium · #484\n\n-    \"psychoactive_class\": \"Opioid; Analgesic (weak); Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# D2PM · #489\n\n-    \"psychoactive_class\": \"Stimulant; Euphoriant\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# 4-Methoxybutyrfentanyl · #520\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Monotropa uniflora · #547\n\n-    \"psychoactive_class\": \"Analgesic; Anxiolytic; Sedative; Depressant\",\n+    \"psychoactive_class\": \"Anxiolytic; Sedative; Depressant\",\n\n# Tapentadol · #549\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Desmethylflunitrazepam · #551\n\n-    \"psychoactive_class\": \"Sedative; Hypnotic; Anxiolytic; GABAergic; Depressant; Muscle Relaxant\",\n+    \"psychoactive_class\": \"Sedative; Anxiolytic; GABAergic; Depressant; Muscle Relaxant\",\n\n# Butorphanol · #598\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative (mild); Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative (mild); Depressant\",\n\n# Acetyldihydrocodeine · #603\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n\n# Acetildenafil · #604\n\n-    \"psychoactive_class\": \"Aphrodisiac\",\n+    \"psychoactive_class\": \"\",\n\n# Beta-meprodine · #612\n\n-    \"psychoactive_class\": \"Opioid; Analgesic; Sedative; Euphoriant; Depressant\",\n+    \"psychoactive_class\": \"Opioid; Sedative; Depressant\",\n\n# Amobarbital · #615\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; GABAergic; Anxiolytic; Anticonvulsant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; GABAergic; Anxiolytic; Anticonvulsant\",\n\n# Carisoprodol · #174\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Muscle Relaxant; Anxiolytic; GABAergic; Analgesic (weak)\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Muscle Relaxant; Anxiolytic; GABAergic\",\n\n# Pentobarbital · #671\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Anticonvulsant; Anxiolytic; Anesthetic; Muscle Relaxant; GABAergic; Euphoriant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anticonvulsant; Anxiolytic; Muscle Relaxant; GABAergic\",\n\n# Secobarbital · #672\n\n-    \"psychoactive_class\": \"Depressant; Sedative; Hypnotic; Anticonvulsant; Anxiolytic; Anesthetic; Muscle Relaxant; GABAergic; Euphoriant\",\n+    \"psychoactive_class\": \"Depressant; Sedative; Anticonvulsant; Anxiolytic; Muscle Relaxant; GABAergic\",",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-182404-cb5da347",
    "createdAt": "2025-10-19T18:24:04.639Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/19/2025, 12:24:02 PM"
    },
    "articles": [
      {
        "id": 41,
        "title": "Modafinil",
        "slug": "modafinil"
      },
      {
        "id": 74,
        "title": "Methamphetamine",
        "slug": "methamphetamine"
      },
      {
        "id": 75,
        "title": "Serdexmethylphenidate",
        "slug": "serdexmethylphenidate"
      },
      {
        "id": 90,
        "title": "Oxazepam",
        "slug": "oxazepam"
      },
      {
        "id": 127,
        "title": "Prazepam",
        "slug": "prazepam"
      },
      {
        "id": 169,
        "title": "Nitrazepam",
        "slug": "nitrazepam"
      },
      {
        "id": 170,
        "title": "Nimetazepam",
        "slug": "nimetazepam"
      },
      {
        "id": 178,
        "title": "Mefloquine",
        "slug": "mefloquine"
      },
      {
        "id": 187,
        "title": "Pemoline",
        "slug": "pemoline"
      },
      {
        "id": 211,
        "title": "Phenethylamine",
        "slug": "phenethylamine"
      },
      {
        "id": 256,
        "title": "Medazepam",
        "slug": "medazepam"
      },
      {
        "id": 258,
        "title": "Phenylephrine",
        "slug": "phenylephrine"
      },
      {
        "id": 305,
        "title": "Thiopental",
        "slug": "thiopental"
      },
      {
        "id": 384,
        "title": "5-IAI",
        "slug": "5-iai"
      },
      {
        "id": 362,
        "title": "Coluracetam",
        "slug": "coluracetam"
      },
      {
        "id": 415,
        "title": "MDMPEA",
        "slug": "mdmpea"
      },
      {
        "id": 431,
        "title": "Phenazolam",
        "slug": "phenazolam"
      },
      {
        "id": 448,
        "title": "MDPV",
        "slug": "mdpv"
      },
      {
        "id": 480,
        "title": "Flumazenil",
        "slug": "flumazenil"
      },
      {
        "id": 488,
        "title": "Rasagiline",
        "slug": "rasagiline"
      },
      {
        "id": 493,
        "title": "GABOB",
        "slug": "gabob"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      }
    ],
    "markdown": "# Modafinil · #41\n\n-    \"psychoactive_class\": \"Stimulant; Eugeroic (wakefulness-promoting agent)\",\n+    \"psychoactive_class\": \"Stimulant; Eugeroic\",\n\n# Methamphetamine · #74\n\n-    \"psychoactive_class\": \"Stimulant (psychostimulant, sympathomimetic)\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Serdexmethylphenidate · #75\n\n-    \"psychoactive_class\": \"Stimulant (CNS stimulant, prodrug of dexmethylphenidate)\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Oxazepam · #90\n\n-    \"psychoactive_class\": \"Depressant (Anxiolytic, Sedative-Hypnotic)\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative; Hypnotic\",\n\n# Prazepam · #127\n\n-    \"psychoactive_class\": \"Depressant (Anxiolytic, Sedative)\",\n+    \"psychoactive_class\": \"Depressant; Anxiolytic; Sedative\",\n\n# Nitrazepam · #169\n\n-    \"psychoactive_class\": \"Depressant (Benzodiazepine)\",\n+    \"psychoactive_class\": \"Depressant; GABAergic; Anxiolytic\",\n\n# Nimetazepam · #170\n\n-    \"psychoactive_class\": \"Depressant (hypnotic, sedative, anxiolytic)\",\n+    \"psychoactive_class\": \"Depressant; Hypnotic; Sedative; Anxiolytic\",\n\n# Mefloquine · #178\n\n-    \"psychoactive_class\": \"Not primarily psychoactive\",\n+    \"psychoactive_class\": \"Not psychoactive\",\n\n# Pemoline · #187\n\n-    \"psychoactive_class\": \"Stimulant (CNS stimulant, centrally-acting sympathomimetic)\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Phenethylamine · #211\n\n-    \"psychoactive_class\": \"Stimulant (not psychoactive at normal doses)\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Medazepam · #256\n\n-    \"psychoactive_class\": \"Depressant (Benzodiazepine)\",\n+    \"psychoactive_class\": \"Depressant; GABAergic; Anxiolytic\",\n\n# Phenylephrine · #258\n\n-    \"psychoactive_class\": \"Stimulant (peripheral sympathomimetic)\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Thiopental · #305\n\n-    \"psychoactive_class\": \"Depressant (general anesthetic, sedative-hypnotic)\",\n+    \"psychoactive_class\": \"Depressant; anesthetic; sedative; hypnotic\",\n\n# 5-IAI · #384\n\n-    \"psychoactive_class\": \"Entactogen; Stimulant (weak)\",\n+    \"psychoactive_class\": \"Entactogen; Stimulant (mild)\",\n\n# Coluracetam · #362\n\n-    \"psychoactive_class\": \"Nootropic; Stimulant (weak)\",\n+    \"psychoactive_class\": \"Nootropic; Stimulant (mild)\",\n\n# MDMPEA · #415\n\n-    \"psychoactive_class\": \"Stimulant (weak); Entactogen (theoretical)\",\n+    \"psychoactive_class\": \"Stimulant (mild); Entactogen (theoretical)\",\n\n# Phenazolam · #431\n\n-    \"psychoactive_class\": \"Depressant ‒ GABAA positive-allosteric modulator\",\n+    \"psychoactive_class\": \"Depressant; GABAergic; Anxiolytic\",\n\n# MDPV · #448\n\n-    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (NDRI)\",\n+    \"psychoactive_class\": \"Stimulant\",\n\n# Flumazenil · #480\n\n-    \"psychoactive_class\": \"Not primarily psychoactive\",\n+    \"psychoactive_class\": \"Not psychoactive\",\n\n# Rasagiline · #488\n\n-    \"psychoactive_class\": \"Not primarily psychoactive\",\n+    \"psychoactive_class\": \"Not psychoactive\",\n\n# GABOB · #493\n\n-    \"psychoactive_class\": \"Anticonvulsant; GABAergic; Depressant (weak)\",\n+    \"psychoactive_class\": \"Anticonvulsant; GABAergic; Depressant (mild)\",\n\n# Ro5-4864 · #530\n\n-    \"psychoactive_class\": \"Not primarily psychoactive\",\n+    \"psychoactive_class\": \"Not psychoactive\",",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-015613-e967778a",
    "createdAt": "2025-10-19T01:56:13.734Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:56:12 PM"
    },
    "articles": [
      {
        "id": 707,
        "title": "Pramiracetam",
        "slug": "pramiracetam"
      }
    ],
    "markdown": "# Pramiracetam · #707\n\n+{\n+  \"title\": \"Pramiracetam\",\n+  \"index-category\": \"nootropic; racetam\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Pramiracetam\",\n+    \"chemical_name\": \"N-[2-(Diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide\",\n+    \"alternative_name\": \"Pramistar; Neupramir; Remen\",\n+    \"chemical_class\": \"Racetam\",\n+    \"psychoactive_class\": \"Nootropic; Stimulant\",\n+    \"mechanism_of_action\": \"Enhanced high-affinity choline uptake (HACU) in the hippocampus; increased acetylcholine synthesis; increased nitric oxide activity (cerebral blood flow enhancement)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 mg\",\n+            \"light\": \"250-500 mg\",\n+            \"common\": \"500-800 mg\",\n+            \"strong\": \"800-1200 mg\",\n+            \"heavy\": \"1200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-7 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Up to 6 hours (residual cognitive enhancement)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Pramiracetam is not considered physically addictive and has a low potential for psychological dependence. It does not appear to cause compulsive redosing patterns. Tolerance develops with prolonged use, which naturally limits abuse potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (potential unpredictable increase in effects; racetams show nonselective MAO activity in animal studies)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Choline supplements (may enhance effects and reduce headaches; generally recommended)\",\n+        \"Stimulants (combined stimulatory effects may increase anxiety or cardiovascular strain)\",\n+        \"Alcohol (may interfere with cognitive benefits and exacerbate side effects)\"\n+      ]\n+    },\n+    \"notes\": \"Pramiracetam is fat-soluble and should be taken with dietary fats for optimal absorption. Never administer sublingually, as this can cause painful chemical burns. The compound is marketed as a prescription drug in parts of Europe for treating memory deficits in aging populations with neurodegenerative disorders. In the United States, it is available as a dietary supplement. Use precise measurement scales for dosing, and consider supplementing with a choline source to enhance effects and reduce the likelihood of headaches. Long-term safety data in healthy individuals is limited.\",\n+    \"subjective_effects\": [\n+      \"Stimulation (comparable to caffeine)\",\n+      \"Focus Enhancement\",\n+      \"Memory Enhancement\",\n+      \"Emotion Suppression\",\n+      \"Mindfulness\",\n+      \"Wakefulness\",\n+      \"Thought Connectivity\",\n+      \"Motivation Enhancement\",\n+      \"Anxiety Suppression\",\n+      \"Dream Potentiation\",\n+      \"Acuity Enhancement\",\n+      \"Headaches\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All racetam nootropics (piracetam, aniracetam, oxiracetam, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"4.5-6.5 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Pramiracetam Vault\",\n+        \"reference\": \"https://erowid.org/smarts/pramiracetam/pramiracetam.shtml\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert: Pramiracetam\",\n+        \"reference\": \"https://nootropicsexpert.com/pramiracetam/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Pramiracetam\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Pramiracetam\"\n+      },\n+      {\n+        \"name\": \"Chang et al. (1985) - Pharmacokinetics of Oral Pramiracetam in Normal Volunteers\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/4008675/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Pramiracetam\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Pramiracetam\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"racetam\",\n+      \"research-chemical\",\n+      \"cognitive-enhancer\"\n+    ]\n+  },\n+  \"id\": 707\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-015216-4b2604df",
    "createdAt": "2025-10-19T01:52:16.855Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:52:14 PM"
    },
    "articles": [
      {
        "id": 706,
        "title": "N-Acetylcysteine",
        "slug": "n-acetylcysteine"
      }
    ],
    "markdown": "# N-Acetylcysteine · #706\n\n+{\n+  \"title\": \"N-Acetylcysteine\",\n+  \"index-category\": \"nootropic; supplement\",\n+  \"drug_info\": {\n+    \"drug_name\": \"N-Acetylcysteine\",\n+    \"chemical_name\": \"(2R)-2-acetamido-3-sulfanylpropanoic acid\",\n+    \"alternative_name\": \"NAC; Acetylcysteine\",\n+    \"chemical_class\": \"Cysteine derivative\",\n+    \"psychoactive_class\": \"Nootropic\",\n+    \"mechanism_of_action\": \"Glutathione precursor; NMDA receptor modulator (via glutathione); AMPA receptor modulator (via glutathione); mGluR2/3 receptor agonist (indirect); Cystine-glutamate antiporter substrate; NF-kB inhibitor\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 mg\",\n+            \"light\": \"400-600 mg\",\n+            \"common\": \"600-1200 mg\",\n+            \"strong\": \"1200-1800 mg\",\n+            \"heavy\": \"1800+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Cumulative benefits with consistent use\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"N-Acetylcysteine is not physically addictive and does not produce psychological dependence. The compound's therapeutic effects appear to be cumulative over time rather than immediate, which discourages compulsive use patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Nitroglycerin (severe vasodilation and headaches)\",\n+        \"Anticoagulants with high doses (increased bleeding risk)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Blood pressure medications (may enhance hypotensive effects)\",\n+        \"Immunosuppressants (azathioprine, cyclophosphamide, prednisone)\",\n+        \"Antibiotics (oxytetracycline, tetracycline)\",\n+        \"Activated charcoal (reduced absorption)\",\n+        \"Alcohol taken 4+ hours after NAC (worsens liver damage)\"\n+      ]\n+    },\n+    \"notes\": \"N-Acetylcysteine is widely available over-the-counter as a dietary supplement and medication in most countries. While generally well-tolerated, individuals with cystinuria (a rare genetic kidney stone disorder) should avoid NAC. Taking NAC with food can minimize gastrointestinal side effects. IV formulations carry a higher risk of anaphylactoid reactions. NAC may cause false positives in ketone urine tests. Long-term high-dose use may deplete zinc stores.\",\n+    \"subjective_effects\": [\n+      \"Addiction Suppression\",\n+      \"Anxiety Suppression\",\n+      \"Focus Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Mindfulness\",\n+      \"Cognitive Clarity\",\n+      \"Appetite Suppression\",\n+      \"Bronchodilation\",\n+      \"Cough Suppression\",\n+      \"Dehydration\",\n+      \"Nausea\",\n+      \"Headaches\",\n+      \"Itchiness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Does not develop with regular use\",\n+      \"half_tolerance\": \"Not applicable\",\n+      \"zero_tolerance\": \"Not applicable\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"5.6 hours (adults); 11 hours (neonates)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Examine.com: N-Acetylcysteine\",\n+        \"reference\": \"https://examine.com/supplements/n-acetylcysteine/\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert: NAC Guide\",\n+        \"reference\": \"https://nootropicsexpert.com/n-acetyl-l-cysteine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: N-Acetylcysteine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/N-Acetylcysteine\"\n+      },\n+      {\n+        \"name\": \"NCBI StatPearls: N-Acetylcysteine\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK537183/\"\n+      },\n+      {\n+        \"name\": \"PMC: Multifaceted Therapeutic Role of NAC\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8719286/\"\n+      },\n+      {\n+        \"name\": \"PMC: NAC Impacts on Human Health\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8234027/\"\n+      },\n+      {\n+        \"name\": \"PMC: NAC in Young Marijuana Users\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2826714/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Acetylcysteine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Acetylcysteine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"supplement\",\n+      \"antioxidant\",\n+      \"glutathione-precursor\"\n+    ]\n+  },\n+  \"id\": 706\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-014931-423e0004",
    "createdAt": "2025-10-19T01:49:31.884Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:49:30 PM"
    },
    "articles": [
      {
        "id": 705,
        "title": "SAM-e",
        "slug": "sam-e"
      }
    ],
    "markdown": "# SAM-e · #705\n\n+{\n+  \"title\": \"SAM-e\",\n+  \"index-category\": \"nootropic; supplement\",\n+  \"drug_info\": {\n+    \"drug_name\": \"SAM-e\",\n+    \"chemical_name\": \"(2S)-2-Amino-4-(((2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl)methyl-methylsulfonio)butanoate\",\n+    \"alternative_name\": \"S-Adenosyl Methionine; S-Adenosylmethionine; AdoMet; Methylguanidoacetic Acid; Ademetionine\",\n+    \"chemical_class\": \"Nitrogenous organic acid\",\n+    \"psychoactive_class\": \"Nootropic\",\n+    \"mechanism_of_action\": \"Methyl group donor in neurotransmitter synthesis; increases serotonin, dopamine, and norepinephrine activity; glutathione precursor; converts nicotinamide to N-methyl-nicotinamide\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200 mg\",\n+            \"light\": \"400-800 mg\",\n+            \"common\": \"800-1200 mg\",\n+            \"strong\": \"1200-1600 mg\",\n+            \"heavy\": \"1600+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"100-180 minutes\",\n+            \"peak\": \"4-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"SAM-e is not habit-forming and has a low potential for abuse. It does not appear capable of causing psychological or physiological dependence among users. Tolerance develops over several weeks of prolonged use, requiring 3-7 days for half-tolerance reduction and 1-2 weeks to return to baseline.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"SSRIs when combined at high doses (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Antidepressants (increased serotonin levels)\",\n+        \"Tramadol (serotonergic effects)\",\n+        \"Dextromethorphan (serotonergic effects)\",\n+        \"Meperidine (serotonergic effects)\"\n+      ],\n+      \"caution\": [\n+        \"Other serotonergic substances\",\n+        \"Stimulants (may increase anxiety)\",\n+        \"Immunosuppressants (theoretical Pneumocystis infection risk)\"\n+      ]\n+    },\n+    \"notes\": \"SAM-e should be taken with B-vitamins (B6, B12, and folate) to prevent homocysteine buildup and ensure optimal efficacy. It is best absorbed when taken on an empty stomach using enteric-coated tablets, which improve bioavailability by 600%. Individuals with bipolar disorder should avoid SAM-e due to risk of triggering mania or hypomania. Those with compromised immune systems should use caution. SAM-e is unstable and should be stored in blister packs away from air and moisture.\",\n+    \"subjective_effects\": [\n+      \"Cognitive Enhancement\",\n+      \"Mood Elevation\",\n+      \"Motivation Enhancement\",\n+      \"Mental Clarity\",\n+      \"Energy Increase\",\n+      \"Focus Enhancement\",\n+      \"Anxiety Reduction\",\n+      \"Pain Relief\",\n+      \"Improved Joint Mobility\",\n+      \"Wakefulness\",\n+      \"Thought Organization\",\n+      \"Reduced Brain Fog\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After several weeks of prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"Not well-established; SAM-e is rapidly metabolized\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Examine.com SAM-e Overview\",\n+        \"reference\": \"https://examine.com/supplements/s-adenosyl-methionine/\"\n+      },\n+      {\n+        \"name\": \"Erowid SAM-e Experience Vaults\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_SAMe.shtml\"\n+      },\n+      {\n+        \"name\": \"NCCIH SAM-e In Depth\",\n+        \"reference\": \"https://www.nccih.nih.gov/health/sadenosyllmethionine-same-in-depth\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert SAM-e Guide\",\n+        \"reference\": \"https://nootropicsexpert.com/sam-e/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki SAM-e\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/SAM-e\"\n+      },\n+      {\n+        \"name\": \"Wikipedia S-Adenosyl methionine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/S-Adenosyl_methionine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"supplement\",\n+      \"mood-enhancer\",\n+      \"cognitive-enhancer\"\n+    ]\n+  },\n+  \"id\": 705\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-014610-7e7cb3ba",
    "createdAt": "2025-10-19T01:46:10.522Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:46:07 PM"
    },
    "articles": [
      {
        "id": 704,
        "title": "L-Tyrosine",
        "slug": "l-tyrosine"
      }
    ],
    "markdown": "# L-Tyrosine · #704\n\n+{\n+  \"title\": \"L-Tyrosine\",\n+  \"index-category\": \"nootropic; stimulant; supplement\",\n+  \"drug_info\": {\n+    \"drug_name\": \"L-Tyrosine\",\n+    \"chemical_name\": \"(S)-2-Amino-3-(4-hydroxyphenyl)propanoic acid\",\n+    \"alternative_name\": \"Tyrosine; 4-Hydroxyphenylalanine; L-Tyr\",\n+    \"chemical_class\": \"Amino acid; Phenethylamine\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Precursor to L-DOPA; converts to dopamine, norepinephrine, and epinephrine (catecholamines); supports catecholamine neurotransmitter synthesis\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"300 mg\",\n+            \"light\": \"500-1000 mg\",\n+            \"common\": \"1000-2000 mg\",\n+            \"strong\": \"2000-3000 mg\",\n+            \"heavy\": \"3000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"6-12 hours (residual fatigue or alertness)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"L-Tyrosine has low physical addiction potential and mild psychological habit-forming properties due to its dopaminergic effects. The desire to use it may increase with repeated use, but it is significantly less addictive and compulsive than traditional stimulants such as amphetamine or methylphenidate.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis due to increased catecholamines)\",\n+        \"Thyroid hormones (may cause excessive thyroid hormone levels)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (may cause dangerously elevated heart rate and blood pressure)\",\n+        \"25x-NBOMe and 25x-NBOH (excessive stimulation, heart strain, potential seizure risk)\",\n+        \"MDMA (increased neurotoxicity and cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (stimulants mask depressant effects, risk of over-intoxication)\",\n+        \"DXM (increased risk of panic, hypertensive crisis, or serotonin syndrome)\",\n+        \"MXE (reports of elevated blood pressure, mania, and psychosis)\",\n+        \"Dissociatives (combined risk of delusions, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Levodopa (may reduce levodopa absorption and effectiveness)\",\n+        \"Other stimulants including cocaine (increased cardiovascular strain)\"\n+      ]\n+    },\n+    \"notes\": \"L-Tyrosine is a non-essential amino acid naturally produced from phenylalanine and found in high-protein foods. As a supplement, it is generally safe with minimal side effects when used responsibly. Individuals with thyroid disorders (hyperthyroidism, Graves disease) should avoid supplementation. Those taking MAOIs, stimulant medications, thyroid medications, or levodopa should consult a healthcare provider before use. Use accurate dosing and avoid taking late in the day to prevent insomnia. Legal and unscheduled worldwide.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Appetite Suppression\",\n+      \"Cognitive Euphoria (mild, at strong doses)\",\n+      \"Focus Enhancement\",\n+      \"Memory Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Creativity Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Wakefulness\",\n+      \"Anxiety Suppression\",\n+      \"Increased Libido\",\n+      \"Stamina Enhancement\",\n+      \"Thought Acceleration\",\n+      \"Headache (at heavy doses)\",\n+      \"Nausea (at heavy doses)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops quickly after repeated and frequent usage\",\n+      \"half_tolerance\": \"7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"Dopaminergic stimulants\",\n+        \"Other catecholamine-enhancing substances\"\n+      ]\n+    },\n+    \"half_life\": \"1-2 hours (plasma levels peak at 1-2 hours, remain elevated for up to 8 hours)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"DrugBank: L-Tyrosine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00135\"\n+      },\n+      {\n+        \"name\": \"Erowid L-Tyrosine Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Tyrosine.shtml\"\n+      },\n+      {\n+        \"name\": \"Examine.com: L-Tyrosine\",\n+        \"reference\": \"https://examine.com/supplements/l-tyrosine/\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert: L-Tyrosine\",\n+        \"reference\": \"https://nootropicsexpert.com/tyrosine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Tyrosine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Tyrosine\"\n+      },\n+      {\n+        \"name\": \"WebMD: L-Tyrosine\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1037/tyrosine\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Tyrosine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Tyrosine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"stimulant\",\n+      \"amino-acid\",\n+      \"supplement\"\n+    ]\n+  },\n+  \"id\": 704\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-014308-a9c6fc4a",
    "createdAt": "2025-10-19T01:43:08.005Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:43:06 PM"
    },
    "articles": [
      {
        "id": 703,
        "title": "Creatine",
        "slug": "creatine"
      }
    ],
    "markdown": "# Creatine · #703\n\n+{\n+  \"title\": \"Creatine\",\n+  \"index-category\": \"nootropic; supplement\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Creatine\",\n+    \"chemical_name\": \"2-[Carbamimidoyl(methyl)amino]acetic acid\",\n+    \"alternative_name\": \"N-Carbamimidoyl-N-methylglycine; Methylguanidoacetic acid; Creatine monohydrate\",\n+    \"chemical_class\": \"Amino acid\",\n+    \"psychoactive_class\": \"Nootropic; Stimulant\",\n+    \"mechanism_of_action\": \"Stores high-energy phosphate groups as phosphocreatine (creatine phosphate); releases phosphate to regenerate ATP during periods of stress or high-intensity exercise\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.25 g\",\n+            \"light\": \"1-5 g\",\n+            \"common\": \"5-10 g\",\n+            \"strong\": \"10-20 g\",\n+            \"heavy\": \"20+ g\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"30-36 hours\",\n+            \"onset\": \"30-90 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Creatine is not habit-forming and has a low potential for abuse. It does not cause psychological or physiological dependence. Tolerance to the effects of creatine does not build with prolonged use.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Caffeine (may reduce effectiveness in some studies)\",\n+        \"NSAIDs (may increase kidney stress)\",\n+        \"Diuretics (may increase dehydration risk)\"\n+      ]\n+    },\n+    \"notes\": \"Creatine is a naturally occurring amino acid and one of the most well-researched dietary supplements. While generally considered safe at recommended doses (3-5 g/day maintenance), proper hydration is essential to prevent cramping and gastrointestinal distress. Individuals with pre-existing kidney disease should consult a healthcare provider before use. Creatine supplementation typically causes temporary water retention (2-4 pounds in the first week). Vegetarians and vegans may see greater benefits from supplementation due to lower baseline creatine stores from diet.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Stamina Enhancement\",\n+      \"Bodily Control Enhancement\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Appetite Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Focus Enhancement\",\n+      \"Memory Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Thought Organization\",\n+      \"Analysis Enhancement\",\n+      \"Wakefulness\",\n+      \"Rejuvenation\",\n+      \"Anxiety Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"No tolerance develops with prolonged use\",\n+      \"half_tolerance\": \"Not applicable\",\n+      \"zero_tolerance\": \"Not applicable\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"3-5 hours (plasma creatine)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Examine.com: Creatine\",\n+        \"reference\": \"https://examine.com/supplements/creatine/\"\n+      },\n+      {\n+        \"name\": \"ISSN Position Stand: Safety and Efficacy of Creatine Supplementation\",\n+        \"reference\": \"https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00412-w\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Creatine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Creatine\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Creatine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Creatine\"\n+      },\n+      {\n+        \"name\": \"Harvard Health: Creatine Benefits and Risks\",\n+        \"reference\": \"https://www.health.harvard.edu/exercise-and-fitness/what-is-creatine-potential-benefits-and-risks-of-this-popular-supplement\"\n+      },\n+      {\n+        \"name\": \"WebMD: Creatine Overview\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-873/creatine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"stimulant\",\n+      \"supplement\",\n+      \"amino-acid\"\n+    ]\n+  },\n+  \"id\": 703\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-014048-6899a7e0",
    "createdAt": "2025-10-19T01:40:48.307Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:40:46 PM"
    },
    "articles": [
      {
        "id": 702,
        "title": "Meclofenoxate",
        "slug": "meclofenoxate"
      }
    ],
    "markdown": "# Meclofenoxate · #702\n\n+{\n+  \"title\": \"Meclofenoxate\",\n+  \"index-category\": \"nootropic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Meclofenoxate\",\n+    \"chemical_name\": \"2-Dimethylaminoethyl (4-chlorophenoxy)acetate\",\n+    \"alternative_name\": \"Centrophenoxine; Lucidril\",\n+    \"chemical_class\": \"Cholinergic\",\n+    \"psychoactive_class\": \"Nootropic\",\n+    \"mechanism_of_action\": \"Metabolizes into DMAE and pCPA; DMAE is converted to choline which serves as a precursor for acetylcholine synthesis; may inhibit MAO-A and MAO-B\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"50-200 mg\",\n+            \"common\": \"400-800 mg\",\n+            \"strong\": \"800-1000 mg\",\n+            \"heavy\": \"1000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Up to 12 hours (residual alertness)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Meclofenoxate is not considered addictive and has no known physical or psychological dependence potential. It is generally regarded as non-habit forming with an extremely low toxicity profile relative to dose.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of unpredictable potentiation due to MAO inhibition)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Acetylcholinesterase inhibitors (may cause cholinergic overactivity)\",\n+        \"Anticholinergic medications (may reduce effectiveness)\",\n+        \"Other cholinergic supplements (risk of excessive acetylcholine)\"\n+      ]\n+    },\n+    \"notes\": \"Meclofenoxate is not FDA-approved in the United States but is sold as a dietary supplement; it is a prescription medication in some countries including Japan and parts of Europe. Individuals with depression, mania, epilepsy, or convulsive disorders should avoid use entirely. The substance is prohibited for athletes under WADA regulations as a stimulant. Quality and purity of supplements vary significantly; only 14% of tested products contained labeled amounts within 10% accuracy. Cycling recommended with 5 days on and 2 days off to prevent acetylcholine toxicity.\",\n+    \"subjective_effects\": [\n+      \"Focus Enhancement\",\n+      \"Memory Enhancement\",\n+      \"Wakefulness\",\n+      \"Mental Clarity\",\n+      \"Motivation Enhancement\",\n+      \"Stamina Enhancement\",\n+      \"Dream Potentiation\",\n+      \"Bodily Control Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Anxiolytic Effects\",\n+      \"Mindfulness\",\n+      \"Increased Alertness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Not well documented; may develop with daily use after several weeks\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"1-2 weeks with cycling protocol\",\n+      \"cross_tolerances\": [\n+        \"Other cholinergic nootropics\",\n+        \"DMAE\"\n+      ]\n+    },\n+    \"half_life\": \"3-5 hours (estimated based on related cholinergic compounds)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Alzheimer's Drug Discovery Foundation: Centrophenoxine Review\",\n+        \"reference\": \"https://www.alzdiscovery.org/cognitive-vitality/ratings/centrophenoxine\"\n+      },\n+      {\n+        \"name\": \"Erowid Meclofenoxate Vault\",\n+        \"reference\": \"https://www.erowid.org/smarts/meclofenoxate/meclofenoxate.shtml\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert: Centrophenoxine\",\n+        \"reference\": \"https://nootropicsexpert.com/centrophenoxine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Meclofenoxate\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Meclofenoxate\"\n+      },\n+      {\n+        \"name\": \"SelfHacked: Centrophenoxine Guide\",\n+        \"reference\": \"https://selfhacked.com/blog/centrophenoxine/\"\n+      },\n+      {\n+        \"name\": \"USADA: Meclofenoxate Information\",\n+        \"reference\": \"https://www.usada.org/spirit-of-sport/athletes-need-know-meclofenoxate/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Meclofenoxate\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Meclofenoxate\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"cholinergic\",\n+      \"cognitive-enhancer\"\n+    ]\n+  },\n+  \"id\": 702\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-013634-1ac97bda",
    "createdAt": "2025-10-19T01:36:34.605Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:36:31 PM"
    },
    "articles": [
      {
        "id": 701,
        "title": "Citicoline",
        "slug": "citicoline"
      }
    ],
    "markdown": "# Citicoline · #701\n\n+{\n+  \"title\": \"Citicoline\",\n+  \"index-category\": \"nootropic; supplement\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Citicoline\",\n+    \"chemical_name\": \"Cytidine 5'-diphosphocholine\",\n+    \"alternative_name\": \"CDP-choline; Cytidine diphosphate choline\",\n+    \"chemical_class\": \"Ammonium salt; Nucleotide\",\n+    \"psychoactive_class\": \"Nootropic\",\n+    \"mechanism_of_action\": \"Metabolizes to choline and cytidine; enhances acetylcholine synthesis via cholinergic pathways; cytidine converts to uridine enhancing phosphatidylcholine synthesis; increases dopamine and norepinephrine levels in CNS; stimulates glutathione synthesis\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100-250 mg\",\n+            \"common\": \"250-1000 mg\",\n+            \"strong\": \"1000-2000 mg\",\n+            \"heavy\": \"2000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"58-74 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"2.5-3.5 hours\",\n+            \"offset\": \"30-40 hours\",\n+            \"after_effects\": \"40-60 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Citicoline is non-addictive and not habit-forming. The desire to use it may actually decrease with continued use, making it self-regulating. Tolerance does not build immediately, and effects may strengthen with prolonged use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (unpredictable potentiation of effects; suspected monoaminergic interaction)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Anticholinergic medications (may reduce effectiveness)\",\n+        \"Dopamine agonists (potential interaction)\",\n+        \"Antipsychotic medications (may exacerbate psychotic episodes)\"\n+      ]\n+    },\n+    \"notes\": \"Citicoline has very high oral bioavailability (over 90%) and is generally well-tolerated with minimal side effects. Not recommended for continuous use beyond two weeks due to its extremely long half-life and cumulative effects. Individuals with trimethylaminuria may experience body odor changes as choline is a precursor to trimethylamine. Pregnant or breastfeeding individuals should avoid use due to insufficient safety data. Store in a cool, dry place and use an accurate scale for dosing.\",\n+    \"subjective_effects\": [\n+      \"Memory Enhancement\",\n+      \"Focus Enhancement\",\n+      \"Wakefulness\",\n+      \"Mental Stimulation\",\n+      \"Dream Potentiation\",\n+      \"Mindfulness\",\n+      \"Acuity Enhancement\",\n+      \"Pain Relief\",\n+      \"Appetite Suppression\",\n+      \"Addiction Suppression\",\n+      \"Headaches (occasional)\",\n+      \"Body Odor Alteration (rare)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Does not develop immediate tolerance; effects strengthen with prolonged use\",\n+      \"half_tolerance\": \"Not applicable\",\n+      \"zero_tolerance\": \"Not recommended to use continuously for more than 2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Potentially with other cholinergic nootropics (Alpha-GPC, phosphatidylcholine)\"\n+      ]\n+    },\n+    \"half_life\": \"56 hours (respiratory elimination as CO2); 71 hours (urinary excretion)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Examine.com: CDP-Choline\",\n+        \"reference\": \"https://examine.com/supplements/cdp-choline/\"\n+      },\n+      {\n+        \"name\": \"Erowid Citicoline Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Citicoline.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Citicoline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Citicoline\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Citicoline\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Citicoline\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"cholinergic\",\n+      \"cognitive-enhancer\",\n+      \"supplement\"\n+    ]\n+  },\n+  \"id\": 701\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-013412-780da5c1",
    "createdAt": "2025-10-19T01:34:12.965Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:34:11 PM"
    },
    "articles": [
      {
        "id": 700,
        "title": "Alpha-GPC",
        "slug": "alpha-gpc"
      }
    ],
    "markdown": "# Alpha-GPC · #700\n\n+{\n+  \"title\": \"Alpha-GPC\",\n+  \"index-category\": \"nootropic; cognitive-enhancer\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Alpha-GPC\",\n+    \"chemical_name\": \"L-alpha-glycerylphosphorylcholine\",\n+    \"alternative_name\": \"Choline Alfoscerate; L-Alpha Glycerylphosphorylcholine; Alfa-GPC\",\n+    \"chemical_class\": \"Choline derivative\",\n+    \"psychoactive_class\": \"Nootropic\",\n+    \"mechanism_of_action\": \"Precursor to choline and glycerophosphate in the brain; increases acetylcholine synthesis and release via enhanced choline availability; supports phospholipid biosynthesis and cell membrane integrity\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100-300 mg\",\n+            \"common\": \"300-500 mg\",\n+            \"strong\": \"500-1000 mg\",\n+            \"heavy\": \"1000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Up to 6 hours (residual cognitive effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Alpha-GPC is not considered habit-forming or addictive. The desire to use it may actually decrease with regular use, as it is self-regulating. No physical or psychological dependence has been reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (may unpredictably potentiate effects)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Scopolamine (may reduce anticholinergic effects)\",\n+        \"Anticholinergic medications (may reduce therapeutic effects)\"\n+      ]\n+    },\n+    \"notes\": \"Alpha-GPC is legal as a dietary supplement in the US and Canada but is a prescription medication in some European countries. A 2021 study found increased stroke risk with long-term use (10+ years), so extended daily use may warrant caution. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals prone to hypotension should consult a healthcare provider before use. Side effects are typically dose-dependent; start with lower doses and increase gradually. Alpha-GPC is approximately 40% choline by weight.\",\n+    \"subjective_effects\": [\n+      \"Focus Enhancement\",\n+      \"Memory Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Wakefulness\",\n+      \"Bodily Control Enhancement\",\n+      \"Subtle Stimulation\",\n+      \"Dream Potentiation\",\n+      \"Mindfulness\",\n+      \"Stamina Enhancement\",\n+      \"Headaches (from excess choline)\",\n+      \"Gastrointestinal Distress\",\n+      \"Fatigue\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated daily usage\",\n+      \"half_tolerance\": \"7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"4-6 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Alpha-GPC\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Alpha-GPC\"\n+      },\n+      {\n+        \"name\": \"Examine: Alpha-GPC Research Breakdown\",\n+        \"reference\": \"https://examine.com/supplements/alpha-gpc/\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: Alpha-GPC\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_alphaGPC.shtml\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert: Alpha-GPC Guide\",\n+        \"reference\": \"https://nootropicsexpert.com/alpha-gpc/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Glycerophosphorylcholine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Glycerophosphorylcholine\"\n+      },\n+      {\n+        \"name\": \"WebMD: Alpha-GPC Overview\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1087/alpha-gpc\"\n+      },\n+      {\n+        \"name\": \"Alzheimer's Drug Discovery Foundation: Alpha-GPC Review\",\n+        \"reference\": \"https://www.alzdiscovery.org/cognitive-vitality/ratings/alpha-gpc-choline-alfoscerate\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"cognitive-enhancer\",\n+      \"choline-supplement\"\n+    ]\n+  },\n+  \"id\": 700\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-013101-c731ad61",
    "createdAt": "2025-10-19T01:31:01.736Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:31:00 PM"
    },
    "articles": [
      {
        "id": 699,
        "title": "Choline Bitartrate",
        "slug": "choline-bitartrate"
      }
    ],
    "markdown": "# Choline Bitartrate · #699\n\n+{\n+  \"title\": \"Choline Bitartrate\",\n+  \"index-category\": \"nootropic; supplement\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Choline Bitartrate\",\n+    \"chemical_name\": \"2-Hydroxy-N,N,N-trimethylethan-1-aminium\",\n+    \"alternative_name\": \"Choline; Vitamin B4\",\n+    \"chemical_class\": \"Ammonium Salt\",\n+    \"psychoactive_class\": \"Nootropic\",\n+    \"mechanism_of_action\": \"Acetylcholine precursor; supports phospholipid synthesis for cell membrane structure; facilitates trimethylamine (betaine) production for osmoregulation and SAM-e synthesis\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100-250 mg\",\n+            \"common\": \"250-1000 mg\",\n+            \"strong\": \"1000-2000 mg\",\n+            \"heavy\": \"2000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Choline bitartrate is not habit-forming and has no known addiction potential. The desire to use it can actually decrease with use as it is self-regulating. It does not cause physical or psychological dependence.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Scopolamine (known adverse interaction)\",\n+        \"High-dose stimulants (potential for overstimulation when combined)\",\n+        \"Anticholinergic drugs (opposing mechanisms)\"\n+      ]\n+    },\n+    \"notes\": \"Choline bitartrate is legally available as a dietary supplement in most countries and is required in non-dairy infant formulas in the United States. Use a precise scale for accurate dosing, especially at higher doses. Individuals with trimethylaminuria may experience fishy body odor as a side effect. When using with racetam nootropics, maintain adequate choline supplementation to prevent headaches and optimize cognitive benefits. Choline bitartrate has lower bioavailability than Alpha-GPC or CDP-choline, requiring higher doses for comparable effects.\",\n+    \"subjective_effects\": [\n+      \"Subtle Stimulation\",\n+      \"Enhanced Focus And Attention\",\n+      \"Improved Memory\",\n+      \"Dream Potentiation\",\n+      \"Mental Clarity\",\n+      \"Mood Enhancement\",\n+      \"Headache (Without Adequate Dosing Or With Racetams)\",\n+      \"Body Odor Alteration (In Some Individuals)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated usage\",\n+      \"half_tolerance\": \"7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Choline Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Vitamins_Choline.shtml\"\n+      },\n+      {\n+        \"name\": \"Nootropics Expert: Choline Bitartrate\",\n+        \"reference\": \"https://nootropicsexpert.com/choline-bitartrate/\"\n+      },\n+      {\n+        \"name\": \"Nootropics Depot: Choline Supplements Guide\",\n+        \"reference\": \"https://nootropicsdepot.com/articles/ultimate-guide-to-nootropics-part-6-choline-supplements/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Choline Bitartrate\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Choline_bitartrate\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nootropic\",\n+      \"supplement\",\n+      \"cholinergic\"\n+    ]\n+  },\n+  \"id\": 699\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-012834-214de31a",
    "createdAt": "2025-10-19T01:28:34.452Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:28:32 PM"
    },
    "articles": [
      {
        "id": 698,
        "title": "PMMA",
        "slug": "pmma"
      }
    ],
    "markdown": "# PMMA · #698\n\n+{\n+  \"title\": \"PMMA\",\n+  \"index-category\": \"entactogen; stimulant; dangerous\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PMMA\",\n+    \"chemical_name\": \"1-(4-Methoxyphenyl)-N-methylpropan-2-amine\",\n+    \"alternative_name\": \"para-Methoxymethamphetamine; 4-Methoxymethamphetamine; 4-MeOMA; Death\",\n+    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n+    \"psychoactive_class\": \"Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"Serotonin-norepinephrine releasing agent (SNRA); potent reversible MAO-A inhibitor (IC50 ~1700 nM); weak dopamine releaser\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"50-80 mg\",\n+            \"common\": \"100-120 mg\",\n+            \"strong\": \"120+ mg (extreme danger)\",\n+            \"heavy\": \"Potentially lethal - avoid completely\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"Variable (typically shortened by toxicity)\",\n+            \"onset\": \"30-90 minutes (slow onset)\",\n+            \"peak\": \"Unknown\",\n+            \"offset\": \"Unknown\",\n+            \"after_effects\": \"Potentially severe or fatal complications\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"PMMA has low addiction potential due to its lack of euphoria and highly aversive effects. However, the slow onset and weak subjective effects may lead to dangerous compulsive redosing in users mistaking it for MDMA.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MDMA (extreme risk of serotonin syndrome and hyperthermia)\",\n+        \"MAOIs (serotonin syndrome, hypertensive crisis - note: PMMA itself is an MAOI)\",\n+        \"SSRIs (serotonin syndrome risk)\",\n+        \"SNRIs (serotonin syndrome risk)\",\n+        \"Tricyclic antidepressants (severe cardiovascular complications)\",\n+        \"Other serotonergic drugs (MDA, MDEA, etc.)\",\n+        \"Amphetamines (severe cardiovascular stress, hyperthermia)\",\n+        \"Cocaine (extreme cardiovascular risk, severe vasoconstriction)\",\n+        \"Methamphetamine (severe hyperthermia and cardiovascular complications)\"\n+      ],\n+      \"unsafe\": [\n+        \"Alcohol (increased dehydration, impaired thermoregulation, masking of warning symptoms)\",\n+        \"Stimulants (tachycardia, hypertension, seizure risk)\",\n+        \"Tramadol (lowers seizure threshold, serotonergic interaction)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (increased anxiety, paranoia, thought loops)\",\n+        \"Caffeine (increased stimulation, cardiovascular stress)\"\n+      ]\n+    },\n+    \"notes\": \"PMMA is an extremely dangerous substance that is frequently mis-sold as MDMA. Due to its slow onset (30-90 minutes), users often redose thinking the initial dose was ineffective, leading to fatal overdoses. PMMA causes severe hyperthermia through its dual action as both a serotonin releaser and MAO-A inhibitor. Even moderate doses can result in life-threatening side effects including seizures, cardiac arrhythmias, extreme hyperthermia, and death. The substance has minimal euphoric effects and is not recreationally desirable. ALWAYS test pills with reagent kits (Marquis, Mecke, Mandelin) before consumption. If PMMA is suspected or confirmed, the substance should be completely avoided. Seek immediate medical attention if symptoms of severe hyperthermia, rapid heartbeat, difficulty breathing, or seizures occur. This substance is Schedule I in the United States as of July 2021.\",\n+    \"subjective_effects\": [\n+      \"Mild Stimulation (at low doses only)\",\n+      \"Abnormal Heartbeat\",\n+      \"Severe Dizziness\",\n+      \"Extreme Hyperthermia\",\n+      \"Nausea and Vomiting\",\n+      \"Anxiety or Dysphoria\",\n+      \"Difficulty Breathing\",\n+      \"Seizures\",\n+      \"Teeth Grinding\",\n+      \"Pupil Dilation\",\n+      \"Vibrating Vision\",\n+      \"Visual Drifting (at higher doses)\",\n+      \"Intoxication (alcohol-like)\",\n+      \"Paresthesia (pins and needles sensation)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Not well documented due to lack of recreational use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Unknown\",\n+      \"cross_tolerances\": [\n+        \"Serotonergic substances (MDMA, other substituted amphetamines)\"\n+      ]\n+    },\n+    \"half_life\": \"Not well established in humans; metabolized to PMA\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: PMA and PMMA\",\n+        \"reference\": \"https://adf.org.au/drug-facts/pma-and-pmma/\"\n+      },\n+      {\n+        \"name\": \"DanceSafe: MDMA Contraindications\",\n+        \"reference\": \"https://dancesafe.org/mdma-contraindications/\"\n+      },\n+      {\n+        \"name\": \"DrugFacts UK: PMMA/PMA\",\n+        \"reference\": \"https://drugfacts.org.uk/index.php?title=PMMA/PMA\"\n+      },\n+      {\n+        \"name\": \"Drugs.ie: PMA/PMMA Harm Reduction\",\n+        \"reference\": \"http://www.drugs.ie/pma\"\n+      },\n+      {\n+        \"name\": \"Erowid: PMMA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/pmma/pmma.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PMMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PMMA\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PMA\"\n+      },\n+      {\n+        \"name\": \"Substance Misuse Resources: PMA/PMMA Guide\",\n+        \"reference\": \"https://www.substancemisuseresources.co.uk/resources/pma-pmma-guide\"\n+      },\n+      {\n+        \"name\": \"TripSit: Drug Combinations Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: para-Methoxymethamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Para-Methoxymethamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"entactogen\",\n+      \"stimulant\",\n+      \"amphetamine\",\n+      \"research-chemical\",\n+      \"extremely-dangerous\"\n+    ]\n+  },\n+  \"id\": 698\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-012502-06af2901",
    "createdAt": "2025-10-19T01:25:02.578Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:25:00 PM"
    },
    "articles": [
      {
        "id": 697,
        "title": "6-APDB",
        "slug": "6-apdb"
      }
    ],
    "markdown": "# 6-APDB · #697\n\n+{\n+  \"title\": \"6-APDB\",\n+  \"index-category\": \"entactogen; stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"6-APDB\",\n+    \"chemical_name\": \"6-(2-aminopropyl)-2,3-dihydrobenzofuran\",\n+    \"alternative_name\": \"4-Desoxy-MDA; EMA-3\",\n+    \"chemical_class\": \"Amphetamine; Benzofuran\",\n+    \"psychoactive_class\": \"Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"Serotonin releaser and reuptake inhibitor; dopamine releaser and reuptake inhibitor; norepinephrine releaser and reuptake inhibitor\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"30-70 mg\",\n+            \"common\": \"70-100 mg\",\n+            \"strong\": \"100-130 mg\",\n+            \"heavy\": \"130+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"Up to 24 hours (residual effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"6-APDB can be moderately addictive with a high potential for abuse and is capable of causing psychological dependence. Chronic use may result in cravings and withdrawal effects upon cessation.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (potentially fatal serotonin syndrome and hypertensive crisis)\",\n+        \"SSRIs (risk of potentially fatal serotonin syndrome; also significantly blunts effects)\",\n+        \"SNRIs (risk of potentially fatal serotonin syndrome; also significantly blunts effects)\",\n+        \"5-HTP (risk of potentially fatal serotonin syndrome)\",\n+        \"MDMA (risk of serotonin syndrome; greatly increased neurotoxicity and cardiotoxicity)\",\n+        \"Serotonin releasers including methylone, mephedrone, 4-FA (risk of potentially fatal serotonin syndrome)\",\n+        \"25x-NBOMe (excessive stimulation, severe hypertension, risk of seizures and heart failure)\",\n+        \"25x-NBOH (excessive stimulation, severe hypertension, risk of seizures and heart failure)\",\n+        \"Tramadol (lowers seizure threshold and risk of serotonin syndrome)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (risk of panic attacks, hypertensive crisis, and serotonin syndrome)\",\n+        \"MXE (may increase blood pressure and risk of mania and psychosis)\",\n+        \"Dissociatives (increased risk of delusions, mania, and psychosis)\",\n+        \"Stimulants (increased heart rate and blood pressure to dangerous levels)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (risk of accidental over-intoxication; stimulant effects mask alcohol depressant effects)\"\n+      ]\n+    },\n+    \"notes\": \"6-APDB was designed as a potentially less neurotoxic alternative to MDMA but may still pose neurotoxic and cardiotoxic risks with repeated or high-dose use. CRITICAL WARNING: As a potent serotonin releaser, 6-APDB carries serious risk of potentially fatal serotonin syndrome when combined with antidepressants, MAOIs, or other serotonergic drugs. The substance causes significant hyperthermia which can be life-threatening; users must monitor body temperature and stay properly hydrated. Individuals with personal or family histories of heart conditions should avoid use. Use accurate milligram scales for dosing, as the therapeutic window is narrow and overdose can be dangerous.\",\n+    \"subjective_effects\": [\n+      \"Intense Physical Euphoria\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Emotional Warmth\",\n+      \"Time Distortion\",\n+      \"Enhanced Music Appreciation\",\n+      \"Sedation And Relaxation\",\n+      \"Mild Visual Geometry\",\n+      \"Tactile Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Teeth Grinding\",\n+      \"Nystagmus\",\n+      \"Dehydration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"21-30 days\",\n+      \"zero_tolerance\": \"2-3 months\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\",\n+        \"MDMA\",\n+        \"MDA\",\n+        \"Other benzofurans (e.g., 5-APB, 6-APB, 5-APDB)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 6-APDB Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_6APDB.shtml\"\n+      },\n+      {\n+        \"name\": \"Monte et al. (1993) - Synthesis and pharmacological examination of benzofuran analogues\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8411003/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 6-APDB\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/6-APDB\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Main 6-APDB Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-main-6-apdb-thread.661435/\"\n+      },\n+      {\n+        \"name\": \"Pharmacological profile of novel psychoactive benzofurans (2015)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC4500375/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 6-APB\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/6-APB\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"entactogen\",\n+      \"stimulant\",\n+      \"benzofuran\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 697\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-012124-778bb71b",
    "createdAt": "2025-10-19T01:21:24.178Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:21:22 PM"
    },
    "articles": [
      {
        "id": 696,
        "title": "MDEA",
        "slug": "mdea"
      }
    ],
    "markdown": "# MDEA · #696\n\n+{\n+  \"title\": \"MDEA\",\n+  \"index-category\": \"entactogen; empathogen\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MDEA\",\n+    \"chemical_name\": \"(RS)-1-(benzo[d][1,3]dioxol-5-yl)-N-ethylpropan-2-amine\",\n+    \"alternative_name\": \"MDE; Eve\",\n+    \"chemical_class\": \"Amphetamines; MDxx\",\n+    \"psychoactive_class\": \"Entactogen\",\n+    \"mechanism_of_action\": \"Serotonin releasing agent and reuptake inhibitor; Norepinephrine releasing agent and reuptake inhibitor; Dopamine releasing agent and reuptake inhibitor\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"70-120 mg\",\n+            \"common\": \"120-180 mg\",\n+            \"strong\": \"180-225 mg\",\n+            \"heavy\": \"225+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"12-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"The chronic use of MDEA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. Evidence of physical addiction is limited.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"25x-NBOMe and 25x-NBOH (risk of excessive stimulation, seizures, and heart failure)\",\n+        \"MAOIs (risk of dangerous increases in neurotransmitters and serotonin syndrome)\",\n+        \"Serotonin releasers such as MDMA, 4-FA, methamphetamine, methylone, and aMT (risk of serotonin syndrome)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (increased risk of panic attacks, hypertensive crisis, and serotonin syndrome)\",\n+        \"MXE (may dangerously increase blood pressure and risk of mania)\",\n+        \"Dissociatives (increased risk of delusions, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cocaine (increased heart strain)\",\n+        \"Other stimulants (increased neurotoxicity and cardiotoxicity)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (risk of accidental over-intoxication and dehydration)\",\n+        \"SSRIs (significantly reduced effects and increased serotonin syndrome risk)\",\n+        \"SNRIs (significantly reduced effects and increased serotonin syndrome risk)\",\n+        \"5-HTP (increased serotonin syndrome risk)\"\n+      ]\n+    },\n+    \"notes\": \"MDEA is a Schedule I controlled substance in most countries. The substance is characterized by a more sedating, 'stoning' quality compared to MDMA, with less emphasis on social connection and more on physical relaxation. MDEA requires careful dosing with an accurate milligram scale, adequate hydration without over-drinking, and temperature regulation in warm environments. Users with personal or family histories of heart conditions or mental health disorders should avoid use. Set and setting influence the experience significantly.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Tactile Enhancement\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Cognitive Euphoria\",\n+      \"Empathy and Sociability Enhancement (less pronounced than MDMA)\",\n+      \"Anxiety Suppression\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Sedation (more pronounced than MDMA)\",\n+      \"Teeth Grinding\",\n+      \"Pupil Dilation\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"1-1.5 months\",\n+      \"zero_tolerance\": \"2-3 months\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\",\n+        \"All serotonergic stimulants and entactogens (MDMA, MDA, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"7-9 hours (estimated, similar to MDMA based on structural similarity)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid MDE Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/mde/mde.shtml\"\n+      },\n+      {\n+        \"name\": \"Freudenmann & Spitzer - The Neuropsychopharmacology and Toxicology of MDEA\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/15179441/\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #106 - MDE\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal106.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki - MDEA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MDEA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia - 3,4-Methylenedioxy-N-ethylamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/3,4-Methylenedioxy-N-ethylamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"entactogen\",\n+      \"amphetamine\",\n+      \"mdxx\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 696\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-011748-7742b9ff",
    "createdAt": "2025-10-19T01:17:48.477Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:17:46 PM"
    },
    "articles": [
      {
        "id": 695,
        "title": "MDAI",
        "slug": "mdai"
      }
    ],
    "markdown": "# MDAI · #695\n\n+{\n+  \"title\": \"MDAI\",\n+  \"index-category\": \"entactogen; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MDAI\",\n+    \"chemical_name\": \"5,6-Methylenedioxy-2-aminoindane\",\n+    \"alternative_name\": \"Sparkle; Mindy; 6,7-Dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine\",\n+    \"chemical_class\": \"Aminoindanes\",\n+    \"psychoactive_class\": \"Entactogen\",\n+    \"mechanism_of_action\": \"Selective serotonin releasing agent (SSRA); selective serotonin reuptake inhibitor (SSRI); minor norepinephrine releasing agent\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"40-100 mg\",\n+            \"common\": \"100-175 mg\",\n+            \"strong\": \"175-300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"2-2.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to 12 hours (residual effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MDAI is considered to have low potential for abuse and is unlikely to cause psychological dependence among most users. Unlike traditional stimulants, MDAI does not significantly increase dopamine concentrations. Compulsive redosing is minimal compared to other entactogens.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (severe risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Serotonin releasers including MDMA, methylone, and mephedrone (serotonin syndrome risk)\",\n+        \"SSRIs such as citalopram and sertraline (serotonin syndrome risk)\",\n+        \"SNRIs such as venlafaxine (serotonin syndrome risk)\",\n+        \"5-HTP (serotonin syndrome risk)\",\n+        \"Amphetamine (neurotoxicity when combined)\"\n+      ],\n+      \"unsafe\": [\n+        \"25x-NBOMe and 25x-NBOH (excessive stimulation, heart strain, seizure risk)\",\n+        \"DXM (panic attacks, hypertensive crisis, serotonin syndrome)\",\n+        \"MXE (increased blood pressure, mania, psychosis risk)\",\n+        \"Dissociatives (increased risk of delusions, mania, psychosis)\",\n+        \"Stimulants including cocaine (dangerous heart rate and blood pressure elevation)\",\n+        \"Tramadol (lowered seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (risk of over-intoxication when stimulant effects mask depressant effects)\"\n+      ]\n+    },\n+    \"notes\": \"MDAI was developed as a putatively non-neurotoxic MDMA analogue, but research indicates it may still cause neurotoxicity when combined with amphetamines or used chronically. Three UK deaths in 2011-2012 were linked to MDAI use with serotonin syndrome as a suspected factor. The substance should be accurately weighed on a milligram scale due to variable purity. Users should be aware that MDAI is primarily sedating rather than stimulating, lacks the dopaminergic effects of MDMA, and is often described as producing empathogenic effects without euphoric stimulation. Set and setting remain important considerations.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Anxiety Suppression\",\n+      \"Empathy Enhancement\",\n+      \"Sociability Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Music Appreciation\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Temperature Regulation Suppression\",\n+      \"Dehydration\",\n+      \"Difficulty Urinating\",\n+      \"Nystagmus\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All entactogens and serotonergic stimulants\",\n+        \"MDMA\",\n+        \"MDA\",\n+        \"Other aminoindanes\"\n+      ]\n+    },\n+    \"half_life\": \"Detected in serum up to 4 days; detected in urine up to 6 days (elimination half-life not well established)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MDAI Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mdai-thread.434331/\"\n+      },\n+      {\n+        \"name\": \"Erowid MDAI Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/mdai/mdai.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: MDAI\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MDAI\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: MDAI\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/MDAI\"\n+      },\n+      {\n+        \"name\": \"Angerer et al. (2024): Acute psychotropic, autonomic, and endocrine effects of MDAI compared with MDMA\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3622\"\n+      },\n+      {\n+        \"name\": \"Corkery et al. (2013): MDAI toxicity - a brief overview and update\",\n+        \"reference\": \"https://onlinelibrary.wiley.com/doi/10.1002/hup.2298\"\n+      },\n+      {\n+        \"name\": \"Oeri (2021): Beyond ecstasy - Alternative entactogens to MDMA\",\n+        \"reference\": \"https://journals.sagepub.com/doi/full/10.1177/0269881120920420\"\n+      },\n+      {\n+        \"name\": \"Release UK: MDAI Information\",\n+        \"reference\": \"https://www.release.org.uk/drugs/mdai/pharmacology\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"entactogen\",\n+      \"aminoindane\",\n+      \"research-chemical\",\n+      \"serotonergic\"\n+    ]\n+  },\n+  \"id\": 695\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-011421-77c38d50",
    "createdAt": "2025-10-19T01:14:21.412Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:14:19 PM"
    },
    "articles": [
      {
        "id": 694,
        "title": "Propylhexedrine",
        "slug": "propylhexedrine"
      }
    ],
    "markdown": "# Propylhexedrine · #694\n\n+{\n+  \"title\": \"Propylhexedrine\",\n+  \"index-category\": \"stimulant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Propylhexedrine\",\n+    \"chemical_name\": \"1-cyclohexyl-N-methylpropan-2-amine\",\n+    \"alternative_name\": \"Benzedrex; Obesin\",\n+    \"chemical_class\": \"Cycloalkylamine\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Serotonin-norepinephrine-dopamine releasing agent (SNDRA); VMAT2 inhibitor; TAAR1 agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"30-60 mg\",\n+            \"common\": \"60-120 mg\",\n+            \"strong\": \"120-180 mg\",\n+            \"heavy\": \"180+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"2-5 hours\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"2-12 hours (residual wakefulness)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Propylhexedrine has moderate abuse potential and can be highly addictive with chronic use. It is capable of causing both psychological and physiological dependence. When addiction develops, cravings and withdrawal effects may occur upon cessation. Compulsive redosing is commonly reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis)\",\n+        \"Tricyclic antidepressants (dangerous potentiation)\",\n+        \"25x-NBOMe (severe cardiovascular strain, seizures)\",\n+        \"25x-NBOH (severe cardiovascular strain, seizures)\",\n+        \"Cocaine (excessive heart strain)\"\n+      ],\n+      \"unsafe\": [\n+        \"Alcohol (risk of over-intoxication)\",\n+        \"DXM (increased risk of panic attacks and hypertensive crisis)\",\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"MXE (dangerously increased blood pressure, mania risk)\",\n+        \"Other dissociatives (increased risk of delusions and psychosis)\",\n+        \"Other stimulants (dangerous cardiovascular strain)\",\n+        \"Tramadol (lowered seizure threshold)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"Propylhexedrine is legally available as an over-the-counter nasal decongestant in the United States under the brand name Benzedrex. Recreational use typically involves extracting the drug-soaked cotton from inhalers, a practice that carries significant health risks that have not been extensively studied. Propylhexedrine produces more pronounced peripheral effects (vasoconstriction, cardiovascular strain) compared to amphetamines due to reduced blood-brain barrier permeability. Use extreme caution with dosing and avoid use if you have cardiovascular conditions or personal/family history of psychotic disorders. Always use harm reduction practices including accurate weighing, avoiding combinations with other stimulants, staying hydrated, and monitoring vital signs.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Focus Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Increased Libido\",\n+      \"Appetite Suppression\",\n+      \"Euphoria\",\n+      \"Vasoconstriction\",\n+      \"Increased Blood Pressure\",\n+      \"Increased Heart Rate\",\n+      \"Nausea\",\n+      \"Anxiety\",\n+      \"Thought Acceleration\",\n+      \"Wakefulness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops rapidly with prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants (amphetamines, methylphenidate, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"2.5-6.5 hours (variable based on urinary pH and cytochrome P450 activity)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Propylhexedrine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/propylhexedrine/propylhexedrine.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Propylhexedrine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Propylhexedrine\"\n+      },\n+      {\n+        \"name\": \"FDA Warning on Propylhexedrine Abuse\",\n+        \"reference\": \"https://www.vumc.org/poison-control/toxicology-question-week/may-4-2021-what-new-old-drug-benzedrex\"\n+      },\n+      {\n+        \"name\": \"Poison Control: Propylhexedrine\",\n+        \"reference\": \"https://www.poison.org/articles/propylhexedrine\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Propylhexedrine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Propylhexedrine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"cycloalkylamine\",\n+      \"over-the-counter\"\n+    ]\n+  },\n+  \"id\": 694\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-011117-553ecef9",
    "createdAt": "2025-10-19T01:11:17.915Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:11:16 PM"
    },
    "articles": [
      {
        "id": 693,
        "title": "Methiopropamine",
        "slug": "methiopropamine"
      }
    ],
    "markdown": "# Methiopropamine · #693\n\n+{\n+  \"title\": \"Methiopropamine\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Methiopropamine\",\n+    \"chemical_name\": \"1-(Thiophen-2-yl)-2-methylaminopropane\",\n+    \"alternative_name\": \"MPA; Blow; N-methylthiopropamine\",\n+    \"chemical_class\": \"Thiophenes\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Norepinephrine-dopamine reuptake inhibitor (NDRI); approximately 1.85 times more selective for norepinephrine than dopamine\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-20 mg\",\n+            \"common\": \"20-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-10 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"30-120 minutes\",\n+            \"after_effects\": \"6-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Methiopropamine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. Compulsive redosing is commonly reported, particularly with insufflated or vaporized routes of administration.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"25x-NBOMe (risk of excessive stimulation and heart strain, seizures, heart failure)\",\n+        \"25x-NBOH (risk of excessive stimulation and heart strain, seizures, heart failure)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Other stimulants (increased heart rate and blood pressure)\",\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"Cocaine (increased cardiovascular strain)\",\n+        \"MXE (increased blood pressure, risk of mania and psychosis)\",\n+        \"Dissociatives (increased risk of delusions, mania and psychosis)\",\n+        \"Tramadol (lowered seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (risk of over-intoxication when stimulant effects wear off)\",\n+        \"DXM (risk of panic attacks and hypertensive crisis)\"\n+      ]\n+    },\n+    \"notes\": \"Methiopropamine has very little history of human use and limited scientific data exists about its pharmacology and toxicity. The substance is controlled in many jurisdictions including the UK (Class B), Germany, France, Switzerland, China, Austria, and Florida. Use accurate scales for dosing and be aware that the substance has been associated with cardiovascular toxicity, gastrointestinal symptoms, and psychotic symptoms. Individuals with cardiovascular conditions or predisposition to psychosis should avoid use. Harm reduction practices are strongly recommended.\",\n+    \"subjective_effects\": [\n+      \"Stimulation (mild to moderate)\",\n+      \"Focus Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Increased Libido\",\n+      \"Appetite Suppression\",\n+      \"Cognitive Euphoria (less intense than traditional stimulants)\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Increased Perspiration\",\n+      \"Teeth Grinding\",\n+      \"Thought Acceleration\",\n+      \"Wakefulness\",\n+      \"Compulsive Redosing\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight Methiopropamine Megathread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-methiopropamine-n-methyl-1-thiophen-2-yl-propan-2-amine-mpa-megathread-v2.655417/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum Methiopropamine Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/methiopropamine-experiences.159678/\"\n+      },\n+      {\n+        \"name\": \"Erowid Methiopropamine Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/methiopropamine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Methiopropamine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Methiopropamine\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Methiopropamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methiopropamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"thiophene\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 693\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-010853-bb6cf834",
    "createdAt": "2025-10-19T01:08:53.670Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:08:51 PM"
    },
    "articles": [
      {
        "id": 692,
        "title": "Theacrine",
        "slug": "theacrine"
      }
    ],
    "markdown": "# Theacrine · #692\n\n+{\n+  \"title\": \"Theacrine\",\n+  \"index-category\": \"stimulant; nootropic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Theacrine\",\n+    \"chemical_name\": \"1,3,7,9-Tetramethyluric acid\",\n+    \"alternative_name\": \"Teacrine; Temorine; Temurin\",\n+    \"chemical_class\": \"Xanthines\",\n+    \"psychoactive_class\": \"Stimulant; Nootropic\",\n+    \"mechanism_of_action\": \"Adenosine receptor antagonist (competitive inhibitor); affects dopamine, acetylcholine, and serotonin receptors; at high doses affects norepinephrine receptors; to a lesser extent affects epinephrine, glutamate, and cortisol\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"50-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"\",\n+            \"common\": \"25-100 mg\",\n+            \"strong\": \"\",\n+            \"heavy\": \"\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"30-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"5-30 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Theacrine produces dependence with chronic use and has a low abuse potential. When dependence develops, cravings and withdrawal effects may occur upon sudden cessation. However, tolerance builds more slowly compared to caffeine, and compulsive redosing is less persistent than with caffeine due to its longer duration of effects.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Tramadol (increased seizure risk)\",\n+        \"Other stimulants (increased seizure risk)\",\n+        \"MAOIs (potential interaction through neurotransmitter effects)\"\n+      ],\n+      \"caution\": [\n+        \"Caffeine (caffeine increases theacrine plasma levels)\",\n+        \"Other adenosine receptor antagonists (cross-tolerance)\",\n+        \"CNS depressants (opposing effects)\",\n+        \"Antidepressants (caution due to serotonergic effects)\"\n+      ]\n+    },\n+    \"notes\": \"Theacrine is a structural analog of caffeine with about two-thirds the potency for stimulation but stronger effects on focus. It has a biphasic dose-response: low doses may be sedating while higher doses are stimulating. Unlike caffeine, theacrine does not appear to significantly affect blood pressure. Effects take longer to manifest (2-3 hours) compared to caffeine (30-60 minutes) but are more persistent. At higher doses, forced stimulation may lead to jaw clenching, involuntary shakes, and loss of motor control. Use a precise milligram scale for accurate dosing.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Focus Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Memory Enhancement\",\n+      \"Wakefulness\",\n+      \"Pain Relief\",\n+      \"Thought Acceleration\",\n+      \"Increased Music Appreciation\",\n+      \"Increased Libido\",\n+      \"Euphoria (Mild)\",\n+      \"Appetite Suppression\",\n+      \"Anxiety\",\n+      \"Nausea (At High Doses)\",\n+      \"Bruxism\",\n+      \"Compulsive Redosing\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Caffeine\",\n+        \"Theobromine\",\n+        \"Other adenosine receptor antagonists\"\n+      ]\n+    },\n+    \"half_life\": \"20-30 hours (plasma elimination half-life based on pharmacokinetic studies)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Theacrine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Theacrine\"\n+      },\n+      {\n+        \"name\": \"WebMD: Theacrine Overview\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1280/theacrine\"\n+      },\n+      {\n+        \"name\": \"RxList: Theacrine Health Benefits and Side Effects\",\n+        \"reference\": \"https://www.rxlist.com/theacrine/supplements.htm\"\n+      },\n+      {\n+        \"name\": \"He et al. (2017): Assessment of Drug-Drug Interaction Potential Between Theacrine and Caffeine\",\n+        \"reference\": \"https://www.memphis.edu/nutraceutical/pdfs/8-2017-jcr-theacrine-pk.pdf\"\n+      },\n+      {\n+        \"name\": \"Scientific Reports (2024): Dose Response Effects of Theacrine on Cognitive Performance and Sleep\",\n+        \"reference\": \"https://www.nature.com/articles/s41598-024-79046-2\"\n+      },\n+      {\n+        \"name\": \"SelfDecode: 3 Potential Benefits of Theacrine\",\n+        \"reference\": \"https://supplements.selfdecode.com/blog/theacrine-benefits/\"\n+      },\n+      {\n+        \"name\": \"Nootropics Depot: TeaCrine Guide\",\n+        \"reference\": \"https://nootropicsdepot.com/articles/teacrine-the-supplement-alternative-to-caffeine/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"nootropic\",\n+      \"xanthine\"\n+    ]\n+  },\n+  \"id\": 692\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-010538-277b6109",
    "createdAt": "2025-10-19T01:05:38.283Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:05:36 PM"
    },
    "articles": [
      {
        "id": 691,
        "title": "Dichloropane",
        "slug": "dichloropane"
      }
    ],
    "markdown": "# Dichloropane · #691\n\n+{\n+  \"title\": \"Dichloropane\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Dichloropane\",\n+    \"chemical_name\": \"Methyl (2S,3S)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate\",\n+    \"alternative_name\": \"RTI-111; O-401\",\n+    \"chemical_class\": \"Phenyltropanes\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI); blocks dopamine transporter (DAT IC50: 0.79 nM); blocks serotonin transporter (SERT IC50: 3.13 nM); blocks norepinephrine transporter (NET IC50: 17.96 nM)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-50 mg\",\n+            \"heavy\": \"50+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"10-20 mg\",\n+            \"common\": \"20-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"60-90 minutes\",\n+            \"after_effects\": \"Up to several hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"60-90 minutes\",\n+            \"after_effects\": \"Up to several hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"60-90 minutes\",\n+            \"after_effects\": \"Up to several hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Dichloropane is considered moderately addictive with a high potential for abuse, though potentially less compulsive than cocaine. Chronic use can lead to psychological dependence, cravings, and withdrawal symptoms including depression, anxiety, fatigue, and intense drug cravings. Evidence suggests less motivation enhancement and compulsive redosing compared to cocaine.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and dangerous elevation of neurotransmitters)\",\n+        \"Other stimulants (severe cardiovascular strain, dangerously elevated heart rate and blood pressure, risk of cardiac arrest)\",\n+        \"Depressants including opioids and benzodiazepines (conflicting cardiovascular effects leading to irregular heart rate and potential cardiac arrest)\",\n+        \"Alcohol (masked intoxication, excessive drinking, respiratory depression when stimulant wears off, formation of potentially toxic metabolites)\"\n+      ],\n+      \"unsafe\": [\n+        \"MDMA (increased neurotoxicity and cardiotoxicity, blocks desirable effects of MDMA while increasing cardiac strain)\",\n+        \"Tramadol (increased seizure risk from combination)\",\n+        \"Psychedelics including NBOMes (severe vasoconstriction, tachycardia, hypertension, risk of heart failure in extreme cases)\"\n+      ],\n+      \"caution\": [\n+        \"Nicotine (may enhance euphoria via dopamine potentiation but increases cardiovascular strain and may promote compulsive tobacco use)\"\n+      ]\n+    },\n+    \"notes\": \"Dichloropane is a novel research chemical with very limited human use history since its appearance around 2010. Due to structural similarity to cocaine, it may carry similar cardiovascular risks including potential for sudden cardiac death at high doses and long-term cardiomyopathy. Regular insufflation can severely damage nasal tissue, causing loss of smell, nosebleeds, and chronic nasal problems. The substance is notably harsh on nasal passages and has a longer, more difficult comedown than cocaine. Always use precise milligram scales, as dosages are in the low milligram range. Start with threshold doses due to individual variation and limited safety data.\",\n+    \"subjective_effects\": [\n+      \"Mental Stimulation\",\n+      \"Thought Acceleration\",\n+      \"Focus Enhancement\",\n+      \"Appetite Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Increased Sociability\",\n+      \"Increased Libido\",\n+      \"Teeth Grinding\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\",\n+      \"Anxiety\",\n+      \"Protracted Comedown\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with prolonged and repeated use\",\n+      \"half_tolerance\": \"2-4 days\",\n+      \"zero_tolerance\": \"1-1.5 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\",\n+        \"Cocaine\",\n+        \"Amphetamines\"\n+      ]\n+    },\n+    \"half_life\": \"Not well established in humans\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: RTI-111 (Dichloropane) Experience Reports\",\n+        \"reference\": \"https://bluelight.org/xf/threads/200-mg-dichloropane-a-k-a-rti-111-first-time-is-this-so-good.576247/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Dichloropane\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Dichloropane\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combinations Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"TripSit RTI-111 Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/rti-111\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Dichloropane\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Dichloropane\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"phenyltropane\"\n+    ]\n+  },\n+  \"id\": 691\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-010254-acf6ece7",
    "createdAt": "2025-10-19T01:02:54.253Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:02:52 PM"
    },
    "articles": [
      {
        "id": 690,
        "title": "mCPP",
        "slug": "mcpp"
      }
    ],
    "markdown": "# mCPP · #690\n\n+{\n+  \"title\": \"mCPP\",\n+  \"index-category\": \"stimulant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"mCPP\",\n+    \"chemical_name\": \"1-(3-Chlorophenyl)piperazine\",\n+    \"alternative_name\": \"meta-Chlorophenylpiperazine; m-CPP\",\n+    \"chemical_class\": \"Phenylpiperazines\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT2A receptor antagonist; serotonin reuptake inhibitor; serotonin releasing agent\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20-50 mg\",\n+            \"common\": \"50-120 mg\",\n+            \"strong\": \"120-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"3-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"mCPP is not known to be addictive and lacks any reinforcing effects. Limited research exists exclusively on its addiction potential, but the predominantly negative subjective effects and dysphoric nature of the experience make recreational abuse unlikely.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (serotonin syndrome risk)\",\n+        \"Serotonin releasers such as MDMA (serotonin syndrome risk)\",\n+        \"25x-NBOMe (excessive stimulation and heart strain)\",\n+        \"25x-NBOH (excessive stimulation and heart strain)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"DXM (hypertensive crisis risk)\",\n+        \"MXE (dangerous blood pressure increase)\",\n+        \"Dissociatives (increased risk of mania and psychosis)\",\n+        \"SSRIs (serotonin syndrome risk)\",\n+        \"SNRIs (serotonin syndrome risk)\",\n+        \"5-HTP (serotonin syndrome risk)\"\n+      ],\n+      \"caution\": [\n+        \"MDMA (increased neurotoxicity)\",\n+        \"Stimulants (increased heart rate and blood pressure)\",\n+        \"Cocaine (increased cardiac strain)\",\n+        \"Alcohol (risk of over-intoxication)\",\n+        \"CYP2D6 inhibitors such as bupropion and fluoxetine (increased mCPP levels)\"\n+      ]\n+    },\n+    \"notes\": \"mCPP is widely considered unpleasant and dysphoric, inducing anxiety, headaches, and migraine attacks in susceptible individuals. It is occasionally sold as ecstasy or in party pills but lacks MDMA's euphoric effects. Individuals with personal or family histories of psychiatric disorders, panic disorder, or obsessive-compulsive disorder should avoid use as mCPP can exacerbate these conditions. CYP2D6 inhibitors including certain antidepressants and grapefruit juice significantly increase mCPP serum levels and risk of adverse effects.\",\n+    \"subjective_effects\": [\n+      \"Forced Stimulation\",\n+      \"Anxiety\",\n+      \"Dysphoria\",\n+      \"Feelings of Impending Doom\",\n+      \"Headaches and Migraines\",\n+      \"Nausea\",\n+      \"Appetite Suppression\",\n+      \"Teeth Grinding\",\n+      \"Difficulty Urinating\",\n+      \"Decreased Libido\",\n+      \"Visual Drifting\",\n+      \"Tracers\",\n+      \"Dehydration\",\n+      \"Abnormal Heartbeat\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Not well documented; likely develops with consecutive daily use\",\n+      \"half_tolerance\": \"Not well documented\",\n+      \"zero_tolerance\": \"Not well documented\",\n+      \"cross_tolerances\": [\n+        \"Other serotonergic compounds\"\n+      ]\n+    },\n+    \"half_life\": \"4-14 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid mCPP Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_mCPP.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: MCPP\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MCPP\"\n+      },\n+      {\n+        \"name\": \"Release UK: mCPP Pharmacology\",\n+        \"reference\": \"https://www.release.org.uk/drugs/mcpp/pharmacology\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: meta-Chlorophenylpiperazine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Meta-Chlorophenylpiperazine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"phenylpiperazine\",\n+      \"research-chemical\",\n+      \"designer-drug\"\n+    ]\n+  },\n+  \"id\": 690\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-010042-885eccf5",
    "createdAt": "2025-10-19T01:00:42.490Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 7:00:41 PM"
    },
    "articles": [
      {
        "id": 689,
        "title": "Pentedrone",
        "slug": "pentedrone"
      }
    ],
    "markdown": "# Pentedrone · #689\n\n+{\n+  \"title\": \"Pentedrone\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Pentedrone\",\n+    \"chemical_name\": \"2-(Methylamino)-1-phenylpentan-1-one\",\n+    \"alternative_name\": \"Drone; Alpha-methylamino-valerophenone\",\n+    \"chemical_class\": \"Cathinone\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Norepinephrine-dopamine reuptake inhibitor (NDRI); minimal serotonin activity\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-25 mg\",\n+            \"heavy\": \"25+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-6 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-10 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-4 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Pentedrone is considered moderately addictive with a high potential for abuse and is readily liable to cause psychological dependence. It has a notable tendency to induce compulsive redosing behaviors and can readily induce paranoid, delusional states and stimulant psychosis when abused.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"25x-NBOMe and 25x-NBOH (risk of excessive stimulation, vasoconstriction, panic attacks, seizures, and heart failure)\",\n+        \"MAOIs (dangerous increase in neurotransmitter levels)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased heart rate and blood pressure to dangerous levels)\",\n+        \"Cocaine (increased strain on the heart)\",\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"MXE (may dangerously increase blood pressure and risk of mania and psychosis)\",\n+        \"Dissociatives (multiplied risk of delusions, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (masks depressant effects, risk of over-intoxication and respiratory depression)\",\n+        \"DXM (increased risk of panic attacks, hypertensive crisis, or serotonin syndrome)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ]\n+    },\n+    \"notes\": \"Pentedrone is a Schedule I controlled substance in the United States and is illegal in many countries. The toxicity and long-term health effects have not been studied in scientific contexts, and exact toxic dosage is unknown. Use accurate milligram scales for dosing. Individuals with cardiovascular conditions or personal or family histories of psychotic disorders should avoid use. Harm reduction practices are strongly recommended including starting with low doses, avoiding combinations, and having a sober sitter present.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Focus Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Compulsive Redosing\",\n+      \"Appetite Suppression\",\n+      \"Increased Heart Rate\",\n+      \"Vasoconstriction\",\n+      \"Teeth Grinding\",\n+      \"Dehydration\",\n+      \"Anxiety\",\n+      \"Paranoia\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Pentedrone\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Pentedrone\"\n+      },\n+      {\n+        \"name\": \"Pentedrone - Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Pentedrone\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: Pentedrone\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Pentedrone.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Pentedrone Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pentedrone.588475/\"\n+      },\n+      {\n+        \"name\": \"Simmler et al. - Monoamine transporter and receptor interaction profiles of designer cathinones\",\n+        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2013.11.008\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"cathinone\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 689\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-005548-966b1fad",
    "createdAt": "2025-10-19T00:55:48.089Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:55:46 PM"
    },
    "articles": [
      {
        "id": 688,
        "title": "Mexedrone",
        "slug": "mexedrone"
      }
    ],
    "markdown": "# Mexedrone · #688\n\n+{\n+  \"title\": \"Mexedrone\",\n+  \"index-category\": \"stimulant; entactogen; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Mexedrone\",\n+    \"chemical_name\": \"3-methoxy-2-(methylamino)-1-(p-tolyl)propan-1-one\",\n+    \"alternative_name\": \"4-MMC-MeO\",\n+    \"chemical_class\": \"Cathinones; Substituted cathinones\",\n+    \"psychoactive_class\": \"Stimulant; Entactogen\",\n+    \"mechanism_of_action\": \"Serotonin releasing agent; serotonin reuptake inhibitor; dopamine reuptake inhibitor (weak); norepinephrine reuptake inhibitor (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100-150 mg\",\n+            \"common\": \"150-250 mg\",\n+            \"strong\": \"250-350 mg\",\n+            \"heavy\": \"350+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"60-80 mg\",\n+            \"common\": \"80-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"peak\": \"1.5-2.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Mexedrone can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. However, anecdotal reports suggest it is less compulsive than mephedrone.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome)\",\n+        \"Serotonin releasers such as MDMA, methylone (risk of serotonin syndrome)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"25x-NBOMe and 25x-NBOH (risk of excessive stimulation, heart strain, and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"MXE (may dangerously increase blood pressure and risk of mania)\",\n+        \"Dissociatives (increased risk of delusions, mania, and psychosis)\",\n+        \"Other stimulants including cocaine (increased heart rate and blood pressure)\",\n+        \"MDMA (any neurotoxic effects are likely increased)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (stimulants mask alcohol's depressant effects, risk of over-intoxication)\",\n+        \"DXM (increased risk of panic attacks and hypertensive crisis)\",\n+        \"SSRIs such as citalopram and sertraline (serotonin syndrome risk)\",\n+        \"SNRIs such as venlafaxine (serotonin syndrome risk)\",\n+        \"5-HTP (serotonin syndrome risk)\"\n+      ]\n+    },\n+    \"notes\": \"Mexedrone is a research chemical with very little history of human use prior to 2015. It was marketed as a legal alternative to mephedrone but is reported to be approximately 10-20 times weaker in potency, requiring higher doses to achieve comparable effects. The substance has been associated with significant sedation rather than stimulation, distinguishing it from mephedrone. Legal status varies by jurisdiction; it is controlled in Sweden, Switzerland, Brazil, and the United Kingdom under blanket bans on cathinones or psychoactive substances. Users should employ accurate milligram scales and practice harm reduction. Clinical reports have documented cases of severe agitation, aggression, delusions, hallucinations with paranoid and supernatural themes, and tachycardia requiring sedation and restraint.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Sedation\",\n+      \"Warm Tingling Sensations\",\n+      \"Mild Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Thought Connectivity\",\n+      \"Auditory Enhancement\",\n+      \"Dehydration\",\n+      \"Increased Perspiration\",\n+      \"Temperature Dysregulation\",\n+      \"Teeth Grinding\",\n+      \"Nystagmus (Eye Wiggles)\",\n+      \"Anxiety\",\n+      \"Cognitive Fatigue\",\n+      \"Depression (Comedown)\",\n+      \"Irritability\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\",\n+        \"Mephedrone\",\n+        \"Other cathinones\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight Mexedrone Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/mexedrone.764088/\"\n+      },\n+      {\n+        \"name\": \"McLaughlin et al. (2017) - Synthesis, characterization and monoamine transporter activity of mexedrone\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/dta.2053\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Mexedrone\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Mexedrone\"\n+      },\n+      {\n+        \"name\": \"WEDINOS Mexedrone Sample Analysis\",\n+        \"reference\": \"http://www.wedinos.org/db/materials/view/00716\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Mexedrone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Mexedrone\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"entactogen\",\n+      \"cathinone\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 688\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-005147-32f2354c",
    "createdAt": "2025-10-19T00:51:47.043Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:51:44 PM"
    },
    "articles": [
      {
        "id": 687,
        "title": "Methylone",
        "slug": "methylone"
      }
    ],
    "markdown": "# Methylone · #687\n\n+{\n+  \"title\": \"Methylone\",\n+  \"index-category\": \"stimulant; entactogen; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Methylone\",\n+    \"chemical_name\": \"3,4-Methylenedioxy-N-methylcathinone\",\n+    \"alternative_name\": \"bk-MDMA; M1; MDMC; beta-keto-MDMA\",\n+    \"chemical_class\": \"Cathinones; Substituted phenethylamines\",\n+    \"psychoactive_class\": \"Stimulant; Entactogen\",\n+    \"mechanism_of_action\": \"Serotonin-norepinephrine-dopamine releasing agent (SNDRA); serotonin reuptake inhibitor; norepinephrine reuptake inhibitor; dopamine reuptake inhibitor\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"75 mg\",\n+            \"light\": \"75-150 mg\",\n+            \"common\": \"150-225 mg\",\n+            \"strong\": \"225-325 mg\",\n+            \"heavy\": \"325+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2.5-4 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"60-90 minutes\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Methylone can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. Compulsive redosing is commonly reported due to the drug's shorter duration compared to MDMA. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome)\",\n+        \"25x-NBOMe and 25x-NBOH (risk of excessive stimulation, heart strain, seizures, and heart failure)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (increased risk of hypertensive crisis and serotonin syndrome)\",\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"MXE (may dangerously increase blood pressure and risk of mania and psychosis)\",\n+        \"Other dissociatives (multiplied risk of delusions, mania, and psychosis)\",\n+        \"Other stimulants including cocaine (dangerous increases in heart rate and blood pressure)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"SSRIs (risk of serotonin syndrome)\",\n+        \"SNRIs (risk of serotonin syndrome)\",\n+        \"5-HTP (risk of serotonin syndrome)\",\n+        \"Other serotonin releasers (risk of serotonin syndrome)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (risk of accidental over-intoxication and severe respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Methylone has a very limited history of human usage and its long-term health effects have not been well-studied in any scientific context. It is strongly recommended to use harm reduction practices including reagent testing, as methylone was frequently mis-sold as MDMA until its scheduling. Accurate weighing with a milligram scale is essential. The drug's shorter duration and reduced empathogenic effects compared to MDMA may lead to compulsive redosing. Users should space sessions at least 2-4 weeks apart to allow serotonin levels to recover and avoid tolerance buildup.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Cognitive Euphoria\",\n+      \"Empathy Enhancement\",\n+      \"Sociability Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Compression\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Pupil Dilation\",\n+      \"Teeth Grinding\",\n+      \"Dehydration\",\n+      \"Difficulty Urinating\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"1-3 weeks\",\n+      \"zero_tolerance\": \"3-6 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\",\n+        \"MDMA and other serotonergic entactogens\"\n+      ]\n+    },\n+    \"half_life\": \"5.8-6.9 hours (following oral doses of 50-200 mg)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy bk-MDMA (Methylone) Thread\",\n+        \"reference\": \"https://bluelight.org/\"\n+      },\n+      {\n+        \"name\": \"Erowid Methylone Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/methylone/\"\n+      },\n+      {\n+        \"name\": \"Erowid Methylone Vault: Dosage\",\n+        \"reference\": \"https://www.erowid.org/chemicals/methylone/methylone_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Methylone Vault: Effects\",\n+        \"reference\": \"https://erowid.org/chemicals/methylone/methylone_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Methylone\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Methylone\"\n+      },\n+      {\n+        \"name\": \"TripSit Factsheets: Methylone\",\n+        \"reference\": \"https://drugs.tripsit.me/methylone\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Drug Combinations\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Methylone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylone\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"entactogen\",\n+      \"cathinone\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 687\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-004923-e44f20d4",
    "createdAt": "2025-10-19T00:49:23.049Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:49:21 PM"
    },
    "articles": [
      {
        "id": 686,
        "title": "Ethylone",
        "slug": "ethylone"
      }
    ],
    "markdown": "# Ethylone · #686\n\n+{\n+  \"title\": \"Ethylone\",\n+  \"index-category\": \"stimulant; entactogen; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Ethylone\",\n+    \"chemical_name\": \"3,4-methylenedioxy-N-ethylcathinone\",\n+    \"alternative_name\": \"bk-MDEA; MDEC; 3,4-MDEC\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"psychoactive_class\": \"Stimulant; Entactogen\",\n+    \"mechanism_of_action\": \"Serotonin reuptake inhibitor and releaser; norepinephrine reuptake inhibitor and releaser; dopamine reuptake inhibitor and releaser\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"75 mg\",\n+            \"light\": \"75-150 mg\",\n+            \"common\": \"150-225 mg\",\n+            \"strong\": \"225-325 mg\",\n+            \"heavy\": \"325+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"60-120 minutes\",\n+            \"after_effects\": \"2-12 hours (residual stimulation)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Ethylone is moderately addictive with a high potential for abuse and can cause psychological dependence among certain users. Users report compulsive redosing tendencies, and chronic use can lead to cravings and withdrawal effects if usage is suddenly stopped. Evidence suggests it may be more reinforcing than methylone for some individuals.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome)\",\n+        \"SSRIs (risk of serotonin syndrome)\",\n+        \"SNRIs (risk of serotonin syndrome)\",\n+        \"Serotonin releasers such as MDMA, methylone, and mephedrone (risk of serotonin syndrome)\",\n+        \"5-HTP (risk of serotonin syndrome)\",\n+        \"25x-NBOMe and 25x-NBOH (risk of excessive stimulation, heart strain, seizures)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Lithium (potential seizure risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Other stimulants (increased heart rate and blood pressure)\",\n+        \"Cocaine (increased cardiovascular strain)\",\n+        \"DXM (increased risk of panic attacks and hypertensive crisis)\",\n+        \"MXE (may dangerously increase blood pressure and psychosis risk)\",\n+        \"Dissociatives (increased risk of delusions, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (risk of accidental over-intoxication; stimulants mask depressant effects)\"\n+      ]\n+    },\n+    \"notes\": \"Ethylone is significantly less potent than MDMA and methylone, producing more classical stimulant effects with reduced empathogenic qualities. Users should weigh dosages carefully on a precision scale (0.001g) due to variable potency. Set and setting remain important factors. Individuals with cardiovascular conditions, personal or family histories of psychotic disorders, or those taking psychiatric medications (especially lithium or MAOIs) should avoid use. Prolonged residual stimulation can make sleep difficult; plan accordingly. Oily meals may delay onset significantly (up to 2 hours). Adequate hydration is essential, but avoid overdrinking. Since late 2011, ethylone has commonly been sold as a substitute for MDMA or methylone; always test substances before use.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Stimulation\",\n+      \"Tactile Enhancement\",\n+      \"Empathy and Sociability Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Increased Libido\",\n+      \"Teeth Grinding\",\n+      \"Dehydration\",\n+      \"Temperature Regulation Suppression\",\n+      \"Vibrating Vision\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Ethylone\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Ethylone\"\n+      },\n+      {\n+        \"name\": \"Erowid: bk-MDEA (Ethylone) Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/bk_mdea/\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Ethylone / BK-MDEA Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/ethylone-bk-mdea.590326/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ethylone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ethylone\"\n+      },\n+      {\n+        \"name\": \"Cozzi et al. (1999) - Beta-ketoamphetamine transporter inhibition\",\n+        \"reference\": \"https://doi.org/10.1016/s0014-2999(99)00538-5\"\n+      },\n+      {\n+        \"name\": \"Simmler et al. (2013) - Pharmacological characterization of designer cathinones\",\n+        \"reference\": \"https://doi.org/10.1111/j.1476-5381.2012.02145.x\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"entactogen\",\n+      \"research-chemical\",\n+      \"cathinone\"\n+    ]\n+  },\n+  \"id\": 686\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-004652-290e9cca",
    "createdAt": "2025-10-19T00:46:52.711Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:46:47 PM"
    },
    "articles": [
      {
        "id": 685,
        "title": "Khat",
        "slug": "khat"
      }
    ],
    "markdown": "# Khat · #685\n\n+{\n+  \"title\": \"Khat\",\n+  \"index-category\": \"stimulant; plant-based\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Khat\",\n+    \"chemical_name\": \"Cathinone (S-(-)-2-amino-1-phenylpropan-1-one)\",\n+    \"alternative_name\": \"Qat; Kat; Chat; Miraa; Gat; Arabian Tea; Abyssinian Tea; Jaad; Qaad\",\n+    \"chemical_class\": \"Phenethylamines; Cathinones\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Dopamine releaser; norepinephrine releaser; serotonin releaser; weak monoamine oxidase inhibitor\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (chewed)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-40 g\",\n+            \"light\": \"40-100 g\",\n+            \"common\": \"100-200 g\",\n+            \"strong\": \"200-300 g\",\n+            \"heavy\": \"300+ g\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (chewed)\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"2-3 hours (plasma cathinone peaks at approximately 2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to several hours (may include insomnia, numbness, difficulty concentrating)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Khat produces moderate psychological dependence, particularly with chronic use. The World Health Organization classifies it as having less addictive potential than alcohol or tobacco. Physical dependence is uncommon, but psychological cravings and compulsive redosing patterns can develop with regular use. Withdrawal symptoms, while generally mild, may include depression, irritability, fatigue, and lethargy.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and cerebral hemorrhage)\",\n+        \"Other stimulants including amphetamines and cocaine (increased risk of cardiovascular complications, overheating, and heart attack)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Antihypertensive medications (khat may reduce effectiveness)\",\n+        \"Caffeine and nicotine (potentiate stimulant effects)\",\n+        \"Amoxicillin and ampicillin (khat interferes with absorption)\",\n+        \"Diabetes medications (may affect blood glucose regulation)\"\n+      ]\n+    },\n+    \"notes\": \"Khat's potency degrades rapidly after harvesting; fresh leaves (within 24-48 hours) contain the highest cathinone content, while older leaves primarily contain the weaker cathine. Legal status varies dramatically worldwide: it is Schedule I in the United States, Class C in the UK, and illegal in most of Europe and Canada, but remains legal and culturally significant in Yemen, Somalia, Ethiopia, Kenya, and Djibouti. Chronic use is associated with cardiovascular problems, oral health issues, and gastrointestinal complications. Individuals with heart conditions, hypertension, or psychiatric disorders should avoid use. The traditional chewing method involves holding the material in the cheek for extended periods during 3-4 hour sessions.\",\n+    \"subjective_effects\": [\n+      \"Increased Energy and Alertness\",\n+      \"Mild Euphoria\",\n+      \"Enhanced Talkativeness and Sociability\",\n+      \"Decreased Appetite\",\n+      \"Mental Clarity and Focus\",\n+      \"Increased Confidence\",\n+      \"Insomnia\",\n+      \"Irritability (at higher doses)\",\n+      \"Anxiety and Restlessness (at higher doses)\",\n+      \"Paranoia or Psychosis (rare, with chronic heavy use)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with regular daily use within several days to weeks\",\n+      \"half_tolerance\": \"3-7 days after cessation\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Amphetamines\",\n+        \"Methamphetamine\",\n+        \"Other cathinone derivatives\",\n+        \"Cocaine (partial cross-tolerance)\"\n+      ]\n+    },\n+    \"half_life\": \"3-5 hours (cathinone); 10+ hours (cathine and norephedrine metabolites)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Khat Vault\",\n+        \"reference\": \"https://www.erowid.org/plants/khat/khat.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Khat Basics\",\n+        \"reference\": \"https://www.erowid.org/plants/khat/khat_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Khat Chemistry Notes\",\n+        \"reference\": \"https://www.erowid.org/plants/khat/khat_info4.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Khat\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Talk:Khat\"\n+      },\n+      {\n+        \"name\": \"European Drug Report: Khat Drug Profile\",\n+        \"reference\": \"https://www.euda.europa.eu/publications/drug-profiles/khat_en\"\n+      },\n+      {\n+        \"name\": \"Khat: A Widely Used Drug of Abuse - PMC\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC3991038/\"\n+      },\n+      {\n+        \"name\": \"Khat, a Cultural Chewing Drug: Toxicokinetic and Toxicodynamic Summary - PMC\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8875844/\"\n+      },\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: Khat\",\n+        \"reference\": \"https://adf.org.au/drug-facts/khat/\"\n+      },\n+      {\n+        \"name\": \"Drugs.com: Khat Uses, Benefits & Dosage\",\n+        \"reference\": \"https://www.drugs.com/npp/khat.html\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Cathinone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Cathinone\"\n+      },\n+      {\n+        \"name\": \"Erowid Khat Legal Status\",\n+        \"reference\": \"https://erowid.org/plants/khat/khat_law.shtml\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"cathinone\",\n+      \"plant-based\",\n+      \"natural\"\n+    ]\n+  },\n+  \"id\": 685\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-004153-19102c80",
    "createdAt": "2025-10-19T00:41:53.185Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:41:51 PM"
    },
    "articles": [
      {
        "id": 684,
        "title": "Methylnaphthidate",
        "slug": "methylnaphthidate"
      }
    ],
    "markdown": "# Methylnaphthidate · #684\n\n+{\n+  \"title\": \"Methylnaphthidate\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Methylnaphthidate\",\n+    \"chemical_name\": \"Methyl (naphthalen-2-yl)(piperidin-2-yl)acetate\",\n+    \"alternative_name\": \"HDMP-28; Methylnapthidate\",\n+    \"chemical_class\": \"Phenidates\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Monoamine triple reuptake inhibitor (dopamine, norepinephrine, serotonin)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"4-8 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-50 mg\",\n+            \"heavy\": \"50+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"4-8 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-5 hours\",\n+            \"onset\": \"1-10 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"1-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Methylnaphthidate has abuse potential comparable to amphetamine, cocaine, or methylphenidate due to its euphoric effects and action on dopamine and serotonin transporters. Acute tolerance develops gradually with repeated extended use, though it is generally considered less recreational than traditional stimulants. Compulsive redosing may occur due to its short-lived euphoric rush.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"25x-NBOMe and 25x-NBOH (excessive stimulation, heart strain, seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"Stimulants and Cocaine (dangerous heart rate and blood pressure elevation)\",\n+        \"MXE (risk of elevated blood pressure, mania, and psychosis)\",\n+        \"Dissociatives (increased risk of delusions, mania, and psychosis)\",\n+        \"DXM (risk of hypertensive crisis and serotonin syndrome)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (stimulants mask depressant effects, risk of over-intoxication)\"\n+      ]\n+    },\n+    \"notes\": \"Methylnaphthidate is a research chemical with very little data on its pharmacological properties, metabolism, and toxicity. It has a limited history of human use and appeared on the research chemical market around 2014. Unlike typical methylphenidate analogs, it displays notable serotonin reuptake inhibition, giving it subjective effects more similar to cocaine or amphetamine. Use precise weighing equipment and start with low doses. Some users report nasal irritation and throat discomfort when insufflated. The naphthalene structure has raised theoretical toxicity concerns, though metabolic pathways likely produce readily excreted acid metabolites. Exercise extreme caution and employ comprehensive harm reduction practices.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Focus Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Thought Acceleration\",\n+      \"Euphoria (Short-Lived And Compulsive)\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Appetite Suppression\",\n+      \"Dehydration\",\n+      \"Increased Heart Rate (Particularly Pronounced)\",\n+      \"Teeth Grinding\",\n+      \"Time Distortion\",\n+      \"Anxiety (During Comedown)\",\n+      \"Cognitive Fatigue (During Comedown)\",\n+      \"Depression (During Comedown)\",\n+      \"Irritability (During Comedown)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After multiple consecutive days of extended use\",\n+      \"half_tolerance\": \"2-4 days\",\n+      \"zero_tolerance\": \"1 week\",\n+      \"cross_tolerances\": [\n+        \"Other phenidates (methylphenidate, ethylphenidate, isopropylphenidate)\",\n+        \"Dopaminergic stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"1-2 hours (short duration of action)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: HDMP-28 or Methylnaphthidate Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/hdmp-28-or-methylnaphthidate.492618/\"\n+      },\n+      {\n+        \"name\": \"Bluelight: New Stimulant Methylnaphthidate Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/new-stimulant-methylnaphthidate-or-hdmp-28.739961/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: HDMP-28 Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/HDMP-28\"\n+      },\n+      {\n+        \"name\": \"Erowid: HDMP-28 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_HDMP28.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Methylnaphthidate\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Methylnaphthidate\"\n+      },\n+      {\n+        \"name\": \"The Drug Classroom: HDMP-28\",\n+        \"reference\": \"https://thedrugclassroom.com/video/hdmp-28/\"\n+      },\n+      {\n+        \"name\": \"TripSit: HDMP-28 Factsheet\",\n+        \"reference\": \"https://tripbot.tripsit.me/factsheet/HDMP-28\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: HDMP-28\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/HDMP-28\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"phenidate\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 684\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-003853-f1d88ece",
    "createdAt": "2025-10-19T00:38:53.855Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:38:52 PM"
    },
    "articles": [
      {
        "id": 683,
        "title": "4F-EPH",
        "slug": "4f-eph"
      }
    ],
    "markdown": "# 4F-EPH · #683\n\n+{\n+  \"title\": \"4F-EPH\",\n+  \"index-category\": \"stimulant; phenidate; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4F-EPH\",\n+    \"chemical_name\": \"Ethyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate\",\n+    \"alternative_name\": \"4-Fluoroethylphenidate; 4-FEPH\",\n+    \"chemical_class\": \"Phenidate; Substituted phenethylamine\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Dopamine reuptake inhibitor; Norepinephrine reuptake inhibitor (likely triple monoamine reuptake inhibitor)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-6 hours\",\n+            \"onset\": \"10-25 minutes\",\n+            \"after_effects\": \"4-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4F-EPH can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. When addiction develops, cravings and withdrawal effects may occur upon cessation. Anecdotal reports suggest it is less compulsive than ethylphenidate but still presents redosing urges.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"25x-NBOMe (risk of excessive stimulation, heart strain, panic attacks, seizures)\",\n+        \"25x-NBOH (risk of excessive stimulation and heart strain)\",\n+        \"MAOIs (potentially fatal increase in neurotransmitter levels)\"\n+      ],\n+      \"unsafe\": [\n+        \"Alcohol (risk of over-intoxication as stimulant masks depressant effects)\",\n+        \"DXM (increased risk of panic attacks and hypertensive crisis)\",\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"MXE (dangerously increased blood pressure, risk of mania and psychosis)\",\n+        \"Dissociatives (increased risk of delusions, mania, and psychosis)\",\n+        \"Other stimulants (dangerous increase in heart rate and blood pressure)\",\n+        \"Tramadol (lowered seizure threshold)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"4F-EPH is a novel research chemical with minimal human use history and unknown long-term toxicity. It is notably less caustic to nasal cavities than ethylphenidate but still causes mild to moderate damage with intranasal use. Users should perform sterile saline nasal rinses after insufflation and allow adequate recovery time between uses. The substance was controlled in the UK as a Class B drug on May 31, 2017, and is illegal in several other countries including Germany, Switzerland, and Turkey. Always use accurate weighing equipment and practice proper harm reduction.\",\n+    \"subjective_effects\": [\n+      \"Mild To Moderate Stimulation\",\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Focus Enhancement\",\n+      \"Thought Acceleration\",\n+      \"Increased Music Appreciation\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Appetite Suppression\",\n+      \"Increased Libido\",\n+      \"Pupil Dilation\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dopaminergic stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight 4F-EPH Review Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4f-eph-review.873749/\"\n+      },\n+      {\n+        \"name\": \"Bluelight 4F-MPH vs 4F-EPH Discussion\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-fluoromethylphenidate-4f-mph-vs-4-fluoromethylphenidate-4f-eph.781436/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 4F-EPH Thread\",\n+        \"reference\": \"https://drugs-forum.com/threads/4f-eph.291385/\"\n+      },\n+      {\n+        \"name\": \"First Death Involving 4F-EPH Case Report (PMC)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9761242/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki 4F-EPH\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4F-EPH\"\n+      },\n+      {\n+        \"name\": \"Wikipedia 4-Fluoroethylphenidate\",\n+        \"reference\": \"https://en.m.wikipedia.org/wiki/4-Fluoroethylphenidate\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"phenidate\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 683\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-003622-11152e97",
    "createdAt": "2025-10-19T00:36:22.165Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:36:20 PM"
    },
    "articles": [
      {
        "id": 682,
        "title": "3,4-Dichloromethylphenidate",
        "slug": "3-4-dichloromethylphenidate"
      }
    ],
    "markdown": "# 3,4-Dichloromethylphenidate · #682\n\n+{\n+  \"title\": \"3,4-Dichloromethylphenidate\",\n+  \"index-category\": \"stimulant; phenidate\",\n+  \"drug_info\": {\n+    \"drug_name\": \"3,4-Dichloromethylphenidate\",\n+    \"chemical_name\": \"Methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate\",\n+    \"alternative_name\": \"3,4-CTMP; 3,4-DCMP; Dichloromethylphenidate\",\n+    \"chemical_class\": \"Phenidates\",\n+    \"psychoactive_class\": \"Stimulant\",\n+    \"mechanism_of_action\": \"Dopamine reuptake inhibitor; norepinephrine reuptake inhibitor; 5-HT2B receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 mg\",\n+            \"light\": \"2-4 mg\",\n+            \"common\": \"4-6 mg\",\n+            \"strong\": \"6-8 mg\",\n+            \"heavy\": \"8+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-18 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"4-8 hours\",\n+            \"after_effects\": \"2-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"3,4-CTMP has been reported to have abuse potential comparable to amphetamine or MDMA due to its dopaminergic activity. Tolerance builds gradually over extended use rather than acutely, with some reports indicating sudden increases in tolerance after prolonged use. The extremely long duration and slow onset may reduce compulsive redosing compared to faster-acting stimulants, but dependency on the substance for wakefulness and productivity can develop with regular use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis)\",\n+        \"25x-NBOMe (risk of excessive stimulation, heart strain, seizures)\",\n+        \"25x-NBOH (risk of excessive stimulation, heart strain, seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Alcohol (masks depressant effects, risk of over-intoxication)\",\n+        \"DXM (risk of panic attacks, hypertensive crisis)\",\n+        \"MDMA (increased neurotoxicity and cardiotoxicity)\",\n+        \"MXE (dangerous blood pressure increases, mania risk)\",\n+        \"Dissociatives (increased risk of delusions, mania, psychosis)\",\n+        \"Stimulants (dangerous increases in heart rate and blood pressure)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"3,4-CTMP is approximately seven times more potent than methylphenidate and has a significantly longer duration of 6-18 hours. A critical safety concern is its agonist activity at 5-HT2B receptors, which can cause pulmonary hypertension and heart valve fibrosis with repeated use. Insufflation is strongly discouraged as the substance has low water solubility, is extremely caustic to nasal tissues, and has poor absorption leading to delayed onset that increases overdose risk. Users must use precise milligram scales due to the extremely low active doses. The very long onset (1-2 hours) and extended duration require careful dose timing to avoid unwanted sleep disruption and accidental overdoses from premature redosing.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Focus Enhancement\",\n+      \"Motivation Enhancement\",\n+      \"Appetite Suppression\",\n+      \"Wakefulness\",\n+      \"Increased Heart Rate\",\n+      \"Vasoconstriction\",\n+      \"Dehydration\",\n+      \"Teeth Grinding\",\n+      \"Thought Acceleration\",\n+      \"Analysis Enhancement\",\n+      \"Time Distortion\",\n+      \"Euphoria (inconsistent)\",\n+      \"Anxiety (at higher doses)\",\n+      \"Headaches\",\n+      \"Pupil Dilation\",\n+      \"Temporary Erectile Dysfunction\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Does not develop acutely; instead builds gradually over regular and extended use\",\n+      \"half_tolerance\": \"Variable; some reports indicate sudden increases after prolonged use\",\n+      \"zero_tolerance\": \"2-4 weeks of abstinence\",\n+      \"cross_tolerances\": [\n+        \"Methylphenidate\",\n+        \"Other phenidates\",\n+        \"Dopaminergic stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Davies et al. (2004) - Synthesis and binding affinities\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/15026073/\"\n+      },\n+      {\n+        \"name\": \"Davidson et al. (2018) - Neurochemical assessment in rat nucleus accumbens\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29892233/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 3,4-CTMP Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/3_4-CTMP\"\n+      },\n+      {\n+        \"name\": \"Erowid 3,4-Dichloromethylphenidate Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_34Dichloromethylphenidate.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki 3,4-CTMP\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/3,4-CTMP\"\n+      },\n+      {\n+        \"name\": \"Wikipedia 3,4-Dichloromethylphenidate\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/3,4-Dichloromethylphenidate\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"stimulant\",\n+      \"phenidate\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 682\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-003309-bca10adf",
    "createdAt": "2025-10-19T00:33:09.305Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:33:06 PM"
    },
    "articles": [
      {
        "id": 681,
        "title": "U-47700",
        "slug": "u-47700"
      }
    ],
    "markdown": "# U-47700 · #681\n\n+{\n+  \"title\": \"U-47700\",\n+  \"index-category\": \"opioid; research-chemical; synthetic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"U-47700\",\n+    \"chemical_name\": \"trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide\",\n+    \"alternative_name\": \"U4; Pink; Pinky\",\n+    \"chemical_class\": \"Benzamides\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"mu-opioid receptor agonist (selective); kappa-opioid receptor agonist (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-5 mg\",\n+            \"light\": \"5-7.5 mg\",\n+            \"common\": \"7.5-15 mg\",\n+            \"strong\": \"15-25 mg\",\n+            \"heavy\": \"25+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"4-6 mg\",\n+            \"common\": \"6-8 mg\",\n+            \"strong\": \"8-10 mg\",\n+            \"heavy\": \"10+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5-1 mg\",\n+            \"light\": \"2-4 mg\",\n+            \"common\": \"4-6 mg\",\n+            \"strong\": \"6-8 mg\",\n+            \"heavy\": \"8+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 mg\",\n+            \"light\": \"4-6 mg\",\n+            \"common\": \"6-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"10-15 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"0-1 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ]\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"stages\": {\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"10-15 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"U-47700 has extremely high addiction potential with rapid development of physical and psychological dependence. The short duration and intense effects drive compulsive redosing behavior. Physical dependence can develop within days of regular use, and withdrawal symptoms emerge as quickly as 2-4 hours after the last dose, making cessation particularly difficult and painful.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (severe respiratory depression, unconsciousness, vomit aspiration risk)\",\n+        \"Benzodiazepines (unpredictable potentiation, rapid unconsciousness, respiratory arrest)\",\n+        \"GHB/GBL (severe CNS depression, unconsciousness, vomit aspiration risk)\",\n+        \"Ketamine (unconsciousness, vomit aspiration risk)\",\n+        \"MAOIs (severe adverse reactions including hypertension, hyperpyrexia, seizures, coma)\",\n+        \"Nitrous oxide (severe ataxia, unconsciousness, vomit aspiration risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (CNS depression, respiratory issues, heart problems, liver toxicity)\",\n+        \"MXE (potentiated effects, increased organ toxicity risk)\",\n+        \"PCP (reduced opioid tolerance, increased overdose risk)\",\n+        \"Tramadol (increased seizure risk, additive CNS depression)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masks respiratory depression, overdose risk when stimulant wears off)\",\n+        \"Grapefruit (may inhibit metabolism, increasing toxicity with repeated doses)\"\n+      ]\n+    },\n+    \"notes\": \"U-47700 is an extremely dangerous synthetic opioid with approximately 7.5 times the potency of morphine and very little history of human use. It is uniquely caustic to mucous membranes and can cause severe tissue damage with insufflated, sublingual, or smoked administration. A laboratory-grade milligram scale is absolutely essential as sub-milligram differences can mean the difference between an active dose and fatal overdose. Respiratory depression is reportedly more severe than with traditional opioids at equivalent doses. U-47700 is now illegal in most jurisdictions worldwide following numerous overdose deaths. The substance should never be vaporized as it severely damages lung tissue, and nasal administration requires diligent saline rinses to prevent permanent nasal damage.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Pain Relief\",\n+      \"Anxiety Suppression\",\n+      \"Sedation\",\n+      \"Respiratory Depression\",\n+      \"Itchiness\",\n+      \"Pupil Constriction\",\n+      \"Constipation\",\n+      \"Cough Suppression\",\n+      \"Difficulty Urinating\",\n+      \"Compulsive Redosing\",\n+      \"Cognitive Fatigue\",\n+      \"Thought Deceleration\",\n+      \"Decreased Libido\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All opioids (morphine, heroin, fentanyl, oxycodone, hydrocodone)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated from duration data)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: Novel Opioid U-47700 Mega Thread and FAQ\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/739960-Novel-opioid-U-47700-Mega-Thread-and-FAQ\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: U-47700\",\n+        \"reference\": \"https://drugs-forum.com/wiki/U-47700\"\n+      },\n+      {\n+        \"name\": \"Erowid: U-47700 Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/u-47700/u-47700.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: U-47700\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/U-47700\"\n+      },\n+      {\n+        \"name\": \"TripSit: U-47700 Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/u-47700\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: U-47700\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/U-47700\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"synthetic-opioid\",\n+      \"research-chemical\",\n+      \"benzamide\"\n+    ]\n+  },\n+  \"id\": 681\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-003039-3369ddd3",
    "createdAt": "2025-10-19T00:30:39.462Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:30:37 PM"
    },
    "articles": [
      {
        "id": 680,
        "title": "Oxymorphone",
        "slug": "oxymorphone"
      }
    ],
    "markdown": "# Oxymorphone · #680\n\n+{\n+  \"title\": \"Oxymorphone\",\n+  \"index-category\": \"opioid; depressant; semi-synthetic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Oxymorphone\",\n+    \"chemical_name\": \"(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one\",\n+    \"alternative_name\": \"Opana; Numorphan; Stop Signs\",\n+    \"chemical_class\": \"Morphinans\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist; delta-opioid receptor agonist (weak); kappa-opioid receptor agonist (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2.5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 mg\",\n+            \"light\": \"2-4 mg\",\n+            \"common\": \"4-6 mg\",\n+            \"strong\": \"6-8 mg\",\n+            \"heavy\": \"8+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Up to 6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"6-14 hours\",\n+            \"onset\": \"1-1.5 hours\",\n+            \"peak\": \"3-5 hours\",\n+            \"offset\": \"4-8 hours\",\n+            \"after_effects\": \"Up to 12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"stages\": {\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-45 minutes\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"Up to 8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Oxymorphone carries an extremely high potential for psychological and physical dependence. Chronic use leads to rapid tolerance development and severe physical dependence, with withdrawal symptoms occurring upon cessation. The drug's potent euphoric effects and compulsive redosing patterns make it highly addictive, comparable to or exceeding other strong opioids like morphine and heroin.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (severe respiratory depression and unconsciousness risk)\",\n+        \"Benzodiazepines (unpredictable potentiation leading to unconsciousness)\",\n+        \"GHB/GBL (rapid unconsciousness and respiratory arrest)\",\n+        \"MAOIs (excitatory or depressive reactions; potentially fatal)\",\n+        \"Other CNS depressants (compounding respiratory depression)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (CNS depression, respiratory difficulty, cardiac issues, hepatotoxicity)\",\n+        \"Ketamine (vomit aspiration risk when unconscious)\",\n+        \"MXE (increased respiratory depression and organ toxicity)\",\n+        \"Nitrous oxide (unexpected loss of consciousness and memory blackouts)\",\n+        \"PCP (may reduce opioid tolerance, increasing overdose risk)\",\n+        \"Stimulants (masked respiratory depression; overdose when stimulant wears off)\",\n+        \"Tramadol (increased seizure risk and additive CNS depression)\"\n+      ],\n+      \"caution\": [\n+        \"Grapefruit (may inhibit CYP3A4 metabolism, increasing toxicity with repeated doses)\"\n+      ]\n+    },\n+    \"notes\": \"Oxymorphone is a Schedule II controlled substance approximately 10 times more potent than morphine parenterally and 3 times more potent orally. The oral bioavailability is only 10-20%, making insufflated and rectal routes more efficient but riskier. A rare blood disorder has been reported with intravenous use of extended-release formulations. Users should start with significantly lower doses than other opioids due to high potency. Always use precise scales for measurement. Naloxone should be available in case of overdose. The drug is contraindicated in patients with moderate to severe hepatic impairment, and caution is required in renal impairment. Extended-release tablets were discontinued in the US in 2017 due to abuse potential, though immediate-release and generic versions remain available.\",\n+    \"subjective_effects\": [\n+      \"Intense Physical Euphoria\",\n+      \"Cognitive Euphoria And Contentment\",\n+      \"Pain Relief\",\n+      \"Sedation And Relaxation\",\n+      \"Respiratory Depression\",\n+      \"Pupil Constriction\",\n+      \"Constipation\",\n+      \"Nausea And Vomiting\",\n+      \"Itchiness\",\n+      \"Dry Mouth\",\n+      \"Difficulty Urinating\",\n+      \"Decreased Libido\",\n+      \"Compulsive Redosing\",\n+      \"Dream Potentiation And Nodding\",\n+      \"Skin Flushing\",\n+      \"Appetite Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops rapidly with daily use, typically within 3-7 days of consecutive dosing\",\n+      \"half_tolerance\": \"Reduction to baseline occurs within 7-14 days after cessation\",\n+      \"zero_tolerance\": \"Complete tolerance reset takes approximately 2-4 weeks of abstinence\",\n+      \"cross_tolerances\": [\n+        \"All opioids (morphine, oxycodone, hydromorphone, heroin, fentanyl, etc.)\",\n+        \"Cross-tolerance is incomplete when switching between opioids\"\n+      ]\n+    },\n+    \"half_life\": \"3-8 hours (immediate release: approximately 3-5 hours; extended release: approximately 8-10 hours)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Oxymorphone Vault\",\n+        \"reference\": \"https://erowid.org/pharms/oxymorphone/oxymorphone.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Oxymorphone\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Oxymorphone\"\n+      },\n+      {\n+        \"name\": \"TripSit Oxymorphone Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/oxymorphone\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Oxymorphone\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Oxymorphone\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Oxymorphone\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01192\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Oxymorphone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Oxymorphone\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"depressant\",\n+      \"semi-synthetic\",\n+      \"morphinan\"\n+    ]\n+  },\n+  \"id\": 680\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-002800-2b2a2c6f",
    "createdAt": "2025-10-19T00:28:00.887Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:27:59 PM"
    },
    "articles": [
      {
        "id": 679,
        "title": "Pethidine",
        "slug": "pethidine"
      }
    ],
    "markdown": "# Pethidine · #679\n\n+{\n+  \"title\": \"Pethidine\",\n+  \"index-category\": \"opioid; depressant; synthetic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Pethidine\",\n+    \"chemical_name\": \"Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate\",\n+    \"alternative_name\": \"Meperidine; Demerol; Dolantin; Dolcontral\",\n+    \"chemical_class\": \"Phenylpiperidine\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist; kappa-opioid receptor agonist; muscarinic acetylcholine receptor antagonist; dopamine reuptake inhibitor; norepinephrine reuptake inhibitor (metabolite norpethidine is a serotonin reuptake inhibitor)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25-50 mg\",\n+            \"light\": \"50-100 mg\",\n+            \"common\": \"100-200 mg\",\n+            \"strong\": \"200-400 mg\",\n+            \"heavy\": \"400+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"25-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"25-50 mg\",\n+            \"common\": \"50-75 mg\",\n+            \"strong\": \"75-100 mg\",\n+            \"heavy\": \"100+ mg (extreme caution - rapid respiratory depression)\"\n+          }\n+        },\n+        {\n+          \"route\": \"subcutaneous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"25-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"2-10 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"10-15 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ]\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"stages\": {\n+            \"total_duration\": \"2-3 hours\",\n+            \"onset\": \"1-5 minutes (nearly instantaneous)\",\n+            \"peak\": \"5-10 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ]\n+        },\n+        {\n+          \"route\": \"subcutaneous\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"10-20 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"subcutaneous\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Pethidine has a high potential for psychological and physical dependence. Prolonged use leads to tolerance and withdrawal symptoms upon cessation. The drug's unique pharmacological profile, including dopamine reuptake inhibition, may contribute to compulsive redosing patterns. Chronic use can result in severe addiction with cravings and withdrawal symptoms if use is suddenly stopped.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (serotonin syndrome, severe hypertensive reactions, coma, death)\",\n+        \"Alcohol (profound respiratory depression, unconsciousness, death)\",\n+        \"Benzodiazepines (severe respiratory depression, unconsciousness, death)\",\n+        \"GHB/GBL (rapid unconsciousness, respiratory failure, death)\",\n+        \"DXM (CNS depression, respiratory failure, liver toxicity)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (masks respiratory depression, overdose risk)\",\n+        \"Tramadol (increased seizure risk, CNS depression)\",\n+        \"Ketamine (vomiting, unconsciousness, aspiration risk)\",\n+        \"MXE (respiratory depression, organ toxicity)\",\n+        \"PCP (reduced opioid tolerance, overdose risk)\"\n+      ],\n+      \"caution\": [\n+        \"Nitrous (increased sedation, unconsciousness)\",\n+        \"SSRIs (serotonin syndrome risk)\",\n+        \"SNRIs (serotonin syndrome risk)\",\n+        \"5-HTP (serotonin syndrome risk)\",\n+        \"Grapefruit (altered metabolism, increased toxicity)\",\n+        \"Serotonin releasers (serotonin syndrome risk)\"\n+      ]\n+    },\n+    \"notes\": \"Pethidine is significantly less safe than other opioids due to its toxic metabolite norpethidine, which accumulates with repeated dosing and can cause seizures, tremors, and CNS excitation. It should not be used for more than 48 hours or at doses exceeding 600 mg per 24 hours. The drug has a particularly high risk of serotonin syndrome compared to other opioids and should never be combined with MAOIs, SSRIs, or other serotonergic drugs. Intravenous administration carries extreme risks and should only be done in medical settings with naloxone and respiratory support immediately available. Norpethidine accumulation is especially dangerous in patients with renal impairment.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Pain Relief\",\n+      \"Anxiety Suppression\",\n+      \"Sedation (or stimulation in some users)\",\n+      \"Respiratory Depression\",\n+      \"Itchiness\",\n+      \"Pupil Constriction\",\n+      \"Nausea\",\n+      \"Constipation\",\n+      \"Difficulty Urinating\",\n+      \"Blurred Vision (anticholinergic effect)\",\n+      \"Warmth and Relaxation\",\n+      \"Dream Potentiation\",\n+      \"Cough Suppression\",\n+      \"Seizures (at high doses due to norpethidine)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All opioids (morphine, oxycodone, hydrocodone, heroin, fentanyl)\"\n+      ]\n+    },\n+    \"half_life\": \"3-5 hours (pethidine); 15-20 hours (norpethidine metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Meperidine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/meperidine/meperidine.shtml\"\n+      },\n+      {\n+        \"name\": \"Meperidine - StatPearls NCBI\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK470362/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki - Pethidine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Pethidine\"\n+      },\n+      {\n+        \"name\": \"Wikipedia - Pethidine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Pethidine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"synthetic-opioid\",\n+      \"phenylpiperidine\",\n+      \"depressant\"\n+    ]\n+  },\n+  \"id\": 679\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-002428-5102e033",
    "createdAt": "2025-10-19T00:24:28.342Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:24:26 PM"
    },
    "articles": [
      {
        "id": 678,
        "title": "Sufentanil",
        "slug": "sufentanil"
      }
    ],
    "markdown": "# Sufentanil · #678\n\n+{\n+  \"title\": \"Sufentanil\",\n+  \"index-category\": \"opioid; synthetic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Sufentanil\",\n+    \"chemical_name\": \"N-[4-(Methoxymethyl)-1-(2-thiofuran-2-ylethyl)-4-piperidyl]-N-phenylpropanamide\",\n+    \"alternative_name\": \"Sufentanyl; Sufenta; Chronogesic\",\n+    \"chemical_class\": \"Anilidopiperidine\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist (highly selective)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1 ug\",\n+            \"light\": \"1-5 ug\",\n+            \"common\": \"5-10 ug\",\n+            \"strong\": \"10-25 ug\",\n+            \"heavy\": \"25+ ug\"\n+          }\n+        },\n+        {\n+          \"route\": \"epidural\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 ug\",\n+            \"light\": \"10-30 ug\",\n+            \"common\": \"30-50 ug\",\n+            \"strong\": \"50-75 ug\",\n+            \"heavy\": \"75+ ug\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"15-30 ug\",\n+            \"common\": \"30-60 ug\",\n+            \"strong\": \"60-90 ug\",\n+            \"heavy\": \"90+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"intravenous\",\n+          \"stages\": {\n+            \"total_duration\": \"30-90 minutes\",\n+            \"onset\": \"1-2 minutes\",\n+            \"peak\": \"5-10 minutes\",\n+            \"offset\": \"15-30 minutes\",\n+            \"after_effects\": \"1-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"iv\"\n+          ]\n+        },\n+        {\n+          \"route\": \"epidural\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"epidural\"\n+          ]\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Sufentanil is highly physically addictive due to its potent mu-opioid agonist activity. Chronic use rapidly leads to tolerance and physical dependence. Discontinuation after regular use results in severe withdrawal symptoms. The extremely short duration of action can promote compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (severe respiratory depression and unconsciousness)\",\n+        \"Benzodiazepines (unpredictable potentiation, rapid unconsciousness, aspiration risk)\",\n+        \"GHB/GBL (severe respiratory depression, unconsciousness)\",\n+        \"Ketamine (respiratory depression, vomit aspiration)\",\n+        \"MAOIs (serotonin syndrome, hypertensive crisis, seizures)\",\n+        \"Nitrous oxide (severe respiratory depression, unconsciousness)\",\n+        \"PCP (increased overdose risk)\",\n+        \"Tramadol (seizure risk, respiratory depression)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (CNS depression, respiratory depression, liver toxicity)\",\n+        \"MXE (potentiated effects, respiratory depression)\",\n+        \"Stimulants (masked respiratory depression, overdose when stimulant wears off)\"\n+      ],\n+      \"caution\": [\n+        \"Grapefruit (CYP3A4 inhibition, prolonged effects)\",\n+        \"Serotonin releasers (serotonin syndrome risk)\",\n+        \"SNRIs (serotonin syndrome risk)\",\n+        \"SSRIs (serotonin syndrome risk)\",\n+        \"5-HTP (serotonin syndrome risk)\"\n+      ]\n+    },\n+    \"notes\": \"Sufentanil is extraordinarily potent and active in the microgram range. Pure powder can cause fatal overdose through skin contact. Never eyeball this substance. Use only volumetric dosing with accurate analytical scales and wear protective gloves when handling. The extremely high potency makes precise measurement critical for safety. Naloxone is the antidote for overdose but may require higher doses than for other opioids. This is a Schedule II controlled substance in most jurisdictions with strict medical use only. Contraindicated in individuals with respiratory depression or compromised respiratory function.\",\n+    \"subjective_effects\": [\n+      \"Pain Relief\",\n+      \"Respiratory Depression\",\n+      \"Sedation\",\n+      \"Physical Euphoria\",\n+      \"Anxiety Suppression\",\n+      \"Constipation\",\n+      \"Cough Suppression\",\n+      \"Difficulty Urinating\",\n+      \"Itchiness\",\n+      \"Muscle Relaxation\",\n+      \"Nausea\",\n+      \"Pupil Constriction\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 1-3 consecutive days of use\",\n+      \"half_tolerance\": \"7-14 days\",\n+      \"zero_tolerance\": \"14-28 days\",\n+      \"cross_tolerances\": [\n+        \"All opioids (morphine, heroin, fentanyl, oxycodone, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"2.7 hours (162 minutes)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Sufentanil\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Sufentanil\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Sufentanil\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Sufentanil\"\n+      },\n+      {\n+        \"name\": \"Erowid: Opioid Analgesics FAQ\",\n+        \"reference\": \"https://erowid.org/chemicals/opiates/opiates_faq_analgesics.shtml\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Sufentanil\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00708\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"synthetic-opioid\",\n+      \"anilidopiperidine\",\n+      \"pharmaceutical\"\n+    ]\n+  },\n+  \"id\": 678\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-001823-c883c336",
    "createdAt": "2025-10-19T00:18:23.638Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:18:21 PM"
    },
    "articles": [
      {
        "id": 677,
        "title": "Ethylmorphine",
        "slug": "ethylmorphine"
      }
    ],
    "markdown": "# Ethylmorphine · #677\n\n+{\n+  \"title\": \"Ethylmorphine\",\n+  \"index-category\": \"opioid; depressant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Ethylmorphine\",\n+    \"chemical_name\": \"7,8-Didehydro-4,5-alpha-epoxy-3-ethoxy-17-methylmorphinan-6-alpha-ol\",\n+    \"alternative_name\": \"Codethyline; Dionine; Ethyl morphine; 3-Ethylmorphine\",\n+    \"chemical_class\": \"Substituted morphinans\",\n+    \"psychoactive_class\": \"Opioid; Depressant\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist (via active metabolite morphine); metabolized by CYP2D6 and CYP3A4\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-20 mg\",\n+            \"light\": \"40-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-5 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Ethylmorphine has a high potential for addiction and can cause psychological dependence with chronic use. Compulsive redosing is common, and withdrawal symptoms including cravings may occur when usage is discontinued abruptly. Evidence suggests a 'ceiling effect' where increased dosage produces diminishing euphoric returns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (respiratory depression, unconsciousness, vomit aspiration risk)\",\n+        \"Benzodiazepines (unpredictable CNS depression, respiratory arrest)\",\n+        \"GHB/GBL (rapid unconsciousness, respiratory depression)\",\n+        \"MAOIs (severe reactions including hyperpyrexia, seizures, coma, potential fatality)\",\n+        \"Tramadol (increased seizure risk, additive CNS depression)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (CNS depression, respiratory issues, hepatotoxicity)\",\n+        \"Ketamine (vomit aspiration risk when unconscious)\",\n+        \"MXE (potentiation plus increased organ toxicity)\",\n+        \"Nitrous oxide (ataxia, sedation, loss of consciousness)\",\n+        \"PCP (reduced opioid tolerance, overdose risk)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masking of respiratory depression until stimulant wears off)\",\n+        \"Grapefruit juice (CYP3A4 inhibition may increase toxicity)\"\n+      ]\n+    },\n+    \"notes\": \"Ethylmorphine is a Schedule II controlled substance in the United States and regulated internationally under Schedule III of the Single Convention on Narcotic Drugs. Contraindications include asthma, respiratory insufficiency, and age under 8 years. The substance is metabolized to morphine by CYP2D6, with significant inter-individual variation in conversion rates affecting efficacy and safety. Users should employ precise scales for dosing and avoid driving or operating heavy machinery. Not marketed in the United States but available as cough suppressant in some European countries.\",\n+    \"subjective_effects\": [\n+      \"Pain Relief\",\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Anxiety Suppression\",\n+      \"Sedation\",\n+      \"Respiratory Depression\",\n+      \"Cough Suppression\",\n+      \"Constipation\",\n+      \"Itchiness\",\n+      \"Nausea\",\n+      \"Difficulty Urinating\",\n+      \"Pupil Constriction\",\n+      \"Compulsive Redosing\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All opioids (morphine, codeine, heroin, oxycodone, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"2 hours (ethylmorphine); active metabolites persist longer\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Ethylmorphine Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Pharms_Ethylmorphine.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Ethylmorphine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Ethylmorphine\"\n+      },\n+      {\n+        \"name\": \"TripSit Ethylmorphine Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/ethylmorphine\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ethylmorphine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ethylmorphine\"\n+      },\n+      {\n+        \"name\": \"Biotransformation and Pharmacokinetics Study (PMC)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC1365072/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Ethylmorphine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01466\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"depressant\",\n+      \"semi-synthetic\",\n+      \"pharmaceutical\"\n+    ]\n+  },\n+  \"id\": 677\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-001531-c8ac86b0",
    "createdAt": "2025-10-19T00:15:31.570Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:15:29 PM"
    },
    "articles": [
      {
        "id": 676,
        "title": "Dextropropoxyphene",
        "slug": "dextropropoxyphene"
      }
    ],
    "markdown": "# Dextropropoxyphene · #676\n\n+{\n+  \"title\": \"Dextropropoxyphene\",\n+  \"index-category\": \"opioid; synthetic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Dextropropoxyphene\",\n+    \"chemical_name\": \"(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate\",\n+    \"alternative_name\": \"Propoxyphene; Darvon; Darvocet\",\n+    \"chemical_class\": \"Phenylpropylamine\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist; weak serotonin reuptake inhibitor; potent nicotinic acetylcholine antagonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-65 mg\",\n+            \"common\": \"65-100 mg\",\n+            \"strong\": \"100-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"20-30 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Dextropropoxyphene has moderate addictive potential with a high potential for abuse and is capable of causing psychological and physical dependence. Chronic use can lead to tolerance development, cravings, and withdrawal symptoms upon cessation. Compulsive redosing patterns have been reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (hypertensive crisis, serotonin syndrome, seizures, death)\",\n+        \"Alcohol (severe CNS depression, unconsciousness, respiratory depression)\",\n+        \"Benzodiazepines (life-threatening respiratory depression, unconsciousness)\",\n+        \"GHB/GBL (rapid unconsciousness, respiratory depression)\",\n+        \"Tramadol (seizure risk, serotonin syndrome)\",\n+        \"Lithium (seizure risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (respiratory arrest when stimulant wears off)\",\n+        \"DXM (toxicity, CNS depression, liver issues)\",\n+        \"Ketamine (unconsciousness, vomiting, aspiration risk)\",\n+        \"MXE (respiratory depression, organ toxicity)\",\n+        \"PCP (reduced tolerance, overdose risk)\",\n+        \"Nitrous (unconsciousness, respiratory depression)\",\n+        \"Serotonin releasers (serotonin syndrome)\",\n+        \"SNRIs (serotonin syndrome)\",\n+        \"SSRIs (serotonin syndrome)\",\n+        \"5-HTP (serotonin syndrome)\"\n+      ],\n+      \"caution\": [\n+        \"Grapefruit (metabolism inhibition via CYP3A4)\",\n+        \"CYP3A4 inhibitors (increased plasma levels and toxicity)\"\n+      ]\n+    },\n+    \"notes\": \"Dextropropoxyphene was withdrawn from the US and European markets in 2010 due to serious cardiac toxicity, including QT prolongation and fatal arrhythmias at therapeutic doses. The drug causes seizures and potentially fatal cardiac complications that cannot be reversed by naloxone. It has a narrow therapeutic index and high toxicity relative to dose. The metabolite norpropoxyphene accumulates with repeated use and contributes to cardiotoxicity. Contraindicated in individuals with suicidal ideation, substance abuse history, or cardiac conditions. Should not be used during benzodiazepine withdrawal as it lowers the seizure threshold. Use a precise milligram scale for dosing if obtained, though this substance is rarely encountered today.\",\n+    \"subjective_effects\": [\n+      \"Pain Relief\",\n+      \"Physical Euphoria (mild)\",\n+      \"Cognitive Euphoria (mild)\",\n+      \"Anxiety Suppression\",\n+      \"Sedation\",\n+      \"Respiratory Depression\",\n+      \"Itchiness\",\n+      \"Pupil Constriction\",\n+      \"Constipation\",\n+      \"Nausea\",\n+      \"Dizziness (higher rate than other opioids)\",\n+      \"Confusion (higher rate than other opioids)\",\n+      \"Cough Suppression\",\n+      \"Decreased Libido\",\n+      \"Difficulty Urinating\",\n+      \"Appetite Suppression\",\n+      \"Dream Potentiation\",\n+      \"Compulsive Redosing\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All other opioids (morphine, codeine, heroin, oxycodone, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"6-12 hours (dextropropoxyphene); 30-36 hours (norpropoxyphene metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"DrugBank: Dextropropoxyphene\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00647\"\n+      },\n+      {\n+        \"name\": \"Erowid Propoxyphene Experience Vaults\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Pharms_Propoxyphene.shtml\"\n+      },\n+      {\n+        \"name\": \"FDA Drug Safety Communication on Propoxyphene\",\n+        \"reference\": \"https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-continued-use-propoxyphene\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Dextropropoxyphene\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Dextropropoxyphene\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Dextropropoxyphene\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Dextropropoxyphene\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"synthetic-opioid\",\n+      \"withdrawn-substance\"\n+    ]\n+  },\n+  \"id\": 676\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-001241-5c11b2d1",
    "createdAt": "2025-10-19T00:12:41.748Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:12:39 PM"
    },
    "articles": [
      {
        "id": 675,
        "title": "Codeine",
        "slug": "codeine"
      }
    ],
    "markdown": "# Codeine · #675\n\n+{\n+  \"title\": \"Codeine\",\n+  \"index-category\": \"opioid; depressant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Codeine\",\n+    \"chemical_name\": \"(5a,6a)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol\",\n+    \"alternative_name\": \"Lean; Purple Drank; Syrup; 3-methylmorphine\",\n+    \"chemical_class\": \"Morphinan\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist (as morphine after first-pass metabolism); prodrug metabolized by CYP2D6 to morphine\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"30 mg\",\n+            \"light\": \"50-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"1-2 hours after onset\",\n+            \"offset\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Codeine has moderate addiction potential with a high potential for abuse and is capable of causing psychological dependence among certain users. Compulsive redosing may occur despite the metabolic ceiling dose of approximately 400mg. When addiction develops, cravings and withdrawal symptoms may occur if use is suddenly stopped.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (respiratory depression, loss of consciousness, vomit aspiration risk)\",\n+        \"Benzodiazepines (respiratory depression, rapid unconsciousness, vomit aspiration)\",\n+        \"GHB/GBL (rapid unconsciousness, respiratory depression, vomit aspiration)\",\n+        \"MAOIs (severe adverse reactions including agitation, hyperpyrexia, seizures, coma, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"DXM (CNS depression, respiratory difficulties, cardiac issues, liver toxicity)\",\n+        \"Ketamine (unconsciousness, vomit aspiration risk)\",\n+        \"MXE (potentiated effects, increased respiratory depression and organ toxicity)\",\n+        \"PCP (reduced opioid tolerance, increased overdose risk)\",\n+        \"Tramadol (increased seizure risk, additive CNS/respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased respiration allows higher opiate doses; respiratory arrest if stimulant wears off first)\",\n+        \"Nitrous oxide (potentiated ataxia and sedation, unconsciousness risk)\",\n+        \"Grapefruit (CYP3A4 inhibition alters metabolism; may increase toxicity with repeated doses)\"\n+      ]\n+    },\n+    \"notes\": \"Codeine is frequently sold over-the-counter in combination with paracetamol (acetaminophen), ibuprofen, or aspirin, which are dangerous or fatal at recreational codeine doses. A cold water extraction should be performed to separate codeine from these compounds. There is a metabolic ceiling dose around 400mg beyond which additional consumption increases side effects without enhancing euphoria. Genetic variations in CYP2D6 enzyme production cause some individuals to experience reduced effects (poor metabolizers) or dangerous hypersensitivity (ultra-rapid metabolizers). Codeine should not be used intravenously as it can cause severe mast-cell degranulation and anaphylactoid reactions.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Pain Relief\",\n+      \"Cognitive Euphoria\",\n+      \"Anxiety Suppression\",\n+      \"Sedation\",\n+      \"Respiratory Depression\",\n+      \"Itchiness\",\n+      \"Constipation\",\n+      \"Cough Suppression\",\n+      \"Nausea\",\n+      \"Pupil Constriction\",\n+      \"Thought Deceleration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All opioids (morphine, heroin, oxycodone, hydrocodone, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"2.5-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Codeine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Codeine\"\n+      },\n+      {\n+        \"name\": \"TripSit Codeine Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Codeine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Codeine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Codeine\"\n+      },\n+      {\n+        \"name\": \"Erowid Codeine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/codeine/\"\n+      },\n+      {\n+        \"name\": \"Erowid Codeine FAQ\",\n+        \"reference\": \"https://www.erowid.org/pharms/codeine/codeine_faq.shtml\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Codeine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Codeine\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Codeine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00318\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Codeine\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK526029/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"morphinan\",\n+      \"alkaloid\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 675\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-000949-1d8e118d",
    "createdAt": "2025-10-19T00:09:49.261Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:09:46 PM"
    },
    "articles": [
      {
        "id": 674,
        "title": "Acetylfentanyl",
        "slug": "acetylfentanyl"
      }
    ],
    "markdown": "# Acetylfentanyl · #674\n\n+{\n+  \"title\": \"Acetylfentanyl\",\n+  \"index-category\": \"opioid; synthetic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Acetylfentanyl\",\n+    \"chemical_name\": \"N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide\",\n+    \"alternative_name\": \"Acetyl Fentanyl; Desmethyl Fentanyl\",\n+    \"chemical_class\": \"Anilidopiperidine\",\n+    \"psychoactive_class\": \"Opioid\",\n+    \"mechanism_of_action\": \"Mu-opioid receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 mg\",\n+            \"light\": \"3-7 mg\",\n+            \"common\": \"7-12 mg\",\n+            \"strong\": \"12-18 mg\",\n+            \"heavy\": \"18+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"1-4 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Acetylfentanyl has an extremely high potential for physical and psychological addiction. As with other opioids, chronic use leads to rapid tolerance development and severe physical dependence. Withdrawal symptoms and cravings occur when use is discontinued, and compulsive redosing is common.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (risk of unconsciousness, vomit aspiration, and respiratory depression)\",\n+        \"Benzodiazepines (unpredictable potentiation, rapid unconsciousness, respiratory depression)\",\n+        \"GHB/GBL (unpredictable potentiation, rapid unconsciousness, respiratory depression)\",\n+        \"Ketamine (risk of vomiting and unconsciousness with severe aspiration risk)\",\n+        \"MXE (potentiation of effects, increased respiratory depression and organ toxicity)\",\n+        \"Nitrous (ataxia, sedation, unconsciousness, aspiration risk)\",\n+        \"Tramadol (increased seizure risk, CNS and respiratory depression)\",\n+        \"MAOIs (severe adverse reactions including agitation, hyperpyrexia, seizures, coma, and death)\",\n+        \"PCP (may reduce tolerance, increasing overdose risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (masking of respiratory depression, overdose risk when stimulant wears off)\",\n+        \"DXM (CNS depression, respiratory issues, heart problems, liver toxicity)\"\n+      ],\n+      \"caution\": [\n+        \"Grapefruit (inhibits CYP3A4 metabolism, may increase toxicity)\",\n+        \"SSRIs (rare risk of serotonin syndrome)\",\n+        \"SNRIs (rare risk of serotonin syndrome)\",\n+        \"5-HTP (rare risk of serotonin syndrome)\",\n+        \"Serotonin releasers like MDMA (rare risk of serotonin syndrome)\"\n+      ]\n+    },\n+    \"notes\": \"Acetylfentanyl is 5-15 times more potent than heroin and 80 times more potent than morphine, making it extremely dangerous and easy to fatally overdose. This substance has been involved in hundreds of deaths worldwide and is often sold misrepresented as heroin or pressed into counterfeit pills. Volumetric dosing is absolutely critical due to extreme potency; unintentional skin contact with powder can result in overdose. Fentanyl test strips should be used on any suspected opioid supply. Have naloxone immediately available and never use alone. Acetylfentanyl is Schedule I in the United States and similarly controlled in most countries.\",\n+    \"subjective_effects\": [\n+      \"Pain Relief\",\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Anxiety Suppression\",\n+      \"Respiratory Depression\",\n+      \"Sedation\",\n+      \"Itchiness (minimal)\",\n+      \"Pupil Constriction\",\n+      \"Constipation\",\n+      \"Decreased Libido\",\n+      \"Dehydration\",\n+      \"Compulsive Redosing\",\n+      \"Double Vision\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All opioids including morphine, heroin, fentanyl, oxycodone, and hydrocodone\"\n+      ]\n+    },\n+    \"half_life\": \"Not well established in humans; estimated 3-8 hours based on structural analogs\",\n+    \"citations\": [\n+      {\n+        \"name\": \"DanceSafe Fentanyl Information\",\n+        \"reference\": \"https://dancesafe.org/fentanyl/\"\n+      },\n+      {\n+        \"name\": \"Erowid Acetylfentanyl Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/acetylfentanyl/acetylfentanyl.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki Acetylfentanyl\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Acetylfentanyl\"\n+      },\n+      {\n+        \"name\": \"TripSit Acetylfentanyl Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Acetylfentanyl\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combinations Chart\",\n+        \"reference\": \"https://combo.tripsit.me/\"\n+      },\n+      {\n+        \"name\": \"US DEA Acetylfentanyl Report\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/acetylfentanyl.pdf\"\n+      },\n+      {\n+        \"name\": \"World Health Organization Acetylfentanyl Critical Review\",\n+        \"reference\": \"http://www.who.int/medicines/access/controlled-substances/5.2_Acetylfentanyl_CRev.pdf\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"opioid\",\n+      \"synthetic-opioid\",\n+      \"fentanyl-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 674\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-000530-086f7fe4",
    "createdAt": "2025-10-19T00:05:30.629Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:05:28 PM"
    },
    "articles": [
      {
        "id": 673,
        "title": "Eszopiclone",
        "slug": "eszopiclone"
      }
    ],
    "markdown": "# Eszopiclone · #673\n\n+{\n+  \"title\": \"Eszopiclone\",\n+  \"index-category\": \"depressant; sedative; prescription\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Eszopiclone\",\n+    \"chemical_name\": \"(S)-6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methyl-1-piperazinecarboxylate\",\n+    \"alternative_name\": \"Lunesta; Eszop\",\n+    \"chemical_class\": \"Cyclopyrrolone\",\n+    \"psychoactive_class\": \"Depressant; Hallucinogen\",\n+    \"mechanism_of_action\": \"GABA-A receptor positive allosteric modulator (preferential affinity for alpha-1, alpha-3, and alpha-5 subunits); increases chloride channel opening frequency when GABA is present\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1-1.5 mg\",\n+            \"common\": \"2-3 mg\",\n+            \"strong\": \"4-5 mg\",\n+            \"heavy\": \"6+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"10-20 minutes\",\n+            \"peak\": \"30-90 minutes (approximately 1 hour)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"Up to 24 hours (next-day impairment possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Eszopiclone is highly physically and psychologically addictive, potentially with even greater addiction potential than benzodiazepines. Physical and psychological dependence develop with regular use, and the risk increases with dose, duration, and concurrent use of other psychoactive substances. Compulsive redosing is commonly reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Opioids (respiratory depression, coma, death)\",\n+        \"Alcohol (severe respiratory depression, blackouts, death)\",\n+        \"Benzodiazepines (respiratory depression, unconsciousness)\",\n+        \"Barbiturates (respiratory depression, fatal overdose)\",\n+        \"GHB/GBL (respiratory depression, unconsciousness)\",\n+        \"Sodium oxybate (contraindicated; severe CNS depression)\"\n+      ],\n+      \"unsafe\": [\n+        \"Other CNS depressants (increased sedation, amnesia, respiratory depression)\",\n+        \"Dissociatives (increased vomiting risk during unconsciousness)\",\n+        \"Other Z-drugs (compounded sedation)\"\n+      ],\n+      \"caution\": [\n+        \"CYP3A4 inhibitors (ketoconazole, itraconazole; increased eszopiclone levels)\",\n+        \"CYP3A4 inducers (rifampicin, carbamazepine; decreased effectiveness)\",\n+        \"Antihistamines (increased drowsiness)\",\n+        \"Muscle relaxants (increased sedation)\",\n+        \"Antipsychotics (combined sedation effects)\"\n+      ]\n+    },\n+    \"notes\": \"Eszopiclone is a Schedule IV controlled substance in the United States. Tolerance develops rapidly within a couple of weeks of daily use. Abrupt cessation after prolonged use can cause severe withdrawal symptoms; gradual tapering or cross-over to long-acting benzodiazepines like diazepam is recommended. Should not be taken with or immediately after high-fat meals as this delays absorption. Users should avoid driving or operating machinery the next day due to potential next-day impairment. Contraindicated in those with severe hepatic impairment (reduce dose to maximum 2 mg) and during activities requiring mental alertness. Complex sleep behaviors including sleep-walking, sleep-driving, and sleep-eating have been reported and may result in serious injury or death.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Respiratory Depression\",\n+      \"Muscle Relaxation\",\n+      \"Dizziness\",\n+      \"Motor Control Loss\",\n+      \"Metallic Taste (Gustatory Hallucination)\",\n+      \"Amnesia\",\n+      \"Anxiety Suppression\",\n+      \"Disinhibition\",\n+      \"Emotion Suppression\",\n+      \"Time Compression\",\n+      \"Shadow People\",\n+      \"Visual Drifting\",\n+      \"External Hallucinations\",\n+      \"Delirium\",\n+      \"Euphoria (Short-Lived, Onset Only)\",\n+      \"Irritability\",\n+      \"Compulsive Redosing\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 weeks of consecutive daily use\",\n+      \"half_tolerance\": \"Not well documented; develops slower than benzodiazepines\",\n+      \"zero_tolerance\": \"7-14 days after cessation\",\n+      \"cross_tolerances\": [\n+        \"All benzodiazepines\",\n+        \"Other Z-drugs (zolpidem, zaleplon, zopiclone)\",\n+        \"Barbiturates\",\n+        \"Most GABAergic depressants\"\n+      ]\n+    },\n+    \"half_life\": \"6 hours (approximately 6.1 hours in healthy adults; prolonged in elderly and hepatic impairment)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"DrugBank: Eszopiclone\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00402\"\n+      },\n+      {\n+        \"name\": \"Drugs.com: Eszopiclone Information\",\n+        \"reference\": \"https://www.drugs.com/eszopiclone.html\"\n+      },\n+      {\n+        \"name\": \"Erowid: Zopiclone/Eszopiclone Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/zopiclone/zopiclone.shtml\"\n+      },\n+      {\n+        \"name\": \"FDA: Lunesta (Eszopiclone) Prescribing Information\",\n+        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf\"\n+      },\n+      {\n+        \"name\": \"Mayo Clinic: Eszopiclone Side Effects & Precautions\",\n+        \"reference\": \"https://www.mayoclinic.org/drugs-supplements/eszopiclone-oral-route/precautions/drg-20063743\"\n+      },\n+      {\n+        \"name\": \"NIAAA: Alcohol-Medication Interactions\",\n+        \"reference\": \"https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/alcohol-medication-interactions-potentially-dangerous-mixes\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Eszopiclone\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Eszopiclone\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Eszopiclone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Eszopiclone\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"depressant\",\n+      \"sedative-hypnotic\",\n+      \"z-drug\",\n+      \"prescription\"\n+    ]\n+  },\n+  \"id\": 673\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251019-000119-5cbcb26a",
    "createdAt": "2025-10-19T00:01:19.763Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 6:01:17 PM"
    },
    "articles": [
      {
        "id": 672,
        "title": "Secobarbital",
        "slug": "secobarbital"
      }
    ],
    "markdown": "# Secobarbital · #672\n\n+{\n+  \"title\": \"Secobarbital\",\n+  \"index-category\": \"depressant; barbiturate\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Secobarbital\",\n+    \"chemical_name\": \"5-[(2R)-pentan-2-yl]-5-prop-2-enyl-1,3-diazinane-2,4,6-trione\",\n+    \"alternative_name\": \"Secobarbitone; Seconal; Reds; Red Birds; Red Devils; Seggy\",\n+    \"chemical_class\": \"Barbiturates\",\n+    \"psychoactive_class\": \"Depressant; Sedative-hypnotic\",\n+    \"mechanism_of_action\": \"GABAA receptor positive allosteric modulator (binds to distinct site from benzodiazepines); increases duration of chloride ion channel opening\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"25-50 mg\",\n+            \"common\": \"50-150 mg\",\n+            \"strong\": \"150-300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"15-60 minutes\",\n+            \"peak\": \"4-8 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"1-24 hours (anxiolytic effects may persist)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Secobarbital is extremely physically and psychologically addictive. Tolerance develops rapidly, often within two weeks of regular use. Barbiturate dependence is considered one of the most dangerous forms of substance dependence, and abrupt discontinuation can result in life-threatening withdrawal symptoms including seizures, psychosis, and death.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (fatal respiratory depression and overdose risk)\",\n+        \"Opioids (fatal respiratory depression and overdose risk)\",\n+        \"Benzodiazepines (synergistic respiratory depression; barbiturates increase benzodiazepine binding affinity)\",\n+        \"GHB/GBL (severe respiratory depression)\",\n+        \"Other barbiturates (compounded CNS depression)\",\n+        \"Methaqualone (respiratory depression)\"\n+      ],\n+      \"unsafe\": [\n+        \"Dissociatives (increased risk of vomiting and aspiration)\",\n+        \"Gabapentinoids (respiratory depression)\",\n+        \"Thienodiazepines (respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masks sedation leading to dangerous redosing; risk of severe dehydration)\",\n+        \"Tramadol (lowers seizure threshold during withdrawal; enzyme induction increases tramadol potency)\",\n+        \"Amphetamines (should be avoided during withdrawal)\",\n+        \"Warfarin (reduced anticoagulant effectiveness)\",\n+        \"Oral contraceptives (reduced effectiveness; use backup contraception)\",\n+        \"Tricyclic antidepressants (prolonged sedation and CNS depression)\"\n+      ]\n+    },\n+    \"notes\": \"Secobarbital has a narrow therapeutic index, meaning the difference between an effective dose and a lethal dose is small. It is a Schedule II controlled substance in most jurisdictions due to high abuse potential. Production was largely discontinued in the early 2000s, making pharmaceutical secobarbital rare. Barbiturate withdrawal requires medical supervision and often involves substitution with phenobarbital or long-acting benzodiazepines. Individuals with respiratory conditions, liver disease, porphyria, or history of substance abuse should not use this medication. Secobarbital drastically reduces the effectiveness of hormonal birth control and many other medications through enzyme induction.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Anxiety Suppression\",\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Motor Control Loss\",\n+      \"Muscle Relaxation\",\n+      \"Amnesia\",\n+      \"Disinhibition\",\n+      \"Thought Deceleration\",\n+      \"Compulsive Redosing\",\n+      \"Slurred Speech\",\n+      \"Delusions of Sobriety\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops rapidly after 2 weeks of continuous use\",\n+      \"half_tolerance\": \"Unknown; barbiturate tolerance persists longer than other depressants\",\n+      \"zero_tolerance\": \"Several weeks to months after discontinuation\",\n+      \"cross_tolerances\": [\n+        \"All barbiturates\",\n+        \"Partial cross-tolerance with alcohol and benzodiazepines\"\n+      ]\n+    },\n+    \"half_life\": \"15-40 hours (plasma elimination)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Secobarbital\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Secobarbital\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: Secobarbital\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Pharms_Secobarbital.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Barbiturate Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/barbiturates/\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Risks of Combining Depressants\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Secobarbital\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00418\"\n+      },\n+      {\n+        \"name\": \"Drugs.com: Secobarbital Interactions\",\n+        \"reference\": \"https://www.drugs.com/drug-interactions/secobarbital.html\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Barbiturate\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Barbiturate\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"depressant\",\n+      \"barbiturate\",\n+      \"sedative-hypnotic\",\n+      \"gaba-modulator\"\n+    ]\n+  },\n+  \"id\": 672\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-235740-bb5638ca",
    "createdAt": "2025-10-18T23:57:40.445Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 5:57:38 PM"
    },
    "articles": [
      {
        "id": 671,
        "title": "Pentobarbital",
        "slug": "pentobarbital"
      }
    ],
    "markdown": "# Pentobarbital · #671\n\n+{\n+  \"title\": \"Pentobarbital\",\n+  \"index-category\": \"depressant; barbiturate; sedative\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Pentobarbital\",\n+    \"chemical_name\": \"5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione\",\n+    \"alternative_name\": \"Pentobarbitone; Nembutal; Yellow Jackets\",\n+    \"chemical_class\": \"Barbiturates\",\n+    \"psychoactive_class\": \"Depressant; Sedative-Hypnotic\",\n+    \"mechanism_of_action\": \"GABAA receptor positive allosteric modulator (binds to barbiturate site, increases chloride ion pore opening duration); AMPA glutamate receptor antagonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"50-100 mg\",\n+            \"common\": \"100-200 mg\",\n+            \"strong\": \"200-300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"15-60 minutes\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-36 hours (prolonged anxiolytic effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Pentobarbital is extremely physically and psychologically addictive. Tolerance develops after prolonged use, particularly to sedative-hypnotic effects. Abrupt discontinuation in dependent individuals may be life-threatening and can lead to seizures, psychosis, and death. Dependence threshold is estimated at over 400 mg daily for more than 90 days, with withdrawal seizures reported at dosages of 600-800 mg daily for more than 35 days.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (severe respiratory depression, potentially fatal)\",\n+        \"Opioids (severe respiratory depression, potentially fatal)\",\n+        \"Benzodiazepines (potentiated respiratory depression; barbiturates increase chloride pore duration while benzodiazepines increase opening frequency)\",\n+        \"GHB/GBL (severe respiratory depression, potentially fatal)\",\n+        \"Other barbiturates (severe respiratory depression, potentially fatal)\",\n+        \"Methaqualone (severe respiratory depression, potentially fatal)\",\n+        \"Gabapentinoids (severe respiratory depression)\",\n+        \"Thienodiazepines (severe respiratory depression)\"\n+      ],\n+      \"unsafe\": [\n+        \"Dissociatives (increased risk of vomiting and aspiration during unconsciousness)\",\n+        \"Tramadol (lowers seizure threshold during withdrawal)\",\n+        \"Amphetamines (masks sedation leading to dangerous redosing; lowers seizure threshold during withdrawal)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masks level of intoxication, risk of severe dehydration)\",\n+        \"MAO inhibitors (potential cardiovascular complications)\",\n+        \"Beta-blockers (pentobarbital increases clearance and reduces effectiveness)\",\n+        \"Anticoagulants (altered metabolism)\",\n+        \"Doxycycline (reduced effectiveness)\",\n+        \"Hormonal contraceptives (reduced effectiveness)\",\n+        \"Corticosteroids (reduced effectiveness)\"\n+      ]\n+    },\n+    \"notes\": \"Pentobarbital is a Schedule II controlled substance in the United States and similarly restricted internationally. It has largely been replaced by benzodiazepines for medical use due to its narrow therapeutic window and high addiction potential. The drug is currently used primarily in veterinary medicine for euthanasia and in some jurisdictions for physician-assisted suicide. Users should be aware that pentobarbital carries significantly higher risks of serious adverse effects when combined with other depressants compared to other sedative classes. Barbiturate overdose is a medical emergency requiring immediate hospitalization. Due to high protein binding and lipid solubility, treatments like forced diuresis and hemodialysis are largely ineffective. Individuals with liver or kidney impairment, cardiovascular disease, respiratory conditions, or porphyria should avoid pentobarbital entirely. Never use pentobarbital during pregnancy as it poses severe risks to fetal development.\",\n+    \"subjective_effects\": [\n+      \"Profound Sedation\",\n+      \"Anxiety Suppression\",\n+      \"Cognitive Euphoria (particularly strong compared to other GABAergic depressants)\",\n+      \"Physical Euphoria\",\n+      \"Motor Control Loss\",\n+      \"Muscle Relaxation\",\n+      \"Amnesia\",\n+      \"Thought Deceleration\",\n+      \"Disinhibition\",\n+      \"Slurred Speech\",\n+      \"Emotion Suppression\",\n+      \"Delusions of Sobriety\",\n+      \"Dizziness\",\n+      \"Compulsive Redosing\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2 weeks of continued daily use at fixed doses (most effectiveness for inducing and maintaining sleep is lost)\",\n+      \"half_tolerance\": \"Unknown; research insufficient\",\n+      \"zero_tolerance\": \"Unknown; likely several weeks to months\",\n+      \"cross_tolerances\": [\n+        \"All barbiturates\",\n+        \"Benzodiazepines (partial cross-tolerance)\",\n+        \"Other GABAergic sedatives\"\n+      ]\n+    },\n+    \"half_life\": \"15-48 hours (average approximately 22 hours); highly variable based on individual metabolism, liver function, and concurrent medications\",\n+    \"citations\": [\n+      {\n+        \"name\": \"DanceSafe Harm Reduction Resources\",\n+        \"reference\": \"https://dancesafe.org/\"\n+      },\n+      {\n+        \"name\": \"Erowid Pentobarbital Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Pharms_Pentobarbital.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Barbiturates Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/barbiturates/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Dangerous Combinations Chart\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Dangerous_combinations\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Pentobarbital\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Pentobarbital\"\n+      },\n+      {\n+        \"name\": \"RollSafe Drug Harm Reduction Guide\",\n+        \"reference\": \"https://rollsafe.org/drug-harm-reduction/\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Pentobarbital Pharmacology\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK545288/\"\n+      },\n+      {\n+        \"name\": \"TripSit Combination Chart\",\n+        \"reference\": \"https://combo.tripsit.me/\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki Drug Combinations\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"depressant\",\n+      \"barbiturate\",\n+      \"sedative-hypnotic\",\n+      \"gabaergic\"\n+    ]\n+  },\n+  \"id\": 671\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-235516-e1ecb329",
    "createdAt": "2025-10-18T23:55:16.703Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 5:55:15 PM"
    },
    "articles": [
      {
        "id": 670,
        "title": "Metizolam",
        "slug": "metizolam"
      }
    ],
    "markdown": "# Metizolam · #670\n\n+{\n+  \"title\": \"Metizolam\",\n+  \"index-category\": \"depressant; thienodiazepine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Metizolam\",\n+    \"chemical_name\": \"4-(2-chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine\",\n+    \"alternative_name\": \"Desmethyletizolam\",\n+    \"chemical_class\": \"Thienodiazepine; Thienotriazolodiazepine\",\n+    \"psychoactive_class\": \"Depressant\",\n+    \"mechanism_of_action\": \"Full agonist at benzodiazepine/GABA-A receptor; enhances GABA efficiency and effects\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1-2 mg\",\n+            \"common\": \"2-4 mg\",\n+            \"strong\": \"4-6 mg\",\n+            \"heavy\": \"6+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"30 minutes-2 hours (plasma peak)\",\n+            \"offset\": \"3-6 hours\",\n+            \"after_effects\": \"10-30 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Thienodiazepines are extremely addictive. Tolerance develops within a couple of days of repeated administration, and the short duration of action encourages compulsive redosing. Abrupt discontinuation following regular use can result in potentially life-threatening withdrawal symptoms including seizures. Limited research exists on metizolam specifically, but similar risks to other thienodiazepines are expected.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Opioids (potentially fatal respiratory depression)\",\n+        \"Alcohol (potentially fatal respiratory depression)\",\n+        \"GHB/GBL (potentially fatal respiratory depression)\",\n+        \"Barbiturates (potentially fatal respiratory depression)\",\n+        \"Gabapentinoids (increased respiratory depression risk)\",\n+        \"Tramadol (lowers seizure threshold during withdrawal)\"\n+      ],\n+      \"unsafe\": [\n+        \"Dissociatives (increased risk of vomiting during unconsciousness and aspiration)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masks sedation leading to excessive intoxication; severe dehydration risk)\",\n+        \"Other depressants (potentiated sedation and amnesia)\"\n+      ]\n+    },\n+    \"notes\": \"Metizolam is a research chemical with very little history of human use and minimal scientific study. It was patented in 1995 but never marketed as a medication. Due to its extreme potency, volumetric liquid dosing is strongly recommended to ensure accurate administration. Abrupt discontinuation after regular use is potentially life-threatening; users should taper their dose gradually over weeks under medical supervision if possible. Metizolam is illegal or controlled in many jurisdictions including Sweden, Germany, Switzerland, Turkey, and the United Kingdom. Individuals with personal or family histories of substance use disorders should avoid this substance entirely due to high addiction potential.\",\n+    \"subjective_effects\": [\n+      \"Anxiety Suppression\",\n+      \"Sedation\",\n+      \"Muscle Relaxation\",\n+      \"Motor Control Loss\",\n+      \"Disinhibition\",\n+      \"Amnesia\",\n+      \"Respiratory Depression\",\n+      \"Dizziness\",\n+      \"Thought Deceleration\",\n+      \"Emotion Suppression\",\n+      \"Delusions of Sobriety\",\n+      \"Compulsive Redosing\",\n+      \"Dream Potentiation\",\n+      \"Euphoria (mild)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2 consecutive days of use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All thienodiazepines\",\n+        \"All benzodiazepines\"\n+      ]\n+    },\n+    \"half_life\": \"3.4 hours (mean elimination half-life, approximately 60% longer than etizolam)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Metizolam\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Metizolam\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Novel Thienodiazepine, Metizolam\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/769635-Novel-Thienodiazepine-Metizolam\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: Metizolam Fact Sheet & Harm Reduction Tips\",\n+        \"reference\": \"https://tripsitter.com/benzodiazepines/metizolam/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Metizolam\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Metizolam\"\n+      },\n+      {\n+        \"name\": \"TripSit: Risks of Combining Depressants\",\n+        \"reference\": \"https://combo.tripsit.me/\"\n+      },\n+      {\n+        \"name\": \"PMC: New/Designer Benzodiazepines - An Analysis of the Literature and Psychonauts' Trip Reports\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569319/\"\n+      },\n+      {\n+        \"name\": \"EMCDDA/EUDA: New benzodiazepines in Europe - a review\",\n+        \"reference\": \"https://www.euda.europa.eu/system/files/publications/13759/TD0221596ENN_002.pdf\"\n+      },\n+      {\n+        \"name\": \"Kintz et al.: Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/dta.2099\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"depressant\",\n+      \"thienodiazepine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 670\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-235216-8e0dc2d9",
    "createdAt": "2025-10-18T23:52:16.572Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 5:52:14 PM"
    },
    "articles": [
      {
        "id": 669,
        "title": "Midazolam",
        "slug": "midazolam"
      }
    ],
    "markdown": "# Midazolam · #669\n\n+{\n+  \"title\": \"Midazolam\",\n+  \"index-category\": \"depressant; benzodiazepine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Midazolam\",\n+    \"chemical_name\": \"8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine\",\n+    \"alternative_name\": \"Versed; Hypnovel; Dormicum\",\n+    \"chemical_class\": \"Benzodiazepine; Imidazobenzodiazepine\",\n+    \"psychoactive_class\": \"Depressant\",\n+    \"mechanism_of_action\": \"GABA-A receptor positive allosteric modulator (increases frequency of chloride channel opening)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2.5-5 mg\",\n+            \"common\": \"5-15 mg\",\n+            \"strong\": \"15-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intranasal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 mg\",\n+            \"light\": \"2-4 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 mg\",\n+            \"light\": \"2-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5-1 mg\",\n+            \"light\": \"1-2.5 mg\",\n+            \"common\": \"2.5-7.5 mg\",\n+            \"strong\": \"7.5-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to 6 hours (residual impairment)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"intranasal\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to 4 hours (residual impairment)\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-4 hours\",\n+            \"onset\": \"2-30 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to 6 hours (residual impairment)\"\n+          },\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ]\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"5-15 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"Up to 4 hours (residual impairment)\"\n+          },\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Midazolam has moderate potential for physical dependence and withdrawal when used regularly for longer than 4 weeks. Tolerance develops rapidly, particularly with continuous use, and withdrawal syndrome can occur with abrupt discontinuation. Risk factors for dependence include prolonged use, higher doses, and history of substance abuse. Infusions may induce tolerance and withdrawal within days.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Opioids (severe respiratory depression and death risk)\",\n+        \"Alcohol (severe respiratory depression and death risk)\",\n+        \"GHB/GBL (severe respiratory depression and death risk)\",\n+        \"Barbiturates (severe respiratory depression and death risk)\",\n+        \"Other CNS depressants (respiratory depression and unconsciousness)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (increased seizure risk)\",\n+        \"Strong CYP3A4 inhibitors (prolonged and intensified effects; includes ketoconazole, itraconazole, erythromycin, clarithromycin, diltiazem, verapamil, protease inhibitors, grapefruit juice)\",\n+        \"Tricyclic antidepressants (increased toxicity)\"\n+      ],\n+      \"caution\": [\n+        \"CYP3A4 inducers (reduced effectiveness; includes St John's Wort, rifampin, phenytoin, carbamazepine)\",\n+        \"Sedating antihistamines (increased sedation)\",\n+        \"Antipsychotics (increased sedation)\",\n+        \"Antiepileptics (altered effects)\"\n+      ]\n+    },\n+    \"notes\": \"Midazolam is a Schedule IV controlled substance in the United States and a prescription-only medication in most countries. It should never be combined with other depressants due to extreme risk of fatal respiratory depression. Users with liver or kidney impairment may experience prolonged effects and should avoid use or reduce doses significantly. The sudden discontinuation after prolonged use can be dangerous or life-threatening and requires medical supervision with gradual tapering. Midazolam causes anterograde amnesia, meaning users will not remember events during peak effects. Paradoxical reactions including agitation, aggression, and hallucinations can occur. Never operate vehicles or machinery after use.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Anxiety Suppression\",\n+      \"Muscle Relaxation\",\n+      \"Disinhibition\",\n+      \"Anterograde Amnesia\",\n+      \"Respiratory Depression\",\n+      \"Motor Control Loss\",\n+      \"Euphoria (mild to moderate)\",\n+      \"Cognitive Impairment\",\n+      \"Dream Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-4 days of continuous use\",\n+      \"half_tolerance\": \"2-4 days after cessation\",\n+      \"zero_tolerance\": \"7-14 days\",\n+      \"cross_tolerances\": [\n+        \"All benzodiazepines\",\n+        \"Other GABAergic depressants\"\n+      ]\n+    },\n+    \"half_life\": \"1.5-3 hours (elimination half-life); active metabolite alpha-1-hydroxymidazolam has similar duration but contributes only 10% of biological activity\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Midazolam Vault\",\n+        \"reference\": \"https://erowid.org/pharms/midazolam/\"\n+      },\n+      {\n+        \"name\": \"Midazolam - StatPearls - NCBI Bookshelf\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK537321/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Midazolam\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Midazolam\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combinations Chart\",\n+        \"reference\": \"https://combo.tripsit.me/\"\n+      },\n+      {\n+        \"name\": \"TripSit Midazolam Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/midazolam\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Midazolam\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Midazolam\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"depressant\",\n+      \"benzodiazepine\",\n+      \"short-acting\",\n+      \"prescription\"\n+    ]\n+  },\n+  \"id\": 669\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-234943-2080087e",
    "createdAt": "2025-10-18T23:49:43.141Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Remove Flualprazolam - 10/18/2025, 5:49:41 PM"
    },
    "articles": [
      {
        "id": 669,
        "title": "Flualprazolam",
        "slug": "flualprazolam"
      }
    ],
    "markdown": "# Flualprazolam · #669\n\n-{\n-  \"title\": \"Flualprazolam\",\n-  \"index-category\": \"depressant; benzodiazepine; research-chemical\",\n-  \"drug_info\": {\n-    \"drug_name\": \"Flualprazolam\",\n-    \"chemical_name\": \"8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine\",\n-    \"alternative_name\": \"Flualp; F-Alp; 2'-Fluoro-Alprazolam\",\n-    \"chemical_class\": \"Triazolobenzodiazepines\",\n-    \"psychoactive_class\": \"Depressant\",\n-    \"mechanism_of_action\": \"GABA-A receptor positive allosteric modulator\",\n-    \"dosages\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.05 mg\",\n-            \"light\": \"0.1-0.3 mg\",\n-            \"common\": \"0.3-0.5 mg\",\n-            \"strong\": \"0.5-1 mg\",\n-            \"heavy\": \"1+ mg\"\n-          }\n-        }\n-      ]\n-    },\n-    \"duration\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"oral\",\n-          \"stages\": {\n-            \"total_duration\": \"5-8 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-6 hours\",\n-            \"after_effects\": \"6-24 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ]\n-        }\n-      ]\n-    },\n-    \"addiction_potential\": \"Flualprazolam is considered highly addictive with a high potential for abuse. It has been reported by users to dramatically and rapidly increase benzodiazepine cross-tolerance. Tolerance to sedative-hypnotic effects develops within a couple of days of continuous use. Withdrawal symptoms may occur after ceasing usage abruptly following steady dosing and can include rebound anxiety, seizures, and potentially life-threatening complications.\",\n-    \"interactions\": {\n-      \"dangerous\": [\n-        \"Alcohol (respiratory depression, loss of consciousness)\",\n-        \"Opioids (respiratory depression, loss of consciousness)\",\n-        \"GHB/GBL (respiratory depression, loss of consciousness)\",\n-        \"Barbiturates (respiratory depression, loss of consciousness)\"\n-      ],\n-      \"unsafe\": [\n-        \"Dissociatives (unpredictable amnesia, sedation, respiratory depression)\",\n-        \"Other benzodiazepines (potentiated CNS depression)\"\n-      ],\n-      \"caution\": [\n-        \"Stimulants (masks sedation, risk of blackouts)\",\n-        \"Tramadol (lowers seizure threshold during withdrawal)\"\n-      ]\n-    },\n-    \"notes\": \"Flualprazolam is a highly potent designer benzodiazepine that is 1.5-5 times stronger than alprazolam by weight. It is typically sold as counterfeit alprazolam (Xanax) tablets or as a research chemical. Accurate weighing with a precise milligram scale is critical due to extreme potency. This substance is particularly hypnotic and sedating compared to alprazolam, with strong amnestic effects and compulsive redosing tendencies. Sudden discontinuation after regular use can be life-threatening; individuals physically dependent on benzodiazepines must taper gradually. Use extreme caution and harm reduction practices. Flualprazolam is Schedule I in the United States as of January 2023 and controlled in many other jurisdictions.\",\n-    \"subjective_effects\": [\n-      \"Sedation\",\n-      \"Muscle Relaxation\",\n-      \"Anxiety Suppression\",\n-      \"Memory Suppression\",\n-      \"Disinhibition\",\n-      \"Physical Euphoria (Short-Lasting)\",\n-      \"Cognitive Euphoria (Short-Lasting)\",\n-      \"Compulsive Redosing\",\n-      \"Delusions of Sobriety\",\n-      \"Motor Control Loss\",\n-      \"Sleepiness\",\n-      \"Emotion Suppression\",\n-      \"Respiratory Depression\",\n-      \"Dizziness\"\n-    ],\n-    \"tolerance\": {\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"7-14 days\",\n-      \"zero_tolerance\": \"2-4 weeks\",\n-      \"cross_tolerances\": [\n-        \"All benzodiazepines\",\n-        \"Thienodiazepines\",\n-        \"Z-drugs (zopiclone, zolpidem)\",\n-        \"Gabapentinoids (pregabalin, gabapentin)\"\n-      ]\n-    },\n-    \"half_life\": \"6-12 hours (approximately double that of alprazolam)\",\n-    \"citations\": [\n-      {\n-        \"name\": \"Bluelight Flualprazolam Discussion Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/flualprazolam.835125/\"\n-      },\n-      {\n-        \"name\": \"DEA Federal Register - Schedule I Placement\",\n-        \"reference\": \"https://www.federalregister.gov/documents/2022/12/23/2022-27278/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam\"\n-      },\n-      {\n-        \"name\": \"Erowid Experience Vaults: Flualprazolam\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_Flualprazolam.shtml\"\n-      },\n-      {\n-        \"name\": \"Forensic Toxicology - Fatal Flualprazolam Intoxication Case Report\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s11419-021-00591-w\"\n-      },\n-      {\n-        \"name\": \"Forensic Toxicology - Flualprazolam Review Article\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s11419-020-00565-4\"\n-      },\n-      {\n-        \"name\": \"Journal of Forensic Sciences - Flualprazolam Distribution Study\",\n-        \"reference\": \"https://onlinelibrary.wiley.com/doi/10.1111/1556-4029.14893\"\n-      },\n-      {\n-        \"name\": \"PsychonautWiki: Flualprazolam\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Flualprazolam\"\n-      },\n-      {\n-        \"name\": \"Reddit r/researchchemicals Flualprazolam Review\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/7m1qns/flualprazolam_review/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Flualprazolam\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Flualprazolam\"\n-      }\n-    ],\n-    \"categories\": [\n-      \"benzodiazepine\",\n-      \"triazolobenzodiazepine\",\n-      \"research-chemical\",\n-      \"depressant\"\n-    ]\n-  },\n-  \"id\": 669\n-}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-234752-2301fc35",
    "createdAt": "2025-10-18T23:47:52.428Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 5:47:50 PM"
    },
    "articles": [
      {
        "id": 669,
        "title": "Flualprazolam",
        "slug": "flualprazolam"
      }
    ],
    "markdown": "# Flualprazolam · #669\n\n+{\n+  \"title\": \"Flualprazolam\",\n+  \"index-category\": \"depressant; benzodiazepine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Flualprazolam\",\n+    \"chemical_name\": \"8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine\",\n+    \"alternative_name\": \"Flualp; F-Alp; 2'-Fluoro-Alprazolam\",\n+    \"chemical_class\": \"Triazolobenzodiazepines\",\n+    \"psychoactive_class\": \"Depressant\",\n+    \"mechanism_of_action\": \"GABA-A receptor positive allosteric modulator\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.1-0.3 mg\",\n+            \"common\": \"0.3-0.5 mg\",\n+            \"strong\": \"0.5-1 mg\",\n+            \"heavy\": \"1+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Flualprazolam is considered highly addictive with a high potential for abuse. It has been reported by users to dramatically and rapidly increase benzodiazepine cross-tolerance. Tolerance to sedative-hypnotic effects develops within a couple of days of continuous use. Withdrawal symptoms may occur after ceasing usage abruptly following steady dosing and can include rebound anxiety, seizures, and potentially life-threatening complications.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (respiratory depression, loss of consciousness)\",\n+        \"Opioids (respiratory depression, loss of consciousness)\",\n+        \"GHB/GBL (respiratory depression, loss of consciousness)\",\n+        \"Barbiturates (respiratory depression, loss of consciousness)\"\n+      ],\n+      \"unsafe\": [\n+        \"Dissociatives (unpredictable amnesia, sedation, respiratory depression)\",\n+        \"Other benzodiazepines (potentiated CNS depression)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masks sedation, risk of blackouts)\",\n+        \"Tramadol (lowers seizure threshold during withdrawal)\"\n+      ]\n+    },\n+    \"notes\": \"Flualprazolam is a highly potent designer benzodiazepine that is 1.5-5 times stronger than alprazolam by weight. It is typically sold as counterfeit alprazolam (Xanax) tablets or as a research chemical. Accurate weighing with a precise milligram scale is critical due to extreme potency. This substance is particularly hypnotic and sedating compared to alprazolam, with strong amnestic effects and compulsive redosing tendencies. Sudden discontinuation after regular use can be life-threatening; individuals physically dependent on benzodiazepines must taper gradually. Use extreme caution and harm reduction practices. Flualprazolam is Schedule I in the United States as of January 2023 and controlled in many other jurisdictions.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Muscle Relaxation\",\n+      \"Anxiety Suppression\",\n+      \"Memory Suppression\",\n+      \"Disinhibition\",\n+      \"Physical Euphoria (Short-Lasting)\",\n+      \"Cognitive Euphoria (Short-Lasting)\",\n+      \"Compulsive Redosing\",\n+      \"Delusions of Sobriety\",\n+      \"Motor Control Loss\",\n+      \"Sleepiness\",\n+      \"Emotion Suppression\",\n+      \"Respiratory Depression\",\n+      \"Dizziness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"7-14 days\",\n+      \"zero_tolerance\": \"2-4 weeks\",\n+      \"cross_tolerances\": [\n+        \"All benzodiazepines\",\n+        \"Thienodiazepines\",\n+        \"Z-drugs (zopiclone, zolpidem)\",\n+        \"Gabapentinoids (pregabalin, gabapentin)\"\n+      ]\n+    },\n+    \"half_life\": \"6-12 hours (approximately double that of alprazolam)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight Flualprazolam Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/flualprazolam.835125/\"\n+      },\n+      {\n+        \"name\": \"DEA Federal Register - Schedule I Placement\",\n+        \"reference\": \"https://www.federalregister.gov/documents/2022/12/23/2022-27278/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: Flualprazolam\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Flualprazolam.shtml\"\n+      },\n+      {\n+        \"name\": \"Forensic Toxicology - Fatal Flualprazolam Intoxication Case Report\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-021-00591-w\"\n+      },\n+      {\n+        \"name\": \"Forensic Toxicology - Flualprazolam Review Article\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-020-00565-4\"\n+      },\n+      {\n+        \"name\": \"Journal of Forensic Sciences - Flualprazolam Distribution Study\",\n+        \"reference\": \"https://onlinelibrary.wiley.com/doi/10.1111/1556-4029.14893\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Flualprazolam\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Flualprazolam\"\n+      },\n+      {\n+        \"name\": \"Reddit r/researchchemicals Flualprazolam Review\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/7m1qns/flualprazolam_review/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Flualprazolam\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Flualprazolam\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"benzodiazepine\",\n+      \"triazolobenzodiazepine\",\n+      \"research-chemical\",\n+      \"depressant\"\n+    ]\n+  },\n+  \"id\": 669\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-212920-d5b53bac",
    "createdAt": "2025-10-18T21:29:20.982Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 3:29:18 PM"
    },
    "articles": [
      {
        "id": 668,
        "title": "Flualprazolam",
        "slug": "flualprazolam"
      }
    ],
    "markdown": "# Flualprazolam · #668\n\n+{\n+  \"title\": \"Flualprazolam\",\n+  \"index-category\": \"depressant; benzodiazepine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Flualprazolam\",\n+    \"chemical_name\": \"8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine\",\n+    \"alternative_name\": \"Flualp; F-Alp; 2'-Fluoro-Alprazolam\",\n+    \"chemical_class\": \"Triazolobenzodiazepines\",\n+    \"psychoactive_class\": \"Depressant\",\n+    \"mechanism_of_action\": \"GABA-A receptor positive allosteric modulator\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.1-0.3 mg\",\n+            \"common\": \"0.3-0.5 mg\",\n+            \"strong\": \"0.5-1 mg\",\n+            \"heavy\": \"1+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Flualprazolam is considered highly addictive with a high potential for abuse. It has been reported by users to dramatically and rapidly increase benzodiazepine cross-tolerance. Tolerance to sedative-hypnotic effects develops within a couple of days of continuous use. Withdrawal symptoms may occur after ceasing usage abruptly following steady dosing and can include rebound anxiety, seizures, and potentially life-threatening complications.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (respiratory depression, loss of consciousness)\",\n+        \"Opioids (respiratory depression, loss of consciousness)\",\n+        \"GHB/GBL (respiratory depression, loss of consciousness)\",\n+        \"Barbiturates (respiratory depression, loss of consciousness)\"\n+      ],\n+      \"unsafe\": [\n+        \"Dissociatives (unpredictable amnesia, sedation, respiratory depression)\",\n+        \"Other benzodiazepines (potentiated CNS depression)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (masks sedation, risk of blackouts)\",\n+        \"Tramadol (lowers seizure threshold during withdrawal)\"\n+      ]\n+    },\n+    \"notes\": \"Flualprazolam is a highly potent designer benzodiazepine that is 1.5-5 times stronger than alprazolam by weight. It is typically sold as counterfeit alprazolam (Xanax) tablets or as a research chemical. Accurate weighing with a precise milligram scale is critical due to extreme potency. This substance is particularly hypnotic and sedating compared to alprazolam, with strong amnestic effects and compulsive redosing tendencies. Sudden discontinuation after regular use can be life-threatening; individuals physically dependent on benzodiazepines must taper gradually. Use extreme caution and harm reduction practices. Flualprazolam is Schedule I in the United States as of January 2023 and controlled in many other jurisdictions.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Muscle Relaxation\",\n+      \"Anxiety Suppression\",\n+      \"Memory Suppression\",\n+      \"Disinhibition\",\n+      \"Physical Euphoria (Short-Lasting)\",\n+      \"Cognitive Euphoria (Short-Lasting)\",\n+      \"Compulsive Redosing\",\n+      \"Delusions of Sobriety\",\n+      \"Motor Control Loss\",\n+      \"Sleepiness\",\n+      \"Emotion Suppression\",\n+      \"Respiratory Depression\",\n+      \"Dizziness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"7-14 days\",\n+      \"zero_tolerance\": \"2-4 weeks\",\n+      \"cross_tolerances\": [\n+        \"All benzodiazepines\",\n+        \"Thienodiazepines\",\n+        \"Z-drugs (zopiclone, zolpidem)\",\n+        \"Gabapentinoids (pregabalin, gabapentin)\"\n+      ]\n+    },\n+    \"half_life\": \"6-12 hours (approximately double that of alprazolam)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight Flualprazolam Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/flualprazolam.835125/\"\n+      },\n+      {\n+        \"name\": \"DEA Federal Register - Schedule I Placement\",\n+        \"reference\": \"https://www.federalregister.gov/documents/2022/12/23/2022-27278/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: Flualprazolam\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Flualprazolam.shtml\"\n+      },\n+      {\n+        \"name\": \"Forensic Toxicology - Fatal Flualprazolam Intoxication Case Report\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-021-00591-w\"\n+      },\n+      {\n+        \"name\": \"Forensic Toxicology - Flualprazolam Review Article\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-020-00565-4\"\n+      },\n+      {\n+        \"name\": \"Journal of Forensic Sciences - Flualprazolam Distribution Study\",\n+        \"reference\": \"https://onlinelibrary.wiley.com/doi/10.1111/1556-4029.14893\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Flualprazolam\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Flualprazolam\"\n+      },\n+      {\n+        \"name\": \"Reddit r/researchchemicals Flualprazolam Review\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/7m1qns/flualprazolam_review/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Flualprazolam\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Flualprazolam\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"benzodiazepine\",\n+      \"triazolobenzodiazepine\",\n+      \"research-chemical\",\n+      \"depressant\"\n+    ]\n+  },\n+  \"id\": 668\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-212638-d3b178bc",
    "createdAt": "2025-10-18T21:26:38.317Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 3:26:35 PM"
    },
    "articles": [
      {
        "id": 667,
        "title": "2M2B",
        "slug": "2m2b"
      }
    ],
    "markdown": "# 2M2B · #667\n\n+{\n+  \"title\": \"2M2B\",\n+  \"index-category\": \"depressant; alcohol\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2M2B\",\n+    \"chemical_name\": \"2-methylbutan-2-ol\",\n+    \"alternative_name\": \"tert-Amyl alcohol; Amylene hydrate; TAA\",\n+    \"chemical_class\": \"Tertiary alcohol\",\n+    \"psychoactive_class\": \"Depressant\",\n+    \"mechanism_of_action\": \"GABA-A receptor positive allosteric modulator (binds to proconvulsant site)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ml\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 ml\",\n+            \"light\": \"1-5 ml\",\n+            \"common\": \"5-10 ml\",\n+            \"strong\": \"10-15 ml\",\n+            \"heavy\": \"15+ ml\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"10-50 minutes\",\n+            \"peak\": \"6-8 hours\",\n+            \"offset\": \"4-6 hours\",\n+            \"after_effects\": \"Up to 24 hours (sedation and lethargy)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2M2B has moderate to high addiction potential and can cause physical dependence. As with other GABA receptor agonists, repeated use leads to tolerance and withdrawal symptoms upon discontinuation resembling alcohol, barbiturate, or benzodiazepine withdrawal, including potentially life-threatening delirium tremens. Users report compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Depressants (alcohol, benzodiazepines, barbiturates, opioids, GHB/GBL) - Potentially fatal respiratory depression\",\n+        \"Dissociatives (ketamine, DXM, PCP) - Unpredictable potentiation of amnesia, sedation, and respiratory depression\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Stimulants - Mask sedative effects leading to dangerous disinhibition and blackout states when stimulant wears off\"\n+      ]\n+    },\n+    \"notes\": \"2M2B is approximately 20 times more potent than ethanol by weight. Fatal overdoses have been reported at doses as low as 18-30 ml. It has an extremely unpleasant taste and smell resembling gasoline, camphor, or solvents. Unlike primary alcohols, 2M2B cannot be metabolized into toxic aldehydes, resulting in significantly reduced hangover effects but extended duration of action lasting up to 24 hours. Precise measurement with graduated equipment is essential due to high potency. The substance is not detected by standard alcohol or drug tests but can be identified via gas chromatography-mass spectrometry. Gelatin capsules are recommended for oral administration to avoid the harsh taste.\",\n+    \"subjective_effects\": [\n+      \"Sedation (significantly more than ethanol)\",\n+      \"Muscle Relaxation\",\n+      \"Motor Control Loss (disproportionately severe)\",\n+      \"Anxiety Suppression\",\n+      \"Cognitive Euphoria (less than ethanol)\",\n+      \"Delusions of Sobriety\",\n+      \"Disinhibition\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Respiratory Depression\",\n+      \"Pain Relief\",\n+      \"Appetite Enhancement\",\n+      \"Dizziness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All GABAergic depressants (alcohol, benzodiazepines, barbiturates, GHB)\"\n+      ]\n+    },\n+    \"half_life\": \"Extended elimination time via glucuronidation; effects last 8-14 hours with residual sedation up to 24 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 2M2B\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2M2B\"\n+      },\n+      {\n+        \"name\": \"TripSit: 2-methyl-2-butanol Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/2-methyl-2-butanol\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: 2-Methyl-2-Butanol\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_2Methyl2Butanol.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: 2M2B Synthetic Alcohols Megathread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/2m2b-2-methyl-2-butanol-synthetic-alcohols-megathread.538800/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: tert-Amyl alcohol\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Tert-Amyl_alcohol\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: 2-Methyl-2-Butanol Discussion\",\n+        \"reference\": \"https://drugs-forum.com/threads/2-methyl-2-butanol-2m2b.146071/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"depressant\",\n+      \"alcohol\",\n+      \"gaba-agonist\",\n+      \"tertiary-alcohol\"\n+    ]\n+  },\n+  \"id\": 667\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-211229-7aaf9a58",
    "createdAt": "2025-10-18T21:12:29.210Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 3:12:26 PM"
    },
    "articles": [
      {
        "id": 666,
        "title": "THJ-018",
        "slug": "thj-018"
      }
    ],
    "markdown": "# THJ-018 · #666\n\n+{\n+  \"title\": \"THJ-018\",\n+  \"index-category\": \"synthetic-cannabinoid; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"THJ-018\",\n+    \"chemical_name\": \"1-Naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone\",\n+    \"alternative_name\": \"SGT-17\",\n+    \"chemical_class\": \"Naphthoylindazoles\",\n+    \"psychoactive_class\": \"Cannabinoid\",\n+    \"mechanism_of_action\": \"CB1 cannabinoid receptor full agonist (Ki 5.84 nM); CB2 cannabinoid receptor full agonist (Ki 4.57 nM, with slight selectivity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"< 1 mg\",\n+            \"light\": \"1-2 mg\",\n+            \"common\": \"2-3 mg\",\n+            \"strong\": \"3-5 mg\",\n+            \"heavy\": \"5+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-3 hours\",\n+            \"onset\": \"5-10 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"5-10 minutes\",\n+            \"after_effects\": \"60-90 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Chronic use of THJ-018 can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. When addiction has developed, cravings and withdrawal effects may occur upon sudden cessation. Evidence of dependence with synthetic cannabinoids is limited but documented.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\"\n+      ],\n+      \"caution\": [\n+        \"Psychedelics (intensified and extended visual and cognitive effects)\",\n+        \"Dissociatives (greatly enhanced geometry, euphoria, dissociation and hallucinatory effects)\",\n+        \"Alcohol (extreme nausea, dizziness, and changes in gravity)\",\n+        \"2C-x compounds (unpredictable effects)\",\n+        \"2C-T-x compounds (unpredictable effects)\",\n+        \"5-MeO-xxT compounds (unpredictable effects)\",\n+        \"aMT (unpredictable effects)\",\n+        \"DOx compounds (unpredictable effects)\",\n+        \"DMT (unpredictable effects)\",\n+        \"LSD (unpredictable effects)\",\n+        \"Mescaline (unpredictable effects)\",\n+        \"Psilocybin mushrooms (unpredictable effects)\",\n+        \"25x-NBOMe compounds (unpredictable effects)\"\n+      ]\n+    },\n+    \"notes\": \"THJ-018 is a synthetic cannabinoid analog of JWH-018 marketed as a legal alternative after JWH-018 was banned in 2009. It appears as a brown, sticky, chunky powder with a naphthalene-like smell. As synthetic cannabinoids are active in the milligram range, accurate weighing with a precision scale is essential. The naphthalene group may be toxic or carcinogenic with chronic use. Unlike cannabis, synthetic cannabinoids have been associated with multiple deaths and dangerous side effects. Individuals with personal or family history of psychotic disorders should avoid use, as prolonged usage may increase disposition to psychosis. It is strongly discouraged to take this substance for extended periods or in excessive doses.\",\n+    \"subjective_effects\": [\n+      \"Spontaneous Physical Sensations\",\n+      \"Sedation\",\n+      \"Motor Control Loss\",\n+      \"Appetite Enhancement\",\n+      \"Pain Relief\",\n+      \"Vasodilation\",\n+      \"Perception of Bodily Lightness\",\n+      \"Dehydration\",\n+      \"Color Enhancement\",\n+      \"Acuity Suppression\",\n+      \"Closed-Eye Geometry\",\n+      \"Emotion Enhancement\",\n+      \"Anxiety\",\n+      \"Paranoia\",\n+      \"Thought Connectivity\",\n+      \"Thought Deceleration\",\n+      \"Conceptual Thinking\",\n+      \"Mindfulness\",\n+      \"Analysis Suppression\",\n+      \"Dream Suppression\",\n+      \"Immersion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Auditory Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All cannabinoids\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"DanceSafe Drug Checking\",\n+        \"reference\": \"https://dancesafe.org/drug-checking/\"\n+      },\n+      {\n+        \"name\": \"Erowid THJ-018 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_THJ018.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki THJ-018\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/THJ-018\"\n+      },\n+      {\n+        \"name\": \"Wikipedia THJ-018\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/THJ-018\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"synthetic-cannabinoid\",\n+      \"research-chemical\",\n+      \"cannabinoid\",\n+      \"naphthoylindazole\"\n+    ]\n+  },\n+  \"id\": 666\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-211007-f1b6cbae",
    "createdAt": "2025-10-18T21:10:07.456Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 3:10:04 PM"
    },
    "articles": [
      {
        "id": 665,
        "title": "JWH-073",
        "slug": "jwh-073"
      }
    ],
    "markdown": "# JWH-073 · #665\n\n+{\n+  \"title\": \"JWH-073\",\n+  \"index-category\": \"cannabinoid; synthetic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"JWH-073\",\n+    \"chemical_name\": \"Naphthalen-1-yl-(1-butylindol-3-yl)methanone\",\n+    \"alternative_name\": \"Spice\",\n+    \"chemical_class\": \"Naphthoylindole\",\n+    \"psychoactive_class\": \"Cannabinoid\",\n+    \"mechanism_of_action\": \"CB1 receptor full agonist; CB2 receptor full agonist (5x lower affinity than CB1)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Under 3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"5-10 minutes\",\n+            \"peak\": \"60-90 minutes\",\n+            \"offset\": \"5-10 minutes\",\n+            \"after_effects\": \"60-90 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"JWH-073 is considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. The short duration of action may lead to more frequent use and strengthen habitual patterns. Cravings and withdrawal effects may occur upon sudden cessation after chronic use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-x series\",\n+        \"2C-x series\",\n+        \"5-MeO-xxT series\",\n+        \"DMT\",\n+        \"DOx series\",\n+        \"LSD\",\n+        \"Mescaline\",\n+        \"Psilocybin mushrooms\",\n+        \"25x-NBOMe series\"\n+      ],\n+      \"caution\": [\n+        \"Amphetamines (increased anxiety and thought loops)\",\n+        \"aMT\",\n+        \"Cocaine (increased anxiety and thought loops)\",\n+        \"Alcohol (extreme nausea, dizziness, changes in gravity when combined)\"\n+      ]\n+    },\n+    \"notes\": \"JWH-073 is a synthetic cannabinoid active in the milligram range and requires precise weighing with a milligram scale to avoid overdose. Unlike cannabis, chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects. Individuals with personal or family history of psychotic disorders should strictly avoid use. The substance may be carcinogenic due to its naphthalene moiety. Set and setting are important factors. JWH-073 was commonly found in Spice and similar synthetic cannabis products.\",\n+    \"subjective_effects\": [\n+      \"Warm Pleasurable Body High\",\n+      \"Sedation\",\n+      \"Motor Control Loss\",\n+      \"Appetite Enhancement\",\n+      \"Pain Relief\",\n+      \"Emotion Enhancement\",\n+      \"Euphoria\",\n+      \"Thought Connectivity\",\n+      \"Color Enhancement\",\n+      \"Visual Geometry (Mild)\",\n+      \"Auditory Enhancement\",\n+      \"Anxiety (Less Than JWH-018)\",\n+      \"Paranoia (Dose-Dependent)\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All cannabinoids including THC, JWH-018, AM-2201, and other synthetic cannabinoids\"\n+      ]\n+    },\n+    \"half_life\": \"Extended half-life with less receptor internalization compared to JWH-018 (specific duration not well-established in humans)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight JWH-073 Discussion Threads\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/jwh-any-advice.538784/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum Cannabinoid Dose and Duration Chart\",\n+        \"reference\": \"https://drugs-forum.com/threads/cannabinoid-dose-and-duration-chart-beta.111754/\"\n+      },\n+      {\n+        \"name\": \"Erowid JWH-073 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_JWH073.shtml\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Neuroscience: JWH-073 and JWH-210 Behavioral Profile\",\n+        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00703/full\"\n+      },\n+      {\n+        \"name\": \"PMC: JWH-073 Electrophysiological Effects in Mice\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9634257/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: JWH-073\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/JWH-073\"\n+      },\n+      {\n+        \"name\": \"ScienceDirect Topics: JWH-073 Overview\",\n+        \"reference\": \"https://www.sciencedirect.com/topics/neuroscience/jwh-073\"\n+      },\n+      {\n+        \"name\": \"WHO Expert Committee on Drug Dependence: JWH-073\",\n+        \"reference\": \"https://ecddrepository.org/en/jwh-073\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: JWH-073\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/JWH-073\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"synthetic-cannabinoid\",\n+      \"cannabinoid\",\n+      \"naphthoylindole\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 665\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-210317-00e34857",
    "createdAt": "2025-10-18T21:03:17.337Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 3:03:14 PM"
    },
    "articles": [
      {
        "id": 664,
        "title": "AB-FUBINACA",
        "slug": "ab-fubinaca"
      }
    ],
    "markdown": "# AB-FUBINACA · #664\n\n+{\n+  \"title\": \"AB-FUBINACA\",\n+  \"index-category\": \"synthetic-cannabinoid; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"AB-FUBINACA\",\n+    \"chemical_name\": \"N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide\",\n+    \"alternative_name\": \"Ab-fubi; AMB-FUBINACA\",\n+    \"chemical_class\": \"Indazolecarboxamide\",\n+    \"psychoactive_class\": \"Cannabinoid\",\n+    \"mechanism_of_action\": \"CB1 cannabinoid receptor full agonist (Ki 0.9 nM, EC50 1.8 nM); CB2 cannabinoid receptor full agonist (Ki 23.2 nM, EC50 3.2 nM) with selectivity for CB2\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"< 1 mg\",\n+            \"light\": \"1-2 mg\",\n+            \"common\": \"2-3 mg\",\n+            \"strong\": \"3-5 mg\",\n+            \"heavy\": \"5+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"0-20 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"10-20 minutes\",\n+            \"after_effects\": \"15-30 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"AB-FUBINACA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. When addiction develops, cravings and withdrawal effects may occur if use is stopped suddenly. Physical dependence has been demonstrated in animal studies, with precipitated withdrawal signs including head twitches and paw tremors.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Amphetamines (increased anxiety and thought loops)\",\n+        \"Cocaine (increased anxiety and thought loops)\"\n+      ],\n+      \"caution\": [\n+        \"2C-T-x (unpredictable interactions)\",\n+        \"2C-x (unpredictable interactions)\",\n+        \"5-MeO-xxT (unpredictable interactions)\",\n+        \"aMT (unpredictable interactions)\",\n+        \"DMT (unpredictable interactions)\",\n+        \"DOx (unpredictable interactions)\",\n+        \"LSD (unpredictable interactions)\",\n+        \"Mescaline (unpredictable interactions)\",\n+        \"Psilocybin mushrooms (unpredictable interactions)\",\n+        \"25x-NBOMe (unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"AB-FUBINACA is a highly potent synthetic cannabinoid that is active at very low milligram doses, making accurate measurement with a precision scale absolutely critical. Unlike cannabis, chronic abuse of synthetic cannabinoids has been associated with multiple deaths, hospitalizations, and more dangerous side effects. The substance is insoluble in water but dissolves in ethanol and lipids. Extended use or high doses are strongly discouraged. Individuals with personal or family histories of psychotic disorders should avoid this substance, as prolonged use may increase disposition to psychosis.\",\n+    \"subjective_effects\": [\n+      \"Sedation\",\n+      \"Spontaneous Physical Sensations (Warm Tingling Body High)\",\n+      \"Motor Control Loss\",\n+      \"Appetite Enhancement (Munchies)\",\n+      \"Changes In Felt Gravity (Vertigo)\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Dehydration\",\n+      \"Dry Mouth\",\n+      \"Nausea\",\n+      \"Visual Recursion\",\n+      \"Visual Haze\",\n+      \"Anxiety\",\n+      \"Paranoia\",\n+      \"Thought Connectivity\",\n+      \"Thought Deceleration\",\n+      \"Conceptual Thinking\",\n+      \"Analysis Suppression\",\n+      \"Dream Suppression\",\n+      \"Immersion Enhancement\",\n+      \"Personal Meaning Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Auditory Distortion\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated daily use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All cannabinoids (including THC and other synthetic cannabinoids)\"\n+      ]\n+    },\n+    \"half_life\": \"Less than 1 hour (brain levels undetectable at 4 hours post-administration)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: AB-FUBINACA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/AB-FUBINACA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: AB-FUBINACA\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AB-FUBINACA\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: AB-FUBINACA\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ABFUBINACA.shtml\"\n+      },\n+      {\n+        \"name\": \"NCBI: The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461724/\"\n+      },\n+      {\n+        \"name\": \"NCBI: Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26134475/\"\n+      },\n+      {\n+        \"name\": \"NCBI: Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996508/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"synthetic-cannabinoid\",\n+      \"research-chemical\",\n+      \"cannabinoid\"\n+    ]\n+  },\n+  \"id\": 664\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-205110-50922f5e",
    "createdAt": "2025-10-18T20:51:10.357Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 2:51:07 PM"
    },
    "articles": [
      {
        "id": 409,
        "title": "Salvia divinorum",
        "slug": "salvia-divinorum"
      }
    ],
    "markdown": "# Salvia divinorum · #409\n\n-      \"atypical-psychedelic\",\n-      \"kappa-opioid-agonist\"\n+      \"kappa-opioid-agonist\",\n+      \"A-typical Hallucinogen\"\n-  \"index-category\": \"dissociative; atypical-psychedelic; entheogen\"\n+  \"index-category\": \"dissociative; entheogen\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-204215-817da4b7",
    "createdAt": "2025-10-18T20:42:15.845Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 2:42:13 PM"
    },
    "articles": [
      {
        "id": 409,
        "title": "Salvia divinorum",
        "slug": "salvia-divinorum"
      }
    ],
    "markdown": "# Salvia divinorum · #409\n\n+{\n+  \"id\": 409,\n+  \"title\": \"Salvia divinorum\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Salvia divinorum\",\n+    \"chemical_name\": \"Methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate\",\n+    \"alternative_name\": \"Salvinorin A; Diviner's Sage; Ska Maria Pastora; Seer's Sage; Sally; Sally D; Magic Mint; Yerba de la Pastora\",\n+    \"chemical_class\": \"Diterpenoid; Neoclerodane\",\n+    \"mechanism_of_action\": \"Kappa-opioid receptor agonist; D2 dopamine receptor agonist (weak)\",\n+    \"psychoactive_class\": \"Dissociative; Atypical psychedelic\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked (dried leaf)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.2 g\",\n+            \"light\": \"0.25 g\",\n+            \"common\": \"0.5 g\",\n+            \"strong\": \"0.75-1 g\",\n+            \"heavy\": \"1+ g\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked (5x extract)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-40 mg\",\n+            \"light\": \"40-100 mg\",\n+            \"common\": \"100-200 mg\",\n+            \"strong\": \"200-300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked (10x extract)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-20 mg\",\n+            \"light\": \"20-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual/quid (fresh leaf)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 g\",\n+            \"light\": \"10 g\",\n+            \"common\": \"30 g\",\n+            \"strong\": \"50 g\",\n+            \"heavy\": \"50+ g\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual/quid (dried leaf)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 g\",\n+            \"light\": \"2 g\",\n+            \"common\": \"6 g\",\n+            \"strong\": \"10 g\",\n+            \"heavy\": \"10+ g\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized (pure salvinorin A)\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200-500 ug\",\n+            \"light\": \"500-800 ug\",\n+            \"common\": \"800-1200 ug\",\n+            \"strong\": \"1200-2000 ug\",\n+            \"heavy\": \"2000+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked (dried leaf)\",\n+          \"stages\": {\n+            \"total_duration\": \"15-90 minutes\",\n+            \"onset\": \"15-60 seconds\",\n+            \"peak\": \"5-20 minutes\",\n+            \"offset\": \"10-30 minutes\",\n+            \"after_effects\": \"15-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked (5x extract)\",\n+          \"stages\": {\n+            \"total_duration\": \"15-90 minutes\",\n+            \"onset\": \"15-60 seconds\",\n+            \"peak\": \"5-20 minutes\",\n+            \"offset\": \"10-30 minutes\",\n+            \"after_effects\": \"15-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked (10x extract)\",\n+          \"stages\": {\n+            \"total_duration\": \"15-90 minutes\",\n+            \"onset\": \"15-60 seconds\",\n+            \"peak\": \"5-20 minutes\",\n+            \"offset\": \"10-30 minutes\",\n+            \"after_effects\": \"15-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"sublingual/quid (fresh leaf)\",\n+          \"stages\": {\n+            \"total_duration\": \"60-180 minutes\",\n+            \"onset\": \"10-20 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"60-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"sublingual/quid (dried leaf)\",\n+          \"stages\": {\n+            \"total_duration\": \"60-180 minutes\",\n+            \"onset\": \"10-20 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"60-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized (pure salvinorin A)\",\n+          \"stages\": {\n+            \"total_duration\": \"15-60 minutes\",\n+            \"onset\": \"15-60 seconds\",\n+            \"peak\": \"2-10 minutes\",\n+            \"offset\": \"10-20 minutes\",\n+            \"after_effects\": \"15-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Salvia divinorum is not considered habit-forming or physically addictive. The desire to use it can actually decrease with repeated use due to its often intense and dysphoric effects. Many users report the experience as so uncomfortable or overwhelming that they are reluctant to repeat it. Some individuals may develop psychological dependence as an escape from reality, but this is uncommon. The substance may even exhibit reverse tolerance, where effects become stronger with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Alcohol (increased neurological, cardiovascular, and gastrointestinal side effects)\",\n+        \"Stimulants (increased cardiovascular stress and unpredictable psychological effects)\",\n+        \"Other psychedelics (potentially overwhelming and confusing experiences)\"\n+      ],\n+      \"caution\": [\n+        \"MAOIs (potential potentiation and prolongation of effects)\",\n+        \"Antidepressants (possible serotonin interactions)\",\n+        \"Cannabis (intensified hallucinatory experience and increased anxiety)\",\n+        \"Prescription medications (unpredictable interactions and altered mental states)\",\n+        \"Dissociatives (may transform experience, proceed with extreme caution)\"\n+      ]\n+    },\n+    \"notes\": \"Salvia divinorum requires exceptional care and preparation, including a dedicated sitter for moderate to high doses due to potential loss of motor control and reality contact. Users should be positioned safely to prevent injury during the experience. The substance has a long history of traditional use by Mazatec shamans for spiritual healing and divination. Set and setting profoundly influence the experience. A butane torch lighter is recommended for smoking to ensure proper vaporization of salvinorin A due to its high boiling point. Extracts vary significantly in potency and should be approached with extreme caution. Individuals with personal or family history of psychotic disorders should avoid use. The experience is often described as more intense, bizarre, and dysphoric compared to classical psychedelics, with many users finding it profoundly uncomfortable rather than recreational.\",\n+    \"subjective_effects\": [\n+      \"Intense Dissociation\",\n+      \"Ego Replacement or Loss\",\n+      \"Reality Distortion\",\n+      \"Becoming Inanimate Objects\",\n+      \"Changes in Felt Gravity (Salvia Gravity)\",\n+      \"Uncontrollable Laughter\",\n+      \"Time Distortion\",\n+      \"Vivid Internal Hallucinations\",\n+      \"Visual Geometry and Fractals\",\n+      \"Machinescapes and Mechanical Visions\",\n+      \"Entity Contact\",\n+      \"Memory Suppression\",\n+      \"Sedation\",\n+      \"Confusion and Cognitive Dysphoria\",\n+      \"Auditory Distortions\",\n+      \"Synesthesia\",\n+      \"Depersonalization\",\n+      \"Body Transformation Sensations\",\n+      \"Pins and Needles Sensation\",\n+      \"Anxiety and Paranoia\",\n+      \"Near-Death Experience Phenomenology\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Salvia exhibits reverse tolerance rather than traditional tolerance\",\n+      \"half_tolerance\": \"Not applicable (reverse tolerance)\",\n+      \"zero_tolerance\": \"Not applicable (reverse tolerance)\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"Not well established for salvinorin A; effects are extremely short-acting\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Salvia divinorum\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Salvia_divinorum\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Salvinorin A\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Salvinorin_A\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia divinorum Vault\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia Dosage Information\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia Effects\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia FAQ\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_faq.shtml\"\n+      },\n+      {\n+        \"name\": \"TripSit Salvia Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/index.php?title=Salvia\"\n+      },\n+      {\n+        \"name\": \"TripSit Salvia Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/salvia\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Salvia Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-salvia-thread-3rd-dimension.654135/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Salvia divinorum\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Salvia_divinorum\"\n+      },\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: Salvia\",\n+        \"reference\": \"https://adf.org.au/drug-facts/salvia/\"\n+      },\n+      {\n+        \"name\": \"Johnson MW et al. (2011) - Human Psychopharmacology and Dose-Effects of Salvinorin A\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19416753/\"\n+      },\n+      {\n+        \"name\": \"Lange JE et al. (2010) - Salvia divinorum: Effects and Use Among YouTube Users\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0376871609004177\"\n+      },\n+      {\n+        \"name\": \"Coffeen E et al. (2019) - Salvia divinorum: From Recreational Use to Analgesic Action\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434906/\"\n+      },\n+      {\n+        \"name\": \"Vohra R et al. (2011) - Salvia divinorum Exposures to Poison Control\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19765944/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"atypical-psychedelic\",\n+      \"plant-based\",\n+      \"entheogen\",\n+      \"kappa-opioid-agonist\"\n+    ]\n+  },\n+  \"index-category\": \"dissociative; atypical-psychedelic; entheogen\"\n+}\n\n# Salvia divinorum\n\n-{\n-  \"id\": null,\n-  \"title\": \"Salvia divinorum\",\n-  \"drug_info\": {\n-    \"drug_name\": \"Salvia divinorum\",\n-    \"chemical_name\": \"Methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate\",\n-    \"alternative_name\": \"Salvinorin A; Diviner's Sage; Ska Maria Pastora; Seer's Sage; Sally; Sally D; Magic Mint; Yerba de la Pastora\",\n-    \"chemical_class\": \"Diterpenoid; Neoclerodane\",\n-    \"mechanism_of_action\": \"Kappa-opioid receptor agonist; D2 dopamine receptor agonist (weak)\",\n-    \"psychoactive_class\": \"Dissociative; Atypical psychedelic\",\n-    \"dosages\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"smoked (dried leaf)\",\n-          \"units\": \"g\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.1-0.2 g\",\n-            \"light\": \"0.25 g\",\n-            \"common\": \"0.5 g\",\n-            \"strong\": \"0.75-1 g\",\n-            \"heavy\": \"1+ g\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked (5x extract)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"20-40 mg\",\n-            \"light\": \"40-100 mg\",\n-            \"common\": \"100-200 mg\",\n-            \"strong\": \"200-300 mg\",\n-            \"heavy\": \"300+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked (10x extract)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10-20 mg\",\n-            \"light\": \"20-50 mg\",\n-            \"common\": \"50-100 mg\",\n-            \"strong\": \"100-150 mg\",\n-            \"heavy\": \"150+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"sublingual/quid (fresh leaf)\",\n-          \"units\": \"g\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5-10 g\",\n-            \"light\": \"10 g\",\n-            \"common\": \"30 g\",\n-            \"strong\": \"50 g\",\n-            \"heavy\": \"50+ g\"\n-          }\n-        },\n-        {\n-          \"route\": \"sublingual/quid (dried leaf)\",\n-          \"units\": \"g\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1-2 g\",\n-            \"light\": \"2 g\",\n-            \"common\": \"6 g\",\n-            \"strong\": \"10 g\",\n-            \"heavy\": \"10+ g\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized (pure salvinorin A)\",\n-          \"units\": \"ug\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"200-500 ug\",\n-            \"light\": \"500-800 ug\",\n-            \"common\": \"800-1200 ug\",\n-            \"strong\": \"1200-2000 ug\",\n-            \"heavy\": \"2000+ ug\"\n-          }\n-        }\n-      ]\n-    },\n-    \"duration\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"smoked\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"15-90 minutes\",\n-            \"onset\": \"15-60 seconds\",\n-            \"peak\": \"5-20 minutes\",\n-            \"offset\": \"10-30 minutes\",\n-            \"after_effects\": \"15-60 minutes\"\n-          }\n-        },\n-        {\n-          \"route\": \"sublingual/quid\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"60-180 minutes\",\n-            \"onset\": \"10-20 minutes\",\n-            \"peak\": \"30-60 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"60-120 minutes\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"15-60 minutes\",\n-            \"onset\": \"15-60 seconds\",\n-            \"peak\": \"2-10 minutes\",\n-            \"offset\": \"10-20 minutes\",\n-            \"after_effects\": \"15-60 minutes\"\n-          }\n-        }\n-      ]\n-    },\n-    \"addiction_potential\": \"Salvia divinorum is not considered habit-forming or physically addictive. The desire to use it can actually decrease with repeated use due to its often intense and dysphoric effects. Many users report the experience as so uncomfortable or overwhelming that they are reluctant to repeat it. Some individuals may develop psychological dependence as an escape from reality, but this is uncommon. The substance may even exhibit reverse tolerance, where effects become stronger with repeated use.\",\n-    \"interactions\": {\n-      \"dangerous\": [],\n-      \"unsafe\": [\n-        \"Alcohol (increased neurological, cardiovascular, and gastrointestinal side effects)\",\n-        \"Stimulants (increased cardiovascular stress and unpredictable psychological effects)\",\n-        \"Other psychedelics (potentially overwhelming and confusing experiences)\"\n-      ],\n-      \"caution\": [\n-        \"MAOIs (potential potentiation and prolongation of effects)\",\n-        \"Antidepressants (possible serotonin interactions)\",\n-        \"Cannabis (intensified hallucinatory experience and increased anxiety)\",\n-        \"Prescription medications (unpredictable interactions and altered mental states)\",\n-        \"Dissociatives (may transform experience, proceed with extreme caution)\"\n-      ]\n-    },\n-    \"notes\": \"Salvia divinorum requires exceptional care and preparation, including a dedicated sitter for moderate to high doses due to potential loss of motor control and reality contact. Users should be positioned safely to prevent injury during the experience. The substance has a long history of traditional use by Mazatec shamans for spiritual healing and divination. Set and setting profoundly influence the experience. A butane torch lighter is recommended for smoking to ensure proper vaporization of salvinorin A due to its high boiling point. Extracts vary significantly in potency and should be approached with extreme caution. Individuals with personal or family history of psychotic disorders should avoid use. The experience is often described as more intense, bizarre, and dysphoric compared to classical psychedelics, with many users finding it profoundly uncomfortable rather than recreational.\",\n-    \"subjective_effects\": [\n-      \"Intense Dissociation\",\n-      \"Ego Replacement or Loss\",\n-      \"Reality Distortion\",\n-      \"Becoming Inanimate Objects\",\n-      \"Changes in Felt Gravity (Salvia Gravity)\",\n-      \"Uncontrollable Laughter\",\n-      \"Time Distortion\",\n-      \"Vivid Internal Hallucinations\",\n-      \"Visual Geometry and Fractals\",\n-      \"Machinescapes and Mechanical Visions\",\n-      \"Entity Contact\",\n-      \"Memory Suppression\",\n-      \"Sedation\",\n-      \"Confusion and Cognitive Dysphoria\",\n-      \"Auditory Distortions\",\n-      \"Synesthesia\",\n-      \"Depersonalization\",\n-      \"Body Transformation Sensations\",\n-      \"Pins and Needles Sensation\",\n-      \"Anxiety and Paranoia\",\n-      \"Near-Death Experience Phenomenology\"\n-    ],\n-    \"tolerance\": {\n-      \"full_tolerance\": \"Salvia exhibits reverse tolerance rather than traditional tolerance\",\n-      \"half_tolerance\": \"Not applicable (reverse tolerance)\",\n-      \"zero_tolerance\": \"Not applicable (reverse tolerance)\",\n-      \"cross_tolerances\": []\n-    },\n-    \"half_life\": \"Not well established for salvinorin A; effects are extremely short-acting\",\n-    \"citations\": [\n-      {\n-        \"name\": \"PsychonautWiki: Salvia divinorum\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Salvia_divinorum\"\n-      },\n-      {\n-        \"name\": \"PsychonautWiki: Salvinorin A\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Salvinorin_A\"\n-      },\n-      {\n-        \"name\": \"Erowid Salvia divinorum Vault\",\n-        \"reference\": \"https://www.erowid.org/plants/salvia/salvia.shtml\"\n-      },\n-      {\n-        \"name\": \"Erowid Salvia Dosage Information\",\n-        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_dose.shtml\"\n-      },\n-      {\n-        \"name\": \"Erowid Salvia Effects\",\n-        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_effects.shtml\"\n-      },\n-      {\n-        \"name\": \"Erowid Salvia FAQ\",\n-        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_faq.shtml\"\n-      },\n-      {\n-        \"name\": \"TripSit Salvia Wiki\",\n-        \"reference\": \"https://wiki.tripsit.me/index.php?title=Salvia\"\n-      },\n-      {\n-        \"name\": \"TripSit Salvia Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/salvia\"\n-      },\n-      {\n-        \"name\": \"Bluelight: The Big & Dandy Salvia Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-salvia-thread-3rd-dimension.654135/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Salvia divinorum\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Salvia_divinorum\"\n-      },\n-      {\n-        \"name\": \"Alcohol and Drug Foundation: Salvia\",\n-        \"reference\": \"https://adf.org.au/drug-facts/salvia/\"\n-      },\n-      {\n-        \"name\": \"Johnson MW et al. (2011) - Human Psychopharmacology and Dose-Effects of Salvinorin A\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19416753/\"\n-      },\n-      {\n-        \"name\": \"Lange JE et al. (2010) - Salvia divinorum: Effects and Use Among YouTube Users\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0376871609004177\"\n-      },\n-      {\n-        \"name\": \"Coffeen E et al. (2019) - Salvia divinorum: From Recreational Use to Analgesic Action\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434906/\"\n-      },\n-      {\n-        \"name\": \"Vohra R et al. (2011) - Salvia divinorum Exposures to Poison Control\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19765944/\"\n-      }\n-    ],\n-    \"categories\": [\n-      \"dissociative\",\n-      \"atypical-psychedelic\",\n-      \"plant-based\",\n-      \"entheogen\",\n-      \"kappa-opioid-agonist\"\n-    ]\n-  },\n-  \"index-category\": \"dissociative;atypical-psychedelic;entheogen\"\n-}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-203830-197464b9",
    "createdAt": "2025-10-18T20:38:30.650Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 2:38:29 PM"
    },
    "articles": [
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Salvia divinorum\n\n+{\n+  \"id\": null,\n+  \"title\": \"Salvia divinorum\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Salvia divinorum\",\n+    \"chemical_name\": \"Methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate\",\n+    \"alternative_name\": \"Salvinorin A; Diviner's Sage; Ska Maria Pastora; Seer's Sage; Sally; Sally D; Magic Mint; Yerba de la Pastora\",\n+    \"chemical_class\": \"Diterpenoid; Neoclerodane\",\n+    \"mechanism_of_action\": \"Kappa-opioid receptor agonist; D2 dopamine receptor agonist (weak)\",\n+    \"psychoactive_class\": \"Dissociative; Atypical psychedelic\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked (dried leaf)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.2 g\",\n+            \"light\": \"0.25 g\",\n+            \"common\": \"0.5 g\",\n+            \"strong\": \"0.75-1 g\",\n+            \"heavy\": \"1+ g\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked (5x extract)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-40 mg\",\n+            \"light\": \"40-100 mg\",\n+            \"common\": \"100-200 mg\",\n+            \"strong\": \"200-300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked (10x extract)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-20 mg\",\n+            \"light\": \"20-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual/quid (fresh leaf)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 g\",\n+            \"light\": \"10 g\",\n+            \"common\": \"30 g\",\n+            \"strong\": \"50 g\",\n+            \"heavy\": \"50+ g\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual/quid (dried leaf)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-2 g\",\n+            \"light\": \"2 g\",\n+            \"common\": \"6 g\",\n+            \"strong\": \"10 g\",\n+            \"heavy\": \"10+ g\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized (pure salvinorin A)\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200-500 ug\",\n+            \"light\": \"500-800 ug\",\n+            \"common\": \"800-1200 ug\",\n+            \"strong\": \"1200-2000 ug\",\n+            \"heavy\": \"2000+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"15-90 minutes\",\n+            \"onset\": \"15-60 seconds\",\n+            \"peak\": \"5-20 minutes\",\n+            \"offset\": \"10-30 minutes\",\n+            \"after_effects\": \"15-60 minutes\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual/quid\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"60-180 minutes\",\n+            \"onset\": \"10-20 minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"60-120 minutes\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"15-60 minutes\",\n+            \"onset\": \"15-60 seconds\",\n+            \"peak\": \"2-10 minutes\",\n+            \"offset\": \"10-20 minutes\",\n+            \"after_effects\": \"15-60 minutes\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Salvia divinorum is not considered habit-forming or physically addictive. The desire to use it can actually decrease with repeated use due to its often intense and dysphoric effects. Many users report the experience as so uncomfortable or overwhelming that they are reluctant to repeat it. Some individuals may develop psychological dependence as an escape from reality, but this is uncommon. The substance may even exhibit reverse tolerance, where effects become stronger with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Alcohol (increased neurological, cardiovascular, and gastrointestinal side effects)\",\n+        \"Stimulants (increased cardiovascular stress and unpredictable psychological effects)\",\n+        \"Other psychedelics (potentially overwhelming and confusing experiences)\"\n+      ],\n+      \"caution\": [\n+        \"MAOIs (potential potentiation and prolongation of effects)\",\n+        \"Antidepressants (possible serotonin interactions)\",\n+        \"Cannabis (intensified hallucinatory experience and increased anxiety)\",\n+        \"Prescription medications (unpredictable interactions and altered mental states)\",\n+        \"Dissociatives (may transform experience, proceed with extreme caution)\"\n+      ]\n+    },\n+    \"notes\": \"Salvia divinorum requires exceptional care and preparation, including a dedicated sitter for moderate to high doses due to potential loss of motor control and reality contact. Users should be positioned safely to prevent injury during the experience. The substance has a long history of traditional use by Mazatec shamans for spiritual healing and divination. Set and setting profoundly influence the experience. A butane torch lighter is recommended for smoking to ensure proper vaporization of salvinorin A due to its high boiling point. Extracts vary significantly in potency and should be approached with extreme caution. Individuals with personal or family history of psychotic disorders should avoid use. The experience is often described as more intense, bizarre, and dysphoric compared to classical psychedelics, with many users finding it profoundly uncomfortable rather than recreational.\",\n+    \"subjective_effects\": [\n+      \"Intense Dissociation\",\n+      \"Ego Replacement or Loss\",\n+      \"Reality Distortion\",\n+      \"Becoming Inanimate Objects\",\n+      \"Changes in Felt Gravity (Salvia Gravity)\",\n+      \"Uncontrollable Laughter\",\n+      \"Time Distortion\",\n+      \"Vivid Internal Hallucinations\",\n+      \"Visual Geometry and Fractals\",\n+      \"Machinescapes and Mechanical Visions\",\n+      \"Entity Contact\",\n+      \"Memory Suppression\",\n+      \"Sedation\",\n+      \"Confusion and Cognitive Dysphoria\",\n+      \"Auditory Distortions\",\n+      \"Synesthesia\",\n+      \"Depersonalization\",\n+      \"Body Transformation Sensations\",\n+      \"Pins and Needles Sensation\",\n+      \"Anxiety and Paranoia\",\n+      \"Near-Death Experience Phenomenology\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Salvia exhibits reverse tolerance rather than traditional tolerance\",\n+      \"half_tolerance\": \"Not applicable (reverse tolerance)\",\n+      \"zero_tolerance\": \"Not applicable (reverse tolerance)\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"Not well established for salvinorin A; effects are extremely short-acting\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Salvia divinorum\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Salvia_divinorum\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Salvinorin A\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Salvinorin_A\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia divinorum Vault\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia Dosage Information\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia Effects\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Salvia FAQ\",\n+        \"reference\": \"https://www.erowid.org/plants/salvia/salvia_faq.shtml\"\n+      },\n+      {\n+        \"name\": \"TripSit Salvia Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/index.php?title=Salvia\"\n+      },\n+      {\n+        \"name\": \"TripSit Salvia Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/salvia\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Salvia Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-salvia-thread-3rd-dimension.654135/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Salvia divinorum\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Salvia_divinorum\"\n+      },\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: Salvia\",\n+        \"reference\": \"https://adf.org.au/drug-facts/salvia/\"\n+      },\n+      {\n+        \"name\": \"Johnson MW et al. (2011) - Human Psychopharmacology and Dose-Effects of Salvinorin A\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19416753/\"\n+      },\n+      {\n+        \"name\": \"Lange JE et al. (2010) - Salvia divinorum: Effects and Use Among YouTube Users\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0376871609004177\"\n+      },\n+      {\n+        \"name\": \"Coffeen E et al. (2019) - Salvia divinorum: From Recreational Use to Analgesic Action\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434906/\"\n+      },\n+      {\n+        \"name\": \"Vohra R et al. (2011) - Salvia divinorum Exposures to Poison Control\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19765944/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"atypical-psychedelic\",\n+      \"plant-based\",\n+      \"entheogen\",\n+      \"kappa-opioid-agonist\"\n+    ]\n+  },\n+  \"index-category\": \"dissociative;atypical-psychedelic;entheogen\"\n+}\n\n# Salvia · #409\n\n-{\n-  \"id\": 409,\n-  \"title\": \"Salvia\",\n-  \"drug_info\": {\n-    \"drug_name\": \"Salvia\",\n-    \"chemical_name\": \"Salvinorin A\",\n-    \"alternative_name\": \"Salvinorin A\",\n-    \"chemical_class\": \"Diterpenoid\",\n-    \"mechanism_of_action\": \"κ-Opioid receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"dosages\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"\\u001fg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"50 \\u001fg\",\n-            \"light\": \"200-500 \\u001fg\",\n-            \"common\": \"500-1000 \\u001fg\",\n-            \"strong\": \"1000-2000 \\u001fg\",\n-            \"heavy\": \"2000+ \\u001fg\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"\\u001fg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"200 \\u001fg\",\n-            \"light\": \"500-1000 \\u001fg\",\n-            \"common\": \"1000-2000 \\u001fg\",\n-            \"strong\": \"2000-4000 \\u001fg\",\n-            \"heavy\": \"4000+ \\u001fg\"\n-          }\n-        }\n-      ]\n-    },\n-    \"duration\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"smoked\",\n-          \"stages\": {\n-            \"total_duration\": \"5-20 minutes\",\n-            \"onset\": \"30 seconds - 2 minutes\",\n-            \"peak\": \"5-10 minutes\",\n-            \"offset\": \"10-20 minutes\",\n-            \"after_effects\": \"30-60 minutes\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"stages\": {\n-            \"total_duration\": \"5-20 minutes\",\n-            \"onset\": \"30 seconds - 2 minutes\",\n-            \"peak\": \"5-10 minutes\",\n-            \"offset\": \"10-20 minutes\",\n-            \"after_effects\": \"30-60 minutes\"\n-          },\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ]\n-        }\n-      ]\n-    },\n-    \"addiction_potential\": \"Salvinorin A is not considered to have significant addiction potential.\",\n-    \"interactions\": {\n-      \"dangerous\": [],\n-      \"unsafe\": [],\n-      \"caution\": [\n-        \"May increase the CNS depressant activities of fluoxetine.\"\n-      ]\n-    },\n-    \"notes\": \"Salvinorin A is a potent kappa-opioid receptor agonist, leading to its unique psychoactive effects. It is known for its intense and short-lived hallucinogenic experiences, often described as dissociative and dream-like. Due to its high potency, precise dosing is crucial to avoid overwhelming experiences.\",\n-    \"subjective_effects\": [\n-      \"Visual hallucinations\",\n-      \"Dissociation\",\n-      \"Time distortion\",\n-      \"Ego dissolution\",\n-      \"Auditory hallucinations\",\n-      \"Intense emotional experiences\"\n-    ],\n-    \"tolerance\": {\n-      \"full_tolerance\": \"Unknown\",\n-      \"half_tolerance\": \"Unknown\",\n-      \"zero_tolerance\": \"Unknown\",\n-      \"cross_tolerances\": []\n-    },\n-    \"half_life\": \"Unknown\",\n-    \"citations\": [\n-      {\n-        \"name\": \"Erowid Salvinorin A Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/salvinorin_a/\"\n-      },\n-      {\n-        \"name\": \"Roth et al. Study on Salvinorin A\",\n-        \"reference\": \"https://erowid.org/plants/salvia/salvia_info5.shtml\"\n-      },\n-      {\n-        \"name\": \"DrugBank on Salvinorin A Interactions\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB12327\"\n-      }\n-    ],\n-    \"categories\": [\n-      \"other dissociatives\",\n-      \"A-typical Hallucinogen\"\n-    ]\n-  },\n-  \"index-category\": \"\"\n-}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-203530-4a661b66",
    "createdAt": "2025-10-18T20:35:30.692Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 2:35:28 PM"
    },
    "articles": [],
    "markdown": "No diff details were provided for this commit.",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-201635-4238f96e",
    "createdAt": "2025-10-18T20:16:35.092Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 2:16:32 PM"
    },
    "articles": [
      {
        "id": 662,
        "title": "Datura",
        "slug": "datura"
      }
    ],
    "markdown": "# Datura · #662\n\n+{\n+  \"title\": \"Datura\",\n+  \"index-category\": \"deliriant; dangerous; anticholinergic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Datura\",\n+    \"chemical_name\": \"Tropane alkaloid mixture (Scopolamine, Hyoscyamine, Atropine)\",\n+    \"alternative_name\": \"Jimson Weed; Devil's Trumpet; Thorn Apple; Moonflower; Devil's Weed; Hell's Bells; Stinkweed; Angel's Trumpets; Devil's Apple; Toloache\",\n+    \"chemical_class\": \"Tropane alkaloids\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"Competitive antagonist at muscarinic acetylcholine receptors M1 and M2 (anticholinergic)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"light\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"common\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"strong\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"heavy\": \"Extremely variable - no safe dosage can be recommended\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"plant material\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"light\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"common\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"strong\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"heavy\": \"Extremely variable - no safe dosage can be recommended\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-18 hours (can extend to 48-72 hours at higher doses)\",\n+            \"onset\": \"20-120 minutes\",\n+            \"peak\": \"5-12 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"6-24 hours (can persist for days or weeks including vision disturbances)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"4-12 hours\",\n+            \"onset\": \"5-10 minutes\",\n+            \"peak\": \"3-8 hours\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Datura has low addiction potential as the vast majority of users report extremely unpleasant experiences and do not wish to repeat use. However, rare cases of psychological dependence and compulsive redosing have been documented, particularly among individuals seeking deliriant experiences despite negative consequences.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Other anticholinergics (severe anticholinergic syndrome)\",\n+        \"MAOIs (unpredictable interactions)\",\n+        \"Alcohol (severe dehydration and unpredictable delirium)\",\n+        \"CNS depressants (respiratory depression risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (cardiac stress and hyperthermia)\",\n+        \"Other deliriants (extreme confusion and toxicity)\",\n+        \"Tramadol (seizure risk)\"\n+      ],\n+      \"caution\": [\n+        \"Any medication or substance (anticholinergic effects interfere with many drugs)\",\n+        \"Cannabis (increased confusion and paranoia)\"\n+      ]\n+    },\n+    \"notes\": \"Datura is extremely dangerous and potentially fatal. Potency varies wildly between plants, plant parts, growing conditions, and even within the same plant (up to 20:1 variation). There is no safe or reliable dosage. The margin between an active dose and a lethal dose is extremely narrow. Datura causes severe anticholinergic syndrome, prolonged delirium lasting days, realistic and terrifying hallucinations, hyperthermia, seizures, and has resulted in numerous deaths and permanent injuries. Medical literature documents extensive cases of poisoning, hospitalization, psychosis, and fatality. Indigenous shamanic use involves years of careful tolerance building under expert guidance and should not be replicated recreationally. Strongly advised to avoid entirely. If encountered medically, seek immediate emergency treatment.\",\n+    \"subjective_effects\": [\n+      \"Realistic And Indistinguishable Hallucinations\",\n+      \"Complete Delirium And Confusion\",\n+      \"Conversations With Imaginary People\",\n+      \"Extreme Dry Mouth And Dehydration\",\n+      \"Severe Pupil Dilation And Vision Impairment\",\n+      \"Amnesia And Memory Loss\",\n+      \"Extreme Paranoia And Fear\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Painful Electric Shock Sensations\",\n+      \"Difficulty Urinating Despite Urge\",\n+      \"Hyperthermia And Flushing\",\n+      \"Tachycardia And Elevated Blood Pressure\",\n+      \"Motor Control Loss And Ataxia\",\n+      \"Complete Inability To Distinguish Reality From Hallucination\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with repeated use within days\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other deliriants (diphenhydramine, dimenhydrinate)\",\n+        \"Other anticholinergics\"\n+      ]\n+    },\n+    \"half_life\": \"Scopolamine: 2-4 hours; Atropine: 2-3 hours; Hyoscyamine: 3-5 hours (effects persist far longer than half-life)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Datura Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/datura-takers.615462/\"\n+      },\n+      {\n+        \"name\": \"DoubleBlind Magazine: Sacred Datura Overview\",\n+        \"reference\": \"https://doubleblindmag.com/sacred-datura-trip-reports/\"\n+      },\n+      {\n+        \"name\": \"Erowid Datura Vault\",\n+        \"reference\": \"https://erowid.org/plants/datura/datura.shtml\"\n+      },\n+      {\n+        \"name\": \"Medscape: Tropane Alkaloid Poisoning Overview\",\n+        \"reference\": \"https://emedicine.medscape.com/article/816657-overview\"\n+      },\n+      {\n+        \"name\": \"PMC: Long-term Intentional Datura Use Consequences\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6767831/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Datura\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Datura\"\n+      },\n+      {\n+        \"name\": \"The Third Wave: Guide to Datura\",\n+        \"reference\": \"https://thethirdwave.co/psychedelics/datura/\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: Datura Risks and Experience\",\n+        \"reference\": \"https://tripsitter.com/datura/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Datura stramonium\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Datura_stramonium\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"anticholinergic\",\n+      \"tropane-alkaloid\",\n+      \"extremely-dangerous\",\n+      \"plant-based\"\n+    ]\n+  },\n+  \"id\": 662\n+}\n\n# Datura · #663\n\n+{\n+  \"title\": \"Datura\",\n+  \"index-category\": \"deliriant; dangerous; anticholinergic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Datura\",\n+    \"chemical_name\": \"Tropane alkaloid mixture (Scopolamine, Hyoscyamine, Atropine)\",\n+    \"alternative_name\": \"Jimson Weed; Devil's Trumpet; Thorn Apple; Moonflower; Devil's Weed; Hell's Bells; Stinkweed; Angel's Trumpets; Devil's Apple; Toloache\",\n+    \"chemical_class\": \"Tropane alkaloids\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"Competitive antagonist at muscarinic acetylcholine receptors M1 and M2 (anticholinergic)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"light\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"common\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"strong\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"heavy\": \"Extremely variable - no safe dosage can be recommended\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"plant material\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"light\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"common\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"strong\": \"Extremely variable - no safe dosage can be recommended\",\n+            \"heavy\": \"Extremely variable - no safe dosage can be recommended\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-18 hours (can extend to 48-72 hours at higher doses)\",\n+            \"onset\": \"20-120 minutes\",\n+            \"peak\": \"5-12 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"6-24 hours (can persist for days or weeks including vision disturbances)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"4-12 hours\",\n+            \"onset\": \"5-10 minutes\",\n+            \"peak\": \"3-8 hours\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Datura has low addiction potential as the vast majority of users report extremely unpleasant experiences and do not wish to repeat use. However, rare cases of psychological dependence and compulsive redosing have been documented, particularly among individuals seeking deliriant experiences despite negative consequences.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Other anticholinergics (severe anticholinergic syndrome)\",\n+        \"MAOIs (unpredictable interactions)\",\n+        \"Alcohol (severe dehydration and unpredictable delirium)\",\n+        \"CNS depressants (respiratory depression risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (cardiac stress and hyperthermia)\",\n+        \"Other deliriants (extreme confusion and toxicity)\",\n+        \"Tramadol (seizure risk)\"\n+      ],\n+      \"caution\": [\n+        \"Any medication or substance (anticholinergic effects interfere with many drugs)\",\n+        \"Cannabis (increased confusion and paranoia)\"\n+      ]\n+    },\n+    \"notes\": \"Datura is extremely dangerous and potentially fatal. Potency varies wildly between plants, plant parts, growing conditions, and even within the same plant (up to 20:1 variation). There is no safe or reliable dosage. The margin between an active dose and a lethal dose is extremely narrow. Datura causes severe anticholinergic syndrome, prolonged delirium lasting days, realistic and terrifying hallucinations, hyperthermia, seizures, and has resulted in numerous deaths and permanent injuries. Medical literature documents extensive cases of poisoning, hospitalization, psychosis, and fatality. Indigenous shamanic use involves years of careful tolerance building under expert guidance and should not be replicated recreationally. Strongly advised to avoid entirely. If encountered medically, seek immediate emergency treatment.\",\n+    \"subjective_effects\": [\n+      \"Realistic And Indistinguishable Hallucinations\",\n+      \"Complete Delirium And Confusion\",\n+      \"Conversations With Imaginary People\",\n+      \"Extreme Dry Mouth And Dehydration\",\n+      \"Severe Pupil Dilation And Vision Impairment\",\n+      \"Amnesia And Memory Loss\",\n+      \"Extreme Paranoia And Fear\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Painful Electric Shock Sensations\",\n+      \"Difficulty Urinating Despite Urge\",\n+      \"Hyperthermia And Flushing\",\n+      \"Tachycardia And Elevated Blood Pressure\",\n+      \"Motor Control Loss And Ataxia\",\n+      \"Complete Inability To Distinguish Reality From Hallucination\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops with repeated use within days\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other deliriants (diphenhydramine, dimenhydrinate)\",\n+        \"Other anticholinergics\"\n+      ]\n+    },\n+    \"half_life\": \"Scopolamine: 2-4 hours; Atropine: 2-3 hours; Hyoscyamine: 3-5 hours (effects persist far longer than half-life)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Datura Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/datura-takers.615462/\"\n+      },\n+      {\n+        \"name\": \"DoubleBlind Magazine: Sacred Datura Overview\",\n+        \"reference\": \"https://doubleblindmag.com/sacred-datura-trip-reports/\"\n+      },\n+      {\n+        \"name\": \"Erowid Datura Vault\",\n+        \"reference\": \"https://erowid.org/plants/datura/datura.shtml\"\n+      },\n+      {\n+        \"name\": \"Medscape: Tropane Alkaloid Poisoning Overview\",\n+        \"reference\": \"https://emedicine.medscape.com/article/816657-overview\"\n+      },\n+      {\n+        \"name\": \"PMC: Long-term Intentional Datura Use Consequences\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6767831/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Datura\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Datura\"\n+      },\n+      {\n+        \"name\": \"The Third Wave: Guide to Datura\",\n+        \"reference\": \"https://thethirdwave.co/psychedelics/datura/\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: Datura Risks and Experience\",\n+        \"reference\": \"https://tripsitter.com/datura/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Datura stramonium\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Datura_stramonium\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"anticholinergic\",\n+      \"tropane-alkaloid\",\n+      \"extremely-dangerous\",\n+      \"plant-based\"\n+    ]\n+  },\n+  \"id\": 663\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-190146-a5116dc1",
    "createdAt": "2025-10-18T19:01:46.432Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/18/2025, 1:01:44 PM"
    },
    "articles": [
      {
        "id": 661,
        "title": "Ayahuasca",
        "slug": "ayahuasca"
      }
    ],
    "markdown": "# Ayahuasca · #661\n\n+{\n+  \"title\": \"Ayahuasca\",\n+  \"index-category\": \"psychedelic; entheogen; traditional\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Ayahuasca\",\n+    \"chemical_name\": \"N,N-Dimethyltryptamine with Harmala Alkaloids (MAOI combination)\",\n+    \"alternative_name\": \"Aya; Caapi; Yage; Yaje; Hoasca; Vegetal; Natem; Shori; Pharmahuasca\",\n+    \"chemical_class\": \"Tryptamines; Beta-carbolines\",\n+    \"psychoactive_class\": \"Psychedelic; Entheogen\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (DMT component); reversible monoamine oxidase-A inhibitor (harmala alkaloids)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (syrian rue + mimosa hostilis)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1.5-2g syrian rue + 3-4g mimosa hostilis\",\n+            \"light\": \"2-2.5g syrian rue + 4-6g mimosa hostilis\",\n+            \"common\": \"2.5-3g syrian rue + 6-8g mimosa hostilis\",\n+            \"strong\": \"3-3.5g syrian rue + 8-10g mimosa hostilis\",\n+            \"heavy\": \"3.5+ g syrian rue + 10+ g mimosa hostilis\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (syrian rue + acacia confusa)\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1.5-2g syrian rue + 3-5g acacia confusa\",\n+            \"light\": \"2-2.5g syrian rue + 5-10g acacia confusa\",\n+            \"common\": \"2.5-3g syrian rue + 10-15g acacia confusa\",\n+            \"strong\": \"3-3.5g syrian rue + 15-20g acacia confusa\",\n+            \"heavy\": \"3.5+ g syrian rue + 20+ g acacia confusa\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pharmahuasca - extracted alkaloids)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50mg harmala alkaloids + 15-20mg DMT\",\n+            \"light\": \"50-75mg harmala alkaloids + 20-30mg DMT\",\n+            \"common\": \"75-100mg harmala alkaloids + 30-50mg DMT\",\n+            \"strong\": \"100-150mg harmala alkaloids + 50-75mg DMT\",\n+            \"heavy\": \"150+ mg harmala alkaloids + 75+ mg DMT\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (traditional b. caapi + p. viridis brew)\",\n+          \"units\": \"variable\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Variable - depends on brew strength and preparation\",\n+            \"light\": \"Small cup (50-75ml of traditional brew)\",\n+            \"common\": \"One cup (75-150ml of traditional brew)\",\n+            \"strong\": \"Large cup (150-200ml of traditional brew)\",\n+            \"heavy\": \"Multiple servings or very concentrated brew\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (syrian rue + mimosa hostilis)\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-8 hours (afterglow and residual effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (syrian rue + acacia confusa)\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-8 hours (afterglow and residual effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (pharmahuasca - extracted alkaloids)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-6 hours (afterglow and residual effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (traditional b. caapi + p. viridis brew)\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-8 hours (afterglow and residual effects)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Ayahuasca is not considered physically addictive and has a low potential for psychological dependence. The intense purgative effects and profound nature of the experience tend to discourage frequent use, and it is typically self-regulating.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome)\",\n+        \"SSRIs (serotonin syndrome risk)\",\n+        \"SNRIs (serotonin syndrome risk)\",\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MDMA (unpredictable potentiation and serotonin syndrome)\",\n+        \"Amphetamines (hypertensive crisis and cardiovascular stress)\",\n+        \"Cocaine (cardiovascular complications)\",\n+        \"5-MeO-MiPT (serotonin syndrome)\",\n+        \"2C-T-7 (serotonin syndrome)\",\n+        \"AMT (serotonin syndrome)\",\n+        \"Tricyclic antidepressants (serotonin syndrome)\",\n+        \"St. John's Wort (serotonin syndrome)\",\n+        \"Dextromethorphan (serotonin syndrome)\",\n+        \"Tyramine-containing foods with irreversible MAOIs (hypertensive crisis - less risk with harmala RIMAs)\"\n+      ],\n+      \"unsafe\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Mescaline (potentiation and altered character)\",\n+        \"Psilocybin mushrooms (significantly increased intensity)\",\n+        \"LSD (greatly increased intensity and unpredictability)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may increase anxiety or trigger psychosis)\",\n+        \"Alcohol (unpredictable effects and increased nausea)\",\n+        \"Benzodiazepines (may dampen experience)\",\n+        \"Nicotine (mild interaction)\"\n+      ]\n+    },\n+    \"notes\": \"Ayahuasca is a brew combining DMT-containing plants with MAOI-containing plants, requiring both components to produce psychoactive effects. Traditional brews vary widely in potency depending on plant sources, preparation methods, and regional practices. The purgative effects (nausea, vomiting, diarrhea) are considered an integral part of the traditional experience and can be intense. Due to the MAOI component, numerous dangerous drug interactions exist, particularly with SSRIs, other antidepressants, stimulants, and certain foods when using irreversible MAOIs. Harmala alkaloids from Syrian rue or B. caapi are reversible MAOIs (RIMAs), posing less dietary restriction risk than pharmaceutical MAOIs, though caution is still advised. Set and setting are crucial, and the substance should ideally be used with an experienced facilitator. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Intense visual hallucinations and patterns\",\n+      \"Internal visions and dreamlike imagery\",\n+      \"Spiritual insight and mystical experiences\",\n+      \"Unity and interconnectedness\",\n+      \"Emotional amplification and catharsis\",\n+      \"Ego death or dissolution\",\n+      \"Time distortion\",\n+      \"Nausea and purging (vomiting, diarrhea)\",\n+      \"Physical discomfort and heaviness\",\n+      \"Autonomous entity contact\",\n+      \"Synesthesia\",\n+      \"Mindfulness and clarity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Tolerance does not develop in the traditional sense\",\n+      \"half_tolerance\": \"Not applicable - ayahuasca can be used repeatedly without tolerance buildup\",\n+      \"zero_tolerance\": \"Immediate - no tolerance develops to ayahuasca\",\n+      \"cross_tolerances\": [\n+        \"Does not produce cross-tolerance with other psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (psilocin active metabolite of DMT); 2-4 hours (harmala alkaloids)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Ayahuasca Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/ayahuasca/ayahuasca.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Ayahuasca\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Ayahuasca\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Ayahuasca\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Ayahuasca\"\n+      },\n+      {\n+        \"name\": \"TripSit Factsheet: DMT\",\n+        \"reference\": \"https://drugs.tripsit.me/DMT\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://combo.tripsit.me/\"\n+      },\n+      {\n+        \"name\": \"Erowid: DMT Freebase Content in Ayahuasca/Pharmahuasca Preparations\",\n+        \"reference\": \"https://www.erowid.org/chemicals/ayahuasca/ayahuasca_info8.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid: Ayahuasca Analogues and Pharmahuasca\",\n+        \"reference\": \"https://erowid.org/chemicals/ayahuasca/ayahuasca_info11.shtml\"\n+      },\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: Ayahuasca\",\n+        \"reference\": \"https://adf.org.au/drug-facts/ayahuasca/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Peganum harmala\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Peganum_harmala\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Harmala alkaloid\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Harmala_alkaloid\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"entheogen\",\n+      \"plant-based\",\n+      \"tryptamine\",\n+      \"maoi-combination\"\n+    ]\n+  },\n+  \"id\": 661\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251018-182735-baddc987",
    "createdAt": "2025-10-18T18:27:35.939Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Remove MGM-15 - 18/10/2025, 20:27:33"
    },
    "articles": [
      {
        "id": 614,
        "title": "MGM-15",
        "slug": "mgm-15"
      }
    ],
    "markdown": "# MGM-15 · #614\n\n- Article removed from the dataset.\n",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-180750-e0b5f747",
    "createdAt": "2025-10-18T18:07:50.516Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 20:07:47"
    },
    "articles": [
      {
        "id": 182,
        "title": "PCP",
        "slug": "pcp"
      }
    ],
    "markdown": "# PCP · #182\n\n-  \"title\": \"Sernyl\",\n+  \"title\": \"PCP\",\n-    \"drug_name\": \"Sernyl\",\n-    \"chemical_name\": \"PCP\",\n-    \"alternative_name\": \"Phencyclidine\",\n+    \"drug_name\": \"PCP\",\n+    \"chemical_name\": \"Phencyclidine\",\n+    \"alternative_name\": \"Sernyl\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"dissociative\",\n-      \"research-chemical\"\n+      \"dissociative\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-180229-56ec8a6c",
    "createdAt": "2025-10-18T18:02:29.253Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 20:02:26"
    },
    "articles": [
      {
        "id": 229,
        "title": "Methylenedioxyphenmetrazine",
        "slug": "methylenedioxyphenmetrazine"
      },
      {
        "id": 291,
        "title": "MDMA",
        "slug": "mdma"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      }
    ],
    "markdown": "# Methylenedioxyphenmetrazine · #229\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"entactogen\",\n\n# MDMA · #291\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\"\n+      \"entactogen\"\n\n# MDA · #62\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"entactogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-180009-6a8da329",
    "createdAt": "2025-10-18T18:00:09.916Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 20:00:07"
    },
    "articles": [
      {
        "id": 291,
        "title": "MDMA",
        "slug": "mdma"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      }
    ],
    "markdown": "# MDMA · #291\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\"\n+      \"entactogen\"\n\n# MDA · #62\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"entactogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-175942-0150e55e",
    "createdAt": "2025-10-18T17:59:42.517Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 19:59:39"
    },
    "articles": [
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      }
    ],
    "markdown": "# MDA · #62\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"entactogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-231137-c5596ffa",
    "createdAt": "2025-10-17T23:11:37.907Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:11:36"
    },
    "articles": [
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 271,
        "title": "AEM",
        "slug": "aem"
      }
    ],
    "markdown": "# MAL · #270\n\n-    \"chemical_class\": \"Scalines; Phenethylamines\",\n+    \"chemical_class\": \"Scalines\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n\n# AEM · #271\n\n-    \"chemical_class\": \"Scalines; Phenethylamines\",\n+    \"chemical_class\": \"Scalines\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-231118-d997ce32",
    "createdAt": "2025-10-17T23:11:18.245Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:11:16"
    },
    "articles": [
      {
        "id": 271,
        "title": "AEM",
        "slug": "aem"
      }
    ],
    "markdown": "# AEM · #271\n\n-    \"chemical_class\": \"Scalines; Phenethylamines\",\n+    \"chemical_class\": \"Scalines\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230906-55286484",
    "createdAt": "2025-10-17T23:09:06.720Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:09:05"
    },
    "articles": [
      {
        "id": 59,
        "title": "Mescaline",
        "slug": "mescaline"
      },
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 271,
        "title": "AEM",
        "slug": "aem"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      }
    ],
    "markdown": "# Mescaline · #59\n\n-    \"chemical_class\": \"Mescaline homologues; Phenethylamines\",\n+    \"chemical_class\": \"Scalines; Phenethylamines\",\n\n# MAL · #270\n\n-    \"chemical_class\": \"Mescaline homologues; Phenethylamines\",\n+    \"chemical_class\": \"Scalines; Phenethylamines\",\n\n# AEM · #271\n\n-    \"chemical_class\": \"Mescaline homologues; Phenethylamines\",\n+    \"chemical_class\": \"Scalines; Phenethylamines\",\n\n# Allylescaline · #646\n\n-    \"chemical_class\": \"Mescaline homologues\",\n+    \"chemical_class\": \"Scalines\",\n\n# Escaline · #647\n\n-    \"chemical_class\": \"Mescaline homologues\",\n+    \"chemical_class\": \"Scalines\",\n\n# Proscaline · #648\n\n-    \"chemical_class\": \"Mescaline homologues\",\n+    \"chemical_class\": \"Scalines\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230611-de87cdeb",
    "createdAt": "2025-10-17T23:06:11.019Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:06:09"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Allylescaline · #646\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"mescaline-analog\"\n+      \"research-chemical\"\n\n# Escaline · #647\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"phenethylamine\",\n-      \"mescaline-analog\",\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# 25N-NBOMe · #654\n\n-  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"nbome\",\n-      \"phenethylamine\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230513-56577c36",
    "createdAt": "2025-10-17T23:05:13.508Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:05:11"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Allylescaline · #646\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"mescaline-analog\"\n+      \"research-chemical\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# 25N-NBOMe · #654\n\n-  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"nbome\",\n-      \"phenethylamine\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230337-b5d7fa64",
    "createdAt": "2025-10-17T23:03:37.485Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:03:35"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# 25N-NBOMe · #654\n\n-  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"nbome\",\n-      \"phenethylamine\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230247-72f6027f",
    "createdAt": "2025-10-17T23:02:47.222Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:02:45"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230207-b2658eaf",
    "createdAt": "2025-10-17T23:02:07.252Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:02:05"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230054-23cef8b5",
    "createdAt": "2025-10-17T23:00:54.567Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:00:52"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225903-124bba46",
    "createdAt": "2025-10-17T22:59:03.878Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:59:02"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225826-341c926a",
    "createdAt": "2025-10-17T22:58:26.327Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:58:24"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225755-1693f827",
    "createdAt": "2025-10-17T22:57:55.924Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:57:54"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamide\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225716-849d325d",
    "createdAt": "2025-10-17T22:57:16.016Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:57:14"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225553-0c946599",
    "createdAt": "2025-10-17T22:55:53.864Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:55:50"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-224638-e2ec09b9",
    "createdAt": "2025-10-17T22:46:38.115Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:46:34"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223937-dd93a95c",
    "createdAt": "2025-10-17T22:39:37.130Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:39:34"
    },
    "articles": [
      {
        "id": 133,
        "title": "Cocaine",
        "slug": "cocaine"
      }
    ],
    "markdown": "# Cocaine · #133\n\n-  \"title\": \"Crack\",\n+  \"title\": \"Cocaine\",\n-    \"drug_name\": \"Crack\",\n-    \"chemical_name\": \"Cocaine\",\n-    \"alternative_name\": \"Cocaine\",\n+    \"drug_name\": \"Cocaine\",\n+    \"chemical_name\": \"Benzoylmethylecgonine\",\n+    \"alternative_name\": \"Coke; Blow; White; Snow; Crack\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n+            \"total_duration\": \"30-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"15-30 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n+            \"total_duration\": \"30-90 minutes\",\n+            \"peak\": \"15-30 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"30-90 minutes\",\n+            \"peak\": \"15-30 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"habit-forming\",\n-      \"research-chemical\"\n+      \"habit-forming\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223318-678eb5f6",
    "createdAt": "2025-10-17T22:33:18.182Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:33:15"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"d-Lysergic acid diethylamide\",\n\n# Psilocybin Mushrooms · #200\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"plant-based\"\n+      \"plant-based\",\n+      \"common\"\n-  \"index-category\": \"psychedelic;classic;tryptamine\"\n+  \"index-category\": \"psychedelic; classic; tryptamine\"\n\n# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n\n# PRO-LAD · #635\n\n-    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n-    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223147-1e6cc8e4",
    "createdAt": "2025-10-17T22:31:47.024Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:31:44"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"d-Lysergic acid diethylamide\",\n\n# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n\n# PRO-LAD · #635\n\n-    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n-    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223101-a0dbd0f3",
    "createdAt": "2025-10-17T22:31:01.480Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:30:58"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n\n# PRO-LAD · #635\n\n-    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n-    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-222634-f8c2838b",
    "createdAt": "2025-10-17T22:26:34.604Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:26:31"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-222215-fbbbfbe1",
    "createdAt": "2025-10-17T22:22:15.676Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:22:13"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-221822-e197294f",
    "createdAt": "2025-10-17T22:18:22.551Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:18:19"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-220954-cba27055",
    "createdAt": "2025-10-17T22:09:54.431Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:09:52"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-220355-972e3296",
    "createdAt": "2025-10-17T22:03:55.871Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:03:53"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-220000-06e441b8",
    "createdAt": "2025-10-17T22:00:00.812Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 17/10/2025, 23:59:58"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-024248-d777a0e9",
    "createdAt": "2025-10-17T02:42:48.647Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 8:42:45 PM"
    },
    "articles": [
      {
        "id": 659,
        "title": "Benzydamine",
        "slug": "benzydamine"
      }
    ],
    "markdown": "# Benzydamine · #659\n\n+{\n+  \"title\": \"Benzydamine\",\n+  \"index-category\": \"deliriant; stimulant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Benzydamine\",\n+    \"chemical_name\": \"3-(1-Benzyl-1H-indazol-3-yloxy)-N,N-dimethylpropan-1-amine\",\n+    \"alternative_name\": \"Tantum Verde; Difflam; Benflogin; Andole\",\n+    \"chemical_class\": \"Indazoles\",\n+    \"psychoactive_class\": \"Deliriant; Stimulant\",\n+    \"mechanism_of_action\": \"Possible CB1 cannabinoid receptor agonist (speculated); possible 5-HT2A receptor agonist (speculated); prostaglandin synthetase inhibitor; mechanism underlying hallucinogenic effects remains unstudied\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"150 mg\",\n+            \"light\": \"300-500 mg\",\n+            \"common\": \"500-1000 mg\",\n+            \"strong\": \"1000-2000 mg\",\n+            \"heavy\": \"2000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"3-8 hours\",\n+            \"after_effects\": \"24-72 hours (residual stimulation and insomnia)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Benzydamine exhibits powerful reinforcing effects in animal models and shows cross-sensitization with drugs like heroin and cocaine. Individuals with prior substance abuse history may be at significantly higher risk for developing benzydamine dependence due to neurobiological sensitivity to its effects.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Other deliriants (overwhelming and unpredictable effects)\",\n+        \"Stimulants (increased cardiovascular stress and anxiety)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (commonly combined; may exacerbate dehydration and confusion)\",\n+        \"Cannabis (frequently co-used by recreational users)\",\n+        \"Benzodiazepines (may blunt effects but can increase confusion)\",\n+        \"CNS depressants (may create unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"Benzydamine products, particularly Tantum Rosa vaginal douching sachets, contain dangerous levels of sodium chloride that can cause severe kidney damage if ingested directly. Proper salt extraction using water filtration is essential before consumption. The substance causes severe and prolonged insomnia lasting up to 48 hours, producing taxing sleep deprivation that often triggers paranoia. Legal and available over-the-counter in many countries for legitimate throat and mouth inflammation treatment. Individuals with personal or family history of psychotic disorders should avoid use due to risk of persistent psychotic symptoms.\",\n+    \"subjective_effects\": [\n+      \"Intense Stimulation\",\n+      \"External Hallucinations (Shadow People, Animals, Autonomous Entities)\",\n+      \"Auditory Hallucinations\",\n+      \"Visual Tracers and After Images\",\n+      \"Delirium and Confusion\",\n+      \"Anxiety and Paranoia\",\n+      \"Feelings of Impending Doom\",\n+      \"Euphoria (During Onset Only)\",\n+      \"Motor Control Loss\",\n+      \"Tactile Suppression\",\n+      \"Time Distortion\",\n+      \"Frequent Urination\",\n+      \"Dehydration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops rapidly with consecutive use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other deliriants (e.g., diphenhydramine, datura)\"\n+      ]\n+    },\n+    \"half_life\": \"7-8 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Benzydamine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Benzydamine\"\n+      },\n+      {\n+        \"name\": \"Erowid Benzydamine Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Benzydamine.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Benzydamine Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/benzydamine-nsaid-stimulant-psychedelic.353442/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: Benzydamine Discussion\",\n+        \"reference\": \"https://drugs-forum.com/threads/so-i-have-benzydamine-hcl-a-deliriant.295883/\"\n+      },\n+      {\n+        \"name\": \"The Benzydamine Experience: A Systematic Review\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8977632/\"\n+      },\n+      {\n+        \"name\": \"Benzydamine - An Affordable OTC Drug with Psychoactive Properties\",\n+        \"reference\": \"https://www.mdpi.com/1424-8247/16/4/566\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"stimulant\",\n+      \"indazole\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 659\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-015044-ecb73ef4",
    "createdAt": "2025-10-17T01:50:44.485Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:50:42 PM"
    },
    "articles": [
      {
        "id": 658,
        "title": "Nitrous Oxide",
        "slug": "nitrous-oxide"
      }
    ],
    "markdown": "# Nitrous Oxide · #658\n\n+{\n+  \"title\": \"Nitrous Oxide\",\n+  \"index-category\": \"dissociative; inhalant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Nitrous Oxide\",\n+    \"chemical_name\": \"Dinitrogen monoxide\",\n+    \"alternative_name\": \"Laughing Gas; Nitrous; NOS; Hippy Crack; N2O; Nangs; Whippits; Nitro\",\n+    \"chemical_class\": \"Nitrogen oxide\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (primary); GABA-A receptor potentiation; glycine receptor potentiation; nACh receptor antagonist (beta2-subunit); two-pore-domain K+ channel activation\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"inhaled\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"4 g\",\n+            \"light\": \"4-8 g (0.5-1 cartridge)\",\n+            \"common\": \"8-16 g (1-2 cartridges)\",\n+            \"strong\": \"16-40 g (2-5 cartridges)\",\n+            \"heavy\": \"40+ g (5+ cartridges)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"inhaled\",\n+          \"stages\": {\n+            \"total_duration\": \"1-5 minutes\",\n+            \"onset\": \"5-10 seconds\",\n+            \"peak\": \"15-30 seconds\",\n+            \"offset\": \"1-5 minutes\",\n+            \"after_effects\": \"15-30 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"inhaled\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Nitrous oxide is considered to have low to moderate abuse potential and low physical addiction potential. However, it is strongly psychologically compelling due to its brief duration and powerful effects, which can lead to compulsive redosing during a session. Frequent use is rare due to rapid tolerance development.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (risk of unconsciousness, vomit aspiration, memory blackouts)\",\n+        \"GHB/GBL (risk of unconsciousness, vomit aspiration, ataxia)\",\n+        \"Opioids (risk of unconsciousness, vomit aspiration, respiratory depression)\",\n+        \"Tramadol (risk of unconsciousness, vomit aspiration)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (potentiates effects)\",\n+        \"Psychedelics (dramatically intensifies visuals and ego dissolution)\",\n+        \"Dissociatives (intensifies disconnection and internal hallucinations)\",\n+        \"MDMA (may cause nausea)\"\n+      ]\n+    },\n+    \"notes\": \"Nitrous oxide can cause severe and potentially irreversible vitamin B12 depletion with frequent or chronic use, leading to serious neurological damage including numbness, tingling, and motor control loss. Always supplement with vitamin B12 when using this substance. Never inhale directly from cartridges or tanks due to extreme cold temperature (-40C) which can cause frostbite to lips, throat, and lungs, and high pressure which can rupture lung tissue. Always release gas into a balloon first to warm and depressurize. Ensure adequate oxygen intake between inhalations to prevent hypoxia and brain damage. Use while seated to prevent injury from falls. Filter gas through cloth or cotton to remove metal particles and industrial residue from food-grade cartridges.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Auditory Distortion\",\n+      \"Visual Geometry\",\n+      \"Ego Death\",\n+      \"Laughter Fits\",\n+      \"Motor Control Loss\",\n+      \"Dissociation\",\n+      \"Time Distortion\",\n+      \"Sedation\",\n+      \"Dizziness\",\n+      \"Tactile Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-4 consecutive uses within hours\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"5-10 minutes (less than 0.004% metabolized)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Nitrous Oxide\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Nitrous\"\n+      },\n+      {\n+        \"name\": \"TripSit Nitrous Oxide Factsheet\",\n+        \"reference\": \"https://tripsit.me/factsheets/nitrous\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Nitrous Oxide\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Nitrous_Oxide\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Basics\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Nitrous Thread (FAQ)\",\n+        \"reference\": \"https://bluelight.org/xf/threads/nitrous-oxide-whippits-nangs-johnny-gas-n2o-faq.54176/\"\n+      },\n+      {\n+        \"name\": \"DanceWize NSW: Nitrous Oxide Harm Reduction\",\n+        \"reference\": \"https://hi-ground.org/substances/nitrous-oxide/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"inhalant\",\n+      \"anesthetic\"\n+    ]\n+  },\n+  \"id\": 658\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-014715-6d864e1c",
    "createdAt": "2025-10-17T01:47:15.427Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:47:12 PM"
    },
    "articles": [
      {
        "id": 657,
        "title": "PCE",
        "slug": "pce"
      }
    ],
    "markdown": "# PCE · #657\n\n+{\n+  \"title\": \"PCE\",\n+  \"index-category\": \"dissociative; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PCE\",\n+    \"chemical_name\": \"N-Ethyl-1-phenylcyclohexanamine\",\n+    \"alternative_name\": \"Eticyclidine; CI-400; Cyclohexamine\",\n+    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (noncompetitive); dopamine-noradrenaline reuptake inhibitor; serotonin reuptake inhibitor; suspected mu-opioid receptor affinity\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"The chronic use of PCE can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, PCE has been reported to be more addictive than MXE, diphenidine, ephenidine, and ketamine. Multiple reports exist of people becoming seriously addicted daily users of this substance.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Depressants (increased risk of unconsciousness, vomiting, and fatal suffocation)\"\n+      ],\n+      \"unsafe\": [\n+        \"Psychedelics (extreme psychological disturbances, psychosis, and mania at significantly higher rates)\",\n+        \"Stimulants (increased risk of anxiety, mania, delusions, and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"PCE is a potent dissociative that causes psychosis and mania at significantly higher rates than other dissociatives. Users should avoid taking the drug multiple days in a row or in high doses. Volumetric liquid dosing is strongly recommended due to the drug's extreme potency, as most standard milligram scales cannot accurately weigh doses below 10-15 mg. Compulsive redosing should be avoided. Long-term use may lead to severe memory loss, disorganized thinking, bladder and urinary tract problems, and schizophrenia-like psychotic episodes. Individuals with personal or family histories of psychotic disorders should avoid use. PCE is internationally controlled as a Schedule I substance.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Suppression\",\n+      \"Motor Control Loss\",\n+      \"Visual Disconnection\",\n+      \"Consciousness Disconnection\",\n+      \"Visual Acuity Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Depersonalization\",\n+      \"Derealization\",\n+      \"Memory Suppression\",\n+      \"Ego Death\",\n+      \"Mania\",\n+      \"Delusion\",\n+      \"Disinhibition\",\n+      \"Compulsive Redosing\",\n+      \"Nausea\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dissociatives\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight PCE Bioassay Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pce-bioassay-eight-human-trials-with-the-unicorn-dissociative-eticyclidine.927036/\"\n+      },\n+      {\n+        \"name\": \"Bluelight PCE Small & Handy Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-pce-eticyclidine-thread.919539/\"\n+      },\n+      {\n+        \"name\": \"Erowid PCE Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_PCE.shtml\"\n+      },\n+      {\n+        \"name\": \"Morris & Wallach 2014: From PCP to MXE\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PCE\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PCE\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"arylcyclohexylamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 657\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-013238-c5f65b8d",
    "createdAt": "2025-10-17T01:32:38.014Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:32:34 PM"
    },
    "articles": [
      {
        "id": 656,
        "title": "4-MeO-PCP",
        "slug": "4-meo-pcp"
      }
    ],
    "markdown": "# 4-MeO-PCP · #656\n\n+{\n+  \"title\": \"4-MeO-PCP\",\n+  \"index-category\": \"dissociative; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-MeO-PCP\",\n+    \"chemical_name\": \"1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine\",\n+    \"alternative_name\": \"Methoxydine; 4-Methoxyphencyclidine; 4-Methoxy-PCP\",\n+    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-170 mg\",\n+            \"strong\": \"170-250 mg\",\n+            \"heavy\": \"250+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-75 mg\",\n+            \"common\": \"75-150 mg\",\n+            \"strong\": \"150+ mg\",\n+            \"heavy\": \"\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"12-20 hours\",\n+            \"onset\": \"45-120 minutes\",\n+            \"peak\": \"3-7 hours\",\n+            \"offset\": \"6-10 hours\",\n+            \"after_effects\": \"6+ hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"12-18 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"3 hours\",\n+            \"after_effects\": \"3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. The long duration may discourage frequent redosing compared to shorter-acting dissociatives.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Depressants (risk of respiratory depression, unconsciousness, vomiting and aspiration)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, mania, delusions and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"4-MeO-PCP is a long-acting dissociative with approximately 70% the potency of PCP. Users have reported substantial differences in active dose; these discrepancies may be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Use a precise milligram scale for dosing. The extended duration of action can be both an advantage and disadvantage, with effects and after-effects persisting well into the next day. Chronic use may lead to urinary tract issues similar to ketamine, though less severe due to higher potency requiring smaller amounts. Set and setting are important, and users should avoid potentially hazardous activities during the experience.\",\n+    \"subjective_effects\": [\n+      \"Consciousness Disconnection\",\n+      \"Visual Disconnection\",\n+      \"Dizziness\",\n+      \"Motor Control Loss\",\n+      \"Physical Euphoria\",\n+      \"Spatial Disorientation\",\n+      \"Tactile Suppression\",\n+      \"Depersonalization\",\n+      \"Derealization\",\n+      \"Amnesia\",\n+      \"Time Distortion\",\n+      \"Creativity Enhancement\",\n+      \"Immersion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Internal Hallucinations\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dissociatives\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-MeO-PCP Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-meo-pcp-thread.391328/\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-MeO-PCP Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4meo_pcp/4meo_pcp.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-MeO-PCP\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=963\"\n+      },\n+      {\n+        \"name\": \"Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-MeO-PCP\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-MeO-PCP\"\n+      },\n+      {\n+        \"name\": \"Roth BL et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor\",\n+        \"reference\": \"https://doi.org/10.1371/journal.pone.0059334\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"arylcyclohexylamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 656\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-012541-c4d47db2",
    "createdAt": "2025-10-17T01:25:41.467Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:25:40 PM"
    },
    "articles": [
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# TMA-6 · #655\n\n+{\n+  \"title\": \"TMA-6\",\n+  \"index-category\": \"psychedelic; stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"TMA-6\",\n+    \"chemical_name\": \"1-(2,4,6-Trimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n+    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potent MAO-A inhibitor (IC50 400 nM)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-20 mg\",\n+            \"common\": \"20-35 mg\",\n+            \"strong\": \"35-50 mg\",\n+            \"heavy\": \"50+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"10-16 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"5-8 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-18 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-7 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"6-11 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"TMA-6 is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with consumption, and rapid tolerance development discourages frequent redosing. It is generally self-regulating.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome; TMA-6 itself is a potent MAO-A inhibitor)\",\n+        \"Lithium (elevated risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Serotonin releasers (MDMA, 4-FA, methamphetamine, methylone, aMT; risk of serotonin syndrome)\",\n+        \"Stimulants (risk of excessive anxiety, panic, thought loops, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (citalopram, sertraline; risk of serotonin syndrome and altered effects)\",\n+        \"SNRIs (venlafaxine; risk of serotonin syndrome)\",\n+        \"5-HTP (risk of serotonin syndrome)\",\n+        \"Other psychedelics (risk of overwhelming intensity and unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"TMA-6 is a potent MAO-A inhibitor, which creates significant interaction risks and requires careful attention to dietary restrictions similar to pharmaceutical MAOIs. Individuals with personal or family histories of psychotic disorders should avoid use. The substance is highly dose-sensitive and produces unpredictable effects with considerable body load and nausea. Set and setting strongly influence the experience. Users should be prepared for an extended duration of 10-16 hours. Always use a precise scale for dosing.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Tactile Enhancement\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Acceleration\",\n+      \"Conceptual Thinking Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Visual Acuity Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Drifting\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Libido\",\n+      \"Music Appreciation Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\",\n+        \"All stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"Not well documented; estimated 3-6 hours based on related compounds\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid TMA-6 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_TMA6.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid TMA-6 Comparison Information\",\n+        \"reference\": \"https://erowid.org/chemicals/tma2/tma2_info1.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design PiHKAL Entry #162 TMA-6\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=162\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki TMA-6\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/TMA-6\"\n+      },\n+      {\n+        \"name\": \"Bluelight TMA Series Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/suprise-substance-of-july-the-tma-series.384752/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia 2,4,6-Trimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,4,6-Trimethoxyamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"amphetamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 655\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-012038-a0dcd9b9",
    "createdAt": "2025-10-17T01:20:38.225Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:20:36 PM"
    },
    "articles": [
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      }
    ],
    "markdown": "# 25N-NBOMe · #654\n\n+{\n+  \"title\": \"25N-NBOMe\",\n+  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25N-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-N-NBOMe; NBOMe-2C-N; N-Bomb\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2C receptor full agonist; 5-HT2B receptor partial agonist; dopamine transporter phosphorylation (increases extracellular dopamine)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"100-300 ug\",\n+            \"common\": \"300-800 ug\",\n+            \"strong\": \"800-1300 ug\",\n+            \"heavy\": \"1300+ ug (potentially fatal)\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Not recommended\",\n+            \"light\": \"Not recommended\",\n+            \"common\": \"Not recommended\",\n+            \"strong\": \"Not recommended\",\n+            \"heavy\": \"Not recommended (extremely dangerous)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25N-NBOMe is not considered habit-forming and the desire to use often decreases with repeated administration. However, animal studies suggest potential dependence liability through dopaminergic pathways, with conditioned place preference effects comparable to methamphetamine in rodent models. The substance exhibits rapid tolerance development.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases seizure risk)\",\n+        \"MAOIs (unpredictable potentiation and duration increase)\",\n+        \"Tramadol (significantly lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Amphetamines (severe cardiovascular strain, tachycardia, hypertension, and increased seizure risk)\",\n+        \"Cocaine (severe cardiovascular strain and vasoconstriction)\",\n+        \"MDMA (unpredictable intensity, reports of blackouts and severe overstimulation)\",\n+        \"MXE (unpleasantly intense potentiation)\",\n+        \"DOx compounds (unpredictable interactions)\",\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (increased cardiovascular risk)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (significantly increases anxiety, paranoia, and psychosis risk)\",\n+        \"Caffeine (uncomfortable overstimulation and anxiety)\",\n+        \"DXM (unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"25N-NBOMe is a highly potent and unpredictable substance that has been linked to numerous hospitalizations and fatalities within the NBOMe series. The compound must only be administered sublingually, as insufflation dramatically increases overdose risk and has been implicated in multiple deaths. Blotter papers may contain uneven dose distribution with dangerous hotspots. Users should employ accurate microgram scales, avoid all drug combinations, and never exceed 1000 ug due to narrow margin between active and toxic doses. Individuals with cardiovascular conditions, seizure disorders, or personal or family history of psychotic disorders should strictly avoid use. The substance is often misrepresented as LSD; always use reagent testing.\",\n+    \"subjective_effects\": [\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Euphoric Body High\",\n+      \"Tactile Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Time Distortion\",\n+      \"Empathy And Sociability Enhancement (Inconsistent)\",\n+      \"Thought Acceleration\",\n+      \"Anxiety And Paranoia\",\n+      \"Mouth Numbing\",\n+      \"Increased Heart Rate\",\n+      \"Vasoconstriction\",\n+      \"Nausea (Especially During Onset)\",\n+      \"Muscle Tension\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, other NBOMes)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated from related compounds)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 25N-NBOMe Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread\"\n+      },\n+      {\n+        \"name\": \"Erowid: NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00078/full\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25N-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25N-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25N-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 25N-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25N-NBOMe\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nbome\",\n+      \"phenethylamine\",\n+      \"psychedelic\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 654\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-011657-22e845ad",
    "createdAt": "2025-10-17T01:16:57.045Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:16:53 PM"
    },
    "articles": [
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      }
    ],
    "markdown": "# 25D-NBOMe · #653\n\n+{\n+  \"title\": \"25D-NBOMe\",\n+  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25D-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"300 ug\",\n+            \"light\": \"300-800 ug\",\n+            \"common\": \"800-1000 ug\",\n+            \"strong\": \"1000-1200 ug\",\n+            \"heavy\": \"1200+ ug\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200 ug\",\n+            \"light\": \"200-600 ug\",\n+            \"common\": \"600-800 ug\",\n+            \"strong\": \"800-1000 ug\",\n+            \"heavy\": \"1000+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"6+ hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n+        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n+        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (unpredictable cardiovascular effects)\",\n+        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n+        \"DXM (unpredictable effects)\",\n+        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n+        \"MXE (potentiation of NBOMe effects)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n+        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n+        \"SSRIs (may blunt or prolong effects)\"\n+      ]\n+    },\n+    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n+    \"subjective_effects\": [\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Visual Geometry\",\n+      \"Tracers and After Images\",\n+      \"Physical Euphoria\",\n+      \"Stimulation\",\n+      \"Tactile Hallucination\",\n+      \"Time Distortion\",\n+      \"Mouth and Tongue Numbness\",\n+      \"Metallic Chemical Taste\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Thought Acceleration\",\n+      \"Music Appreciation Enhancement\",\n+      \"Emotional Amplification\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Temperature Regulation Suppression\",\n+      \"Muscle Tension and Cramps\",\n+      \"Headaches\",\n+      \"Anxiety and Paranoia\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops immediately after use\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\",\n+        \"Other NBOMe compounds\",\n+        \"2C-x series\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n+        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n+      },\n+      {\n+        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25D-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 25D-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n+        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"research-chemical\",\n+      \"nbome-series\",\n+      \"phenethylamine\"\n+    ]\n+  },\n+  \"id\": 653\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-011004-caa3a24b",
    "createdAt": "2025-10-17T01:10:04.318Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:10:02 PM"
    },
    "articles": [
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      }
    ],
    "markdown": "# 25C-NBOH · #652\n\n+{\n+  \"title\": \"25C-NBOH\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25C-NBOH\",\n+    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n+    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"250-500 ug\",\n+            \"common\": \"500-750 ug\",\n+            \"strong\": \"750-1000 ug\",\n+            \"heavy\": \"1000+ ug (potentially fatal)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-6 days (afterglow may persist)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (potentially dangerous interaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n+    \"subjective_effects\": [\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Color Enhancement\",\n+      \"Time Distortion\",\n+      \"Spontaneous Euphoric Tingling Sensations\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Mouth And Tongue Numbing\",\n+      \"Nausea (Typically During Come-Up)\",\n+      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n+      \"Mild Cognitive Effects (Notably Light Headspace)\",\n+      \"Increased Sociability And Empathy (Inconsistent)\",\n+      \"Enhanced Music Appreciation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n+      },\n+      {\n+        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n+      },\n+      {\n+        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n+        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n+      },\n+      {\n+        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n+        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25C-NBOH\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25C-NBOH\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n+      },\n+      {\n+        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n+        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"nboh-series\"\n+    ]\n+  },\n+  \"id\": 652\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-010656-f750f60d",
    "createdAt": "2025-10-17T01:06:56.440Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:06:53 PM"
    },
    "articles": [
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      }
    ],
    "markdown": "# DOI · #651\n\n+{\n+  \"title\": \"DOI\",\n+  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DOI\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n+    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n+    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"16-24 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"24-48 hours (residual stimulation)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n+        \"MAOIs (potential for unpredictable interactions)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n+        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n+        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n+        \"Caffeine (may cause anxiety and physical discomfort)\",\n+        \"Amphetamines (uncomfortable body load and thought loops)\",\n+        \"Cocaine (uncomfortable body load and thought loops)\",\n+        \"Ketamine (potentiation; go slowly)\",\n+        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n+      ]\n+    },\n+    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n+    \"subjective_effects\": [\n+      \"Extreme Stimulation\",\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Energetic Body High\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Internal And External Hallucinations\",\n+      \"Time Distortion\",\n+      \"Emotional Amplification\",\n+      \"Enhanced Music Appreciation\",\n+      \"Nausea\",\n+      \"Muscle Tension And Vasoconstriction\",\n+      \"Increased Body Temperature\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n+        \"reference\": \"https://doi.org/10.1139/v73-210\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki DOI Profile\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n+      },\n+      {\n+        \"name\": \"TripSit DOI Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/DOI\"\n+      },\n+      {\n+        \"name\": \"Erowid DOI Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n+        \"reference\": \"Transform Press, 1991\"\n+      },\n+      {\n+        \"name\": \"Bluelight DOI Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"substituted-amphetamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 651\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-005710-3997dc11",
    "createdAt": "2025-10-17T00:57:10.029Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:57:08 PM"
    },
    "articles": [
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      }
    ],
    "markdown": "# 2,5-DMA · #650\n\n+{\n+  \"title\": \"2,5-DMA\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2,5-DMA\",\n+    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n+    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n+    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n+        \"Other psychedelics (may intensify effects unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Pupil Dilation\",\n+      \"Muscle Tension\",\n+      \"Tremors\",\n+      \"Body Load\",\n+      \"Enhanced Interest In Surroundings\",\n+      \"Cardiovascular Stimulation\",\n+      \"Temperature Regulation Suppression\",\n+      \"Increased Perspiration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n+      \"cross_tolerances\": [\n+        \"Psychedelics (unlikely but possible)\",\n+        \"Stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n+        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n+      },\n+      {\n+        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 2,5-DMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"amphetamine\",\n+      \"phenethylamine\",\n+      \"dox-family\",\n+      \"research-chemical\",\n+      \"stimulant\"\n+    ]\n+  },\n+  \"id\": 650\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-005331-24a27364",
    "createdAt": "2025-10-17T00:53:31.846Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:53:29 PM"
    },
    "articles": [
      {
        "id": 649,
        "title": "2C-T",
        "slug": "2c-t"
      }
    ],
    "markdown": "# 2C-T · #649\n\n+{\n+  \"title\": \"2C-T\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2C-T\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n+    \"alternative_name\": \"Tesseract\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"40-60 mg\",\n+            \"common\": \"60-100 mg\",\n+            \"strong\": \"100-120 mg\",\n+            \"heavy\": \"125+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"30-115 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n+        \"Stimulants (increased neurotransmitter release)\",\n+        \"5-MeO-MiPT (serotonergic overload)\",\n+        \"2C-T-7 (serotonergic overload)\",\n+        \"AMT (MAOI properties)\",\n+        \"Cocaine (cardiovascular stress)\",\n+        \"Methamphetamine (neurotoxicity risk)\",\n+        \"MDMA (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"2-AI (serotonergic interaction)\",\n+        \"A-PVP (cardiovascular stress)\",\n+        \"Amphetamine (increased strain)\",\n+        \"Mephedrone (combined stimulation)\"\n+      ]\n+    },\n+    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Spontaneous Bodily Sensations\",\n+      \"Tactile Enhancement\",\n+      \"Bodily Control Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Colour Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Nausea\",\n+      \"Vasoconstriction\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n+        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #39: 2C-T\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 2C-T\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n+      },\n+      {\n+        \"name\": \"Erowid 2C-T-2 Basics\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n+        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"2c-x\"\n+    ]\n+  },\n+  \"id\": 649\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-004937-559d1cc3",
    "createdAt": "2025-10-17T00:49:37.836Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:49:35 PM"
    },
    "articles": [
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      }
    ],
    "markdown": "# Proscaline · #648\n\n+{\n+  \"title\": \"Proscaline\",\n+  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Proscaline\",\n+    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n+    \"chemical_class\": \"Phenethylamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"3-5 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (potentially hazardous serotonergic interaction)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased cardiovascular strain)\",\n+        \"Cannabis (may intensify and prolong effects unpredictably)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n+      ]\n+    },\n+    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Enhancement\",\n+      \"Color Enhancement\",\n+      \"Time Distortion\",\n+      \"Enhanced Music Appreciation\",\n+      \"Tactile Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Conceptual Thinking\",\n+      \"Increased Body Temperature\",\n+      \"Nausea\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Drifting Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Proscaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n+      },\n+      {\n+        \"name\": \"Erowid PiHKAL: Proscaline\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Proscaline Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Proscaline Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n+      },\n+      {\n+        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n+        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"mescaline-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 648\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-004607-55af38b6",
    "createdAt": "2025-10-17T00:46:07.580Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:46:03 PM"
    },
    "articles": [
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      }
    ],
    "markdown": "# Escaline · #647\n\n+{\n+  \"title\": \"Escaline\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Escaline\",\n+    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n+    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-25 mg\",\n+            \"light\": \"30-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"40-120 minutes\",\n+            \"peak\": \"5-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-5 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n+      ]\n+    },\n+    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Enhanced Music Appreciation\",\n+      \"Visual Patterning And Drifting\",\n+      \"Color Enhancement\",\n+      \"Thought Acceleration And Connectivity\",\n+      \"Time Distortion\",\n+      \"Bodily Sensations\",\n+      \"Pupil Dilation\",\n+      \"Increased Heart Rate\",\n+      \"Muscle Tension\",\n+      \"Euphoria\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n+      },\n+      {\n+        \"name\": \"Erowid Escaline Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Escaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"mescaline-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 647\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-003112-5d53dfd6",
    "createdAt": "2025-10-17T00:31:12.900Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:31:10 PM"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-  \"title\": \"Psilocybin mushrooms\",\n+  \"title\": \"Psilocybin Mushrooms\",\n-    \"drug_name\": \"Psilocybin mushrooms\",\n-    \"chemical_name\": \"Psilocybin\",\n-    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n+    \"drug_name\": \"Psilocybin Mushrooms\",\n+    \"chemical_name\": \"4-Phosphoryloxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Magic Mushrooms; Shrooms; Mushies; Psychedelic Mushrooms; Boomers; Magic Truffles\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (psilocin acts as prodrug)\",\n-          \"units\": \"g (dried mushrooms)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"0.25 g\",\n-            \"light\": \"0.5 - 1 g\",\n-            \"common\": \"1 - 2.5 g\",\n-            \"strong\": \"2.5 - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"0.1-0.5 g\",\n+            \"light\": \"0.5-1.5 g\",\n+            \"common\": \"1.5-3.5 g\",\n+            \"strong\": \"3.5-5 g\",\n+            \"heavy\": \"5+ g\"\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.3 g\",\n+            \"light\": \"0.3-1 g\",\n+            \"common\": \"1-2.5 g\",\n+            \"strong\": \"2.5-3.5 g\",\n+            \"heavy\": \"3.5+ g\"\n+          }\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"20 - 60 minutes\",\n-            \"peak\": \"2 - 3 hours\",\n-            \"offset\": \"1 - 2 hours\",\n-            \"after_effects\": \"Up to 24 hours (residual effects, afterglow)\"\n-          },\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n-          ]\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.\",\n+    \"addiction_potential\": \"Psilocybin mushrooms are not considered physically addictive and have low potential for psychological dependence. Rapid tolerance development discourages frequent use. They are not associated with compulsive drug-seeking behavior or withdrawal symptoms.\",\n-        \"MAOIs (can dangerously potentiate effects)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n-        \"SSRIs (may blunt effects)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Other psychedelics (unpredictable and overwhelming intensity)\"\n-        \"Other psychedelics (increased risk of overwhelming experience)\"\n+        \"Cannabis (unpredictable and significantly intensified effects; increased anxiety, paranoia, and psychosis risk)\",\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Benzodiazepines (may dampen experience; useful for trip abortion)\",\n+        \"Alcohol (may cause dehydration and nausea; can reduce anxiety in low doses)\",\n+        \"MDMA (unknown toxicity; may increase neurotoxicity)\"\n-    \"notes\": \"Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.\",\n+    \"notes\": \"Psilocybin mushrooms vary widely in potency by species, strain, and individual specimen; accurate weighing with a precise scale is essential. Dried mushrooms are approximately 10 times more potent by weight than fresh mushrooms. Exercise extreme caution when foraging wild mushrooms due to the risk of consuming poisonous look-alike species; identification should only be performed by experts. Individuals with personal or family history of psychotic disorders should avoid use. Set and setting strongly influence the experience; ensure a safe, comfortable, familiar environment and consider having a trusted sober trip sitter present, especially for first-time users or higher doses.\",\n-      \"Visual distortions\",\n-      \"Euphoria\",\n-      \"Altered thinking\",\n-      \"Time dilation\",\n-      \"Synesthesia\",\n-      \"Spiritual or mystical experiences\",\n-      \"Emotional lability\",\n-      \"Introspection\",\n-      \"Body high\",\n-      \"Nausea (sometimes)\"\n+      \"Visual Geometry and Patterning\",\n+      \"Enhanced Mood and Euphoria\",\n+      \"Time Distortion\",\n+      \"Emotional Enhancement and Amplification\",\n+      \"Spirituality and Mystical Experiences\",\n+      \"Ego Loss and Dissolution\",\n+      \"Enhanced Introspection\",\n+      \"Conceptual Thinking\",\n+      \"Unity and Interconnectedness\",\n+      \"Nausea (especially during come-up)\",\n+      \"Sedation and Body Heaviness\",\n+      \"Confusion\",\n+      \"Anxiety or Feelings of Impending Doom (typically during onset)\",\n+      \"Synaesthesia\",\n+      \"Tactile Enhancement\",\n+      \"Excessive Yawning\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"full_tolerance\": \"After 1-2 consecutive days of use\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"Other tryptamine psychedelics (e.g., LSD, DMT)\"\n+        \"All psychedelics (LSD, mescaline, 2C-x, tryptamines)\"\n-    \"half_life\": \"1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin\",\n+    \"half_life\": \"1-3 hours (psilocin active metabolite)\",\n-        \"name\": \"Bluelight - Penis Envy Mushrooms Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949\"\n+        \"name\": \"Erowid Psilocybin Mushroom Dosage\",\n+        \"reference\": \"https://erowid.org/plants/mushrooms/mushrooms_dose.shtml\"\n-        \"name\": \"Bluelight - Getting the Most Out of Mushrooms\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2\"\n+        \"name\": \"PsychonautWiki: Psilocybin Mushrooms\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushrooms\"\n-        \"name\": \"Tripsitter Substack: Penis Envy Mushrooms\",\n-        \"reference\": \"https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z\"\n+        \"name\": \"TripSit Mushrooms Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Mushrooms\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Psilocybin Mushrooms Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-psilocybin-mushrooms-thread.58587/\"\n+      },\n+      {\n+        \"name\": \"Drug Science: Psilocybin\",\n+        \"reference\": \"https://www.drugscience.org.uk/psilocybin\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Psychiatry: Therapeutic use of psilocybin\",\n+        \"reference\": \"https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Psilocybin Mushroom Lemon Tek\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushroom_lemon_tek\"\n-      \"common\"\n+      \"classic-psychedelic\",\n+      \"tryptamine\",\n+      \"plant-based\"\n-  \"index-category\": \"\"\n+  \"index-category\": \"psychedelic;classic;tryptamine\"\n\n# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}\n\n# Allylescaline · #646\n\n+{\n+  \"title\": \"Allylescaline\",\n+  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Allylescaline\",\n+    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"45-240 minutes\",\n+            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (increased seizure risk with psychedelics)\",\n+        \"Tramadol (lowers seizure threshold with psychedelics)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n+        \"Stimulants (increased body load and cardiovascular strain)\",\n+        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n+        \"Dissociatives (unpredictable combination effects)\"\n+      ]\n+    },\n+    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Drifting and Flowing Visuals\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Empathy and Sociability\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Allylescaline Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki - Allylescaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n+      },\n+      {\n+        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n+        \"reference\": \"https://bluelight.org\"\n+      },\n+      {\n+        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"mescaline-analog\"\n+    ]\n+  },\n+  \"id\": 646\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-002601-680627a7",
    "createdAt": "2025-10-17T00:26:01.353Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:25:59 PM"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-  \"title\": \"Psilocybin mushrooms\",\n+  \"title\": \"Psilocybin Mushrooms\",\n-    \"drug_name\": \"Psilocybin mushrooms\",\n-    \"chemical_name\": \"Psilocybin\",\n-    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n+    \"drug_name\": \"Psilocybin Mushrooms\",\n+    \"chemical_name\": \"4-Phosphoryloxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Magic Mushrooms; Shrooms; Mushies; Psychedelic Mushrooms; Boomers; Magic Truffles\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (psilocin acts as prodrug)\",\n-          \"units\": \"g (dried mushrooms)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"0.25 g\",\n-            \"light\": \"0.5 - 1 g\",\n-            \"common\": \"1 - 2.5 g\",\n-            \"strong\": \"2.5 - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"0.1-0.5 g\",\n+            \"light\": \"0.5-1.5 g\",\n+            \"common\": \"1.5-3.5 g\",\n+            \"strong\": \"3.5-5 g\",\n+            \"heavy\": \"5+ g\"\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.3 g\",\n+            \"light\": \"0.3-1 g\",\n+            \"common\": \"1-2.5 g\",\n+            \"strong\": \"2.5-3.5 g\",\n+            \"heavy\": \"3.5+ g\"\n+          }\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"20 - 60 minutes\",\n-            \"peak\": \"2 - 3 hours\",\n-            \"offset\": \"1 - 2 hours\",\n-            \"after_effects\": \"Up to 24 hours (residual effects, afterglow)\"\n-          },\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n-          ]\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.\",\n+    \"addiction_potential\": \"Psilocybin mushrooms are not considered physically addictive and have low potential for psychological dependence. Rapid tolerance development discourages frequent use. They are not associated with compulsive drug-seeking behavior or withdrawal symptoms.\",\n-        \"MAOIs (can dangerously potentiate effects)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n-        \"SSRIs (may blunt effects)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Other psychedelics (unpredictable and overwhelming intensity)\"\n-        \"Other psychedelics (increased risk of overwhelming experience)\"\n+        \"Cannabis (unpredictable and significantly intensified effects; increased anxiety, paranoia, and psychosis risk)\",\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Benzodiazepines (may dampen experience; useful for trip abortion)\",\n+        \"Alcohol (may cause dehydration and nausea; can reduce anxiety in low doses)\",\n+        \"MDMA (unknown toxicity; may increase neurotoxicity)\"\n-    \"notes\": \"Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.\",\n+    \"notes\": \"Psilocybin mushrooms vary widely in potency by species, strain, and individual specimen; accurate weighing with a precise scale is essential. Dried mushrooms are approximately 10 times more potent by weight than fresh mushrooms. Exercise extreme caution when foraging wild mushrooms due to the risk of consuming poisonous look-alike species; identification should only be performed by experts. Individuals with personal or family history of psychotic disorders should avoid use. Set and setting strongly influence the experience; ensure a safe, comfortable, familiar environment and consider having a trusted sober trip sitter present, especially for first-time users or higher doses.\",\n-      \"Visual distortions\",\n-      \"Euphoria\",\n-      \"Altered thinking\",\n-      \"Time dilation\",\n-      \"Synesthesia\",\n-      \"Spiritual or mystical experiences\",\n-      \"Emotional lability\",\n-      \"Introspection\",\n-      \"Body high\",\n-      \"Nausea (sometimes)\"\n+      \"Visual Geometry and Patterning\",\n+      \"Enhanced Mood and Euphoria\",\n+      \"Time Distortion\",\n+      \"Emotional Enhancement and Amplification\",\n+      \"Spirituality and Mystical Experiences\",\n+      \"Ego Loss and Dissolution\",\n+      \"Enhanced Introspection\",\n+      \"Conceptual Thinking\",\n+      \"Unity and Interconnectedness\",\n+      \"Nausea (especially during come-up)\",\n+      \"Sedation and Body Heaviness\",\n+      \"Confusion\",\n+      \"Anxiety or Feelings of Impending Doom (typically during onset)\",\n+      \"Synaesthesia\",\n+      \"Tactile Enhancement\",\n+      \"Excessive Yawning\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"full_tolerance\": \"After 1-2 consecutive days of use\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"Other tryptamine psychedelics (e.g., LSD, DMT)\"\n+        \"All psychedelics (LSD, mescaline, 2C-x, tryptamines)\"\n-    \"half_life\": \"1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin\",\n+    \"half_life\": \"1-3 hours (psilocin active metabolite)\",\n-        \"name\": \"Bluelight - Penis Envy Mushrooms Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949\"\n+        \"name\": \"Erowid Psilocybin Mushroom Dosage\",\n+        \"reference\": \"https://erowid.org/plants/mushrooms/mushrooms_dose.shtml\"\n-        \"name\": \"Bluelight - Getting the Most Out of Mushrooms\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2\"\n+        \"name\": \"PsychonautWiki: Psilocybin Mushrooms\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushrooms\"\n-        \"name\": \"Tripsitter Substack: Penis Envy Mushrooms\",\n-        \"reference\": \"https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z\"\n+        \"name\": \"TripSit Mushrooms Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Mushrooms\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Psilocybin Mushrooms Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-psilocybin-mushrooms-thread.58587/\"\n+      },\n+      {\n+        \"name\": \"Drug Science: Psilocybin\",\n+        \"reference\": \"https://www.drugscience.org.uk/psilocybin\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Psychiatry: Therapeutic use of psilocybin\",\n+        \"reference\": \"https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Psilocybin Mushroom Lemon Tek\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushroom_lemon_tek\"\n-      \"common\"\n+      \"classic-psychedelic\",\n+      \"tryptamine\",\n+      \"plant-based\"\n-  \"index-category\": \"\"\n+  \"index-category\": \"psychedelic;classic;tryptamine\"\n\n# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-002145-da9fd05b",
    "createdAt": "2025-10-17T00:21:45.181Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:21:43 PM"
    },
    "articles": [
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      }
    ],
    "markdown": "# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001831-4cf48d4f",
    "createdAt": "2025-10-17T00:18:31.587Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:18:29 PM"
    },
    "articles": [
      {
        "id": 644,
        "title": "5-MeO-DiPT",
        "slug": "5-meo-dipt"
      }
    ],
    "markdown": "# 5-MeO-DiPT · #644\n\n+{\n+  \"title\": \"5-MeO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"5-MeO-DiPT\",\n+    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n+    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-4 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-4 mg\",\n+            \"light\": \"4-7 mg\",\n+            \"common\": \"7-12 mg\",\n+            \"strong\": \"12-18 mg\",\n+            \"heavy\": \"18+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-8 mg\",\n+            \"strong\": \"8-12 mg\",\n+            \"heavy\": \"12+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n+        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n+        \"aMT (increased risk of serotonin syndrome)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-X (both classes unpredictable alone)\",\n+        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n+        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n+        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n+        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n+        \"Mescaline (unpredictable interactions)\",\n+        \"DXM (little information; possible unpredictable effects)\",\n+        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n+        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n+        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n+      ]\n+    },\n+    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n+    \"subjective_effects\": [\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Emotional Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Libido\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Auditory Distortions\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Body Load\",\n+      \"Diarrhea\",\n+      \"Time Distortion\",\n+      \"Visual Drifting (at higher doses)\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"3-6 hours (estimated from duration data)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combinations Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n+        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n+      },\n+      {\n+        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n+        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n+      },\n+      {\n+        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"entactogen\"\n+    ]\n+  },\n+  \"id\": 644\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001600-2209a8ec",
    "createdAt": "2025-10-17T00:16:00.464Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:15:58 PM"
    },
    "articles": [
      {
        "id": 643,
        "title": "4-HO-MPT",
        "slug": "4-ho-mpt"
      }
    ],
    "markdown": "# 4-HO-MPT · #643\n\n+{\n+  \"title\": \"4-HO-MPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-MPT\",\n+    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n+    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"45-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"15-45 minutes\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Distortions And Patterning\",\n+      \"Color Enhancement And Shifting\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Pupil Dilation\",\n+      \"Thought Loops\",\n+      \"Vertigo Or Dizziness\",\n+      \"Memory Suppression\",\n+      \"Internal And External Hallucinations\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-HO-MPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki 4-HO-MPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n+      },\n+      {\n+        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n+        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 643\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001249-69555e3a",
    "createdAt": "2025-10-17T00:12:49.407Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:12:46 PM"
    },
    "articles": [
      {
        "id": 642,
        "title": "4-HO-EPT",
        "slug": "4-ho-ept"
      }
    ],
    "markdown": "# 4-HO-EPT · #642\n\n+{\n+  \"title\": \"4-HO-EPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-EPT\",\n+    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Eprocin\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-20 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-30 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Color Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Euphoric Body High\",\n+      \"Increased Music Appreciation\",\n+      \"Conceptual Thinking\",\n+      \"Analysis Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Sedation\",\n+      \"Memory Suppression\",\n+      \"Thought Loops\",\n+      \"Nausea\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-HO-EPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n+      },\n+      {\n+        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 642\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000922-9ad8186d",
    "createdAt": "2025-10-17T00:09:22.650Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:09:20 PM"
    },
    "articles": [
      {
        "id": 641,
        "title": "4-HO-DiPT",
        "slug": "4-ho-dipt"
      }
    ],
    "markdown": "# 4-HO-DiPT · #641\n\n+{\n+  \"title\": \"4-HO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n+    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n+    \"subjective_effects\": [\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Introspective Insights\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Sexual Enhancement\",\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Muscle Tremors\",\n+      \"Nausea\",\n+      \"Pupil Dilation\",\n+      \"Stimulation\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DiPT\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n+        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 641\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000655-9eafe3b2",
    "createdAt": "2025-10-17T00:06:55.306Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:06:53 PM"
    },
    "articles": [
      {
        "id": 640,
        "title": "4-HO-DET",
        "slug": "4-ho-det"
      }
    ],
    "markdown": "# 4-HO-DET · #640\n\n+{\n+  \"title\": \"4-HO-DET\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DET\",\n+    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n+    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"20-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Memory Suppression\",\n+      \"Excessive Yawning\",\n+      \"Temperature Regulation Suppression\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DET\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 640\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000420-1266ad24",
    "createdAt": "2025-10-17T00:04:20.477Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:04:18 PM"
    },
    "articles": [
      {
        "id": 639,
        "title": "4-AcO-MiPT",
        "slug": "4-aco-mipt"
      }
    ],
    "markdown": "# 4-AcO-MiPT · #639\n\n+{\n+  \"title\": \"4-AcO-MiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-MiPT\",\n+    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n+    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-20 mg\",\n+            \"strong\": \"20-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Colour Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Sedation With Mild Euphoria\",\n+      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n+      \"Excessive Yawning\",\n+      \"Enhanced Music Appreciation\",\n+      \"Auditory Distortions (Downward Pitch Shift)\",\n+      \"Emotion Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Internal Hallucinations (Dark Environments)\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n+      },\n+      {\n+        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n+        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 639\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235801-dbfacf25",
    "createdAt": "2025-10-16T23:58:01.469Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:57:59 PM"
    },
    "articles": [
      {
        "id": 638,
        "title": "4-AcO-DiPT",
        "slug": "4-aco-dipt"
      }
    ],
    "markdown": "# 4-AcO-DiPT · #638\n\n+{\n+  \"title\": \"4-AcO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n+    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"15-40 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-1.5 hours\",\n+            \"after_effects\": \"2-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n+        \"Alcohol (physically taxing, may dull effects)\",\n+        \"Benzodiazepines (may reduce trip intensity)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Increased Libido\",\n+      \"Sedation Followed By Stimulation\",\n+      \"Disinhibition\",\n+      \"Enhanced Sociability\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Changes In Felt Bodily Form\",\n+      \"Music Appreciation Enhancement\",\n+      \"Empathy And Affection Enhancement\",\n+      \"Minimal Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n+      },\n+      {\n+        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n+      },\n+      {\n+        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 638\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235243-ca7cd977",
    "createdAt": "2025-10-16T23:52:43.680Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:52:42 PM"
    },
    "articles": [
      {
        "id": 637,
        "title": "EPT",
        "slug": "ept"
      }
    ],
    "markdown": "# EPT · #637\n\n+{\n+  \"title\": \"EPT\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"EPT\",\n+    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-110 mg\",\n+            \"heavy\": \"110+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-60 mg\",\n+            \"strong\": \"60-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (unknown interactions with increased potency)\",\n+        \"Stimulants (increased anxiety and physical strain)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Cannabis (may intensify anxiety or confusion)\"\n+      ]\n+    },\n+    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting And Morphing\",\n+      \"Dissociative Feeling\",\n+      \"Body Heaviness\",\n+      \"Time Distortion\",\n+      \"Memory Suppression\",\n+      \"Increased Libido\",\n+      \"Nausea\",\n+      \"Motor Control Loss\",\n+      \"Pupil Dilation\",\n+      \"Thought Acceleration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: EPT Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: EPT\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: EPT\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 637\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-234801-e17fa4f6",
    "createdAt": "2025-10-16T23:48:01.414Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:47:59 PM"
    },
    "articles": [
      {
        "id": 636,
        "title": "DET",
        "slug": "det"
      }
    ],
    "markdown": "# DET · #636\n\n+{\n+  \"title\": \"DET\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DET\",\n+    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n+    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-70 mg\",\n+            \"strong\": \"70-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk and amplified intensity)\",\n+        \"MAOIs (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n+      ]\n+    },\n+    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Internal Hallucinations\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Pupil Dilation\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid DET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Erowid)\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 636\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-233259-3b3ee166",
    "createdAt": "2025-10-16T23:32:59.430Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:32:57 PM"
    },
    "articles": [
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# PRO-LAD · #635\n\n+{\n+  \"title\": \"PRO-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PRO-LAD\",\n+    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n+    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_class\": \"Lysergamide\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 ug\",\n+            \"light\": \"50-100 ug\",\n+            \"common\": \"100-200 ug\",\n+            \"strong\": \"200-350 ug\",\n+            \"heavy\": \"350+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n+        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n+        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n+        \"Dissociatives (greatly enhanced effects and confusion)\",\n+        \"Other psychedelics (unpredictable synergistic intensification)\"\n+      ]\n+    },\n+    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Color Enhancement\",\n+      \"Introspection\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Enhanced Sense Of Humor\",\n+      \"Thought Connectivity\",\n+      \"Physical Euphoria\",\n+      \"Emotional Amplification\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PRO-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 635\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-225756-89bd9e8d",
    "createdAt": "2025-10-16T22:57:56.453Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:57:54 PM"
    },
    "articles": [
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# LSM-775 · #634\n\n+{\n+  \"title\": \"LSM-775\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSM-775\",\n+    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n+    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"250 ug\",\n+            \"light\": \"500-750 ug\",\n+            \"common\": \"750-1250 ug\",\n+            \"strong\": \"1250-1500 ug\",\n+            \"heavy\": \"1500+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Variable (residual sedation possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n+        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n+        \"Alcohol (increases dehydration and physical discomfort)\",\n+        \"Other psychedelics (unpredictable intensification)\"\n+      ]\n+    },\n+    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n+    \"subjective_effects\": [\n+      \"Dream-Like Sedation\",\n+      \"Prominent Nausea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Time Distortion (Particularly Pronounced)\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations (Tingling)\",\n+      \"Music Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Drifting (Melting, Breathing, Morphing)\",\n+      \"Internal Hallucinations\",\n+      \"Analysis Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSM-775\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: LSM-775\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: LSM-775\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+      },\n+      {\n+        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n+      },\n+      {\n+        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"novel-psychoactive-substance\"\n+    ]\n+  },\n+  \"id\": 634\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224845-2e3cf1ee",
    "createdAt": "2025-10-16T22:48:45.174Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:48:42 PM"
    },
    "articles": [
      {
        "id": 633,
        "title": "MET",
        "slug": "met"
      }
    ],
    "markdown": "# MET · #633\n\n+{\n+  \"title\": \"MET\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MET\",\n+    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n+    \"alternative_name\": \"Methylethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-60 mg\",\n+            \"strong\": \"60-90 mg\",\n+            \"heavy\": \"90+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"60-70 mg\",\n+            \"light\": \"70-80 mg\",\n+            \"common\": \"80-110 mg\",\n+            \"strong\": \"110-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"30-75 minutes\",\n+            \"onset\": \"30-60 seconds\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"20-40 minutes\",\n+            \"after_effects\": \"20-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"30-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Lithium (increased seizure risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may dampen or prolong effects)\",\n+        \"Cannabis (may intensify experience unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry And Patterning\",\n+      \"Internal Hallucinations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Color Enhancement And Shifting\",\n+      \"Cognitive Euphoria\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Confusion\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other psychedelic tryptamines (minimal to none)\",\n+        \"Classic psychedelics (minimal to none)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n+      },\n+      {\n+        \"name\": \"Erowid MET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: MET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Methylethyltryptamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 633\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224503-b5466f8d",
    "createdAt": "2025-10-16T22:45:03.789Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:45:01 PM"
    },
    "articles": [
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      }
    ],
    "markdown": "# MiPLA · #632\n\n+{\n+  \"title\": \"MiPLA\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MiPLA\",\n+    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"100-150 ug\",\n+            \"common\": \"150-200 ug\",\n+            \"strong\": \"200-250 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Minimal residual stimulation\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"SSRIs (may alter or blunt effects)\"\n+      ]\n+    },\n+    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Geometric Patterns\",\n+      \"Cognitive Euphoria\",\n+      \"Analysis Enhancement\",\n+      \"Music Appreciation Enhancement\",\n+      \"Time Distortion\",\n+      \"Ego Death (at higher doses)\",\n+      \"Nausea\",\n+      \"Increased Body Temperature\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (due to 5-HT2A receptor activity)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: MiPLA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n+      },\n+      {\n+        \"name\": \"Erowid MiPLA Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n+      },\n+      {\n+        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n+      },\n+      {\n+        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n+        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 632\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223851-15e5eaa2",
    "createdAt": "2025-10-16T22:38:51.510Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:38:49 PM"
    },
    "articles": [
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      }
    ],
    "markdown": "# LSA · #631\n\n+{\n+  \"title\": \"LSA\",\n+  \"index-category\": \"psychedelic; natural\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSA\",\n+    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n+    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-50 seeds\",\n+            \"light\": \"50-100 seeds\",\n+            \"common\": \"100-250 seeds\",\n+            \"strong\": \"250-400 seeds\",\n+            \"heavy\": \"400+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-3 seeds\",\n+            \"light\": \"3-5 seeds\",\n+            \"common\": \"5-7 seeds\",\n+            \"strong\": \"7-12 seeds\",\n+            \"heavy\": \"12+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may suppress visual and cognitive effects)\",\n+        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n+        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n+        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n+        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n+        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+      ]\n+    },\n+    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Sedation (setting-dependent)\",\n+      \"Physical Euphoria\",\n+      \"Visual Enhancements and Distortions\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Motor Control Loss\",\n+      \"Nausea and Vasoconstriction\",\n+      \"Dream-Like State\",\n+      \"Introspection and Analysis Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Internal and External Hallucinations\",\n+      \"Thought Connectivity\",\n+      \"Music Appreciation Enhancement\",\n+      \"Spirituality Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: LSA\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Dosage\",\n+        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: LSA Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ergine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n+      },\n+      {\n+        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n+        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"natural\",\n+      \"ergoline\"\n+    ]\n+  },\n+  \"id\": 631\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223526-fd17483e",
    "createdAt": "2025-10-16T22:35:26.906Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:35:25 PM"
    },
    "articles": [
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      }
    ],
    "markdown": "# ETH-LAD · #630\n\n+{\n+  \"title\": \"ETH-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ETH-LAD\",\n+    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"30-60 ug\",\n+            \"common\": \"60-150 ug\",\n+            \"strong\": \"150-225 ug\",\n+            \"heavy\": \"225+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"8-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Intricate Visual Geometry\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Auditory Distortions and Hallucinations\",\n+      \"Analysis Enhancement\",\n+      \"Introspective Thought Patterns\",\n+      \"Time Distortion\",\n+      \"Synaesthesia\",\n+      \"Enhanced Color Perception\",\n+      \"Nausea and Bodily Discomfort\",\n+      \"Temperature Dysregulation\",\n+      \"Emotional Neutrality or Detachment\",\n+      \"Thought Acceleration\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n+      },\n+      {\n+        \"name\": \"Erowid ETH-LAD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n+        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ETH-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 630\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223152-65eead67",
    "createdAt": "2025-10-16T22:31:52.581Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:31:51 PM"
    },
    "articles": [
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      }
    ],
    "markdown": "# ALD-52 · #629\n\n+{\n+  \"title\": \"ALD-52\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ALD-52\",\n+    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n+    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"30 ug\",\n+            \"light\": \"30-100 ug\",\n+            \"common\": \"100-175 ug\",\n+            \"strong\": \"175-325 ug\",\n+            \"heavy\": \"325+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n+        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n+        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n+        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n+        \"SSRIs (may blunt or alter effects)\"\n+      ]\n+    },\n+    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Sensory Perception\",\n+      \"Time Distortion\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Physical Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Music Appreciation\",\n+      \"Pupil Dilation\",\n+      \"Increased Energy And Stimulation\",\n+      \"Novel Thought Patterns\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid ALD-52 Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ALD-52\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n+        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 629\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222911-e7a3cfaa",
    "createdAt": "2025-10-16T22:29:11.119Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:29:09 PM"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n+{\n+  \"title\": \"1V-LSD\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"1V-LSD\",\n+    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"25-75 ug\",\n+            \"common\": \"75-150 ug\",\n+            \"strong\": \"150-300 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n+        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n+        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n+        \"Benzodiazepines (reduce intensity of effects)\",\n+        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n+      ]\n+    },\n+    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n+    \"subjective_effects\": [\n+      \"Geometric Visual Hallucinations\",\n+      \"Time Distortion\",\n+      \"Enhanced Introspection\",\n+      \"Ego Loss\",\n+      \"Stimulation\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Creativity Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Unity And Interconnectedness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n+      ]\n+    },\n+    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 1V-LSD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n+      },\n+      {\n+        \"name\": \"Erowid 1V-LSD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n+        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 628\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222618-76ba04c5",
    "createdAt": "2025-10-16T22:26:18.516Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:26:16 PM"
    },
    "articles": [
      {
        "id": 626,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 627,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      }
    ],
    "markdown": "# Diphenhydramine · #626\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 626\n+}\n\n# Diphenhydramine · #627\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 627\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-211713-87b4367c",
    "createdAt": "2025-10-16T21:17:13.242Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:17:09"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"LSD\",\n-    \"alternative_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"alternative_name\": \"Lucy; Acid\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210951-3bc6b2e2",
    "createdAt": "2025-10-16T21:09:51.985Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:09:48"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 200,
        "title": "Psilocybin mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Psilocybin mushrooms · #200\n\n-  \"title\": \"Penis Envy\",\n+  \"title\": \"Psilocybin mushrooms\",\n-    \"drug_name\": \"Penis Envy\",\n-    \"chemical_name\": \"Penis Envy\",\n-    \"alternative_name\": \"Psilocybe cubensis, Penis Envy strain\",\n+    \"drug_name\": \"Psilocybin mushrooms\",\n+    \"chemical_name\": \"Psilocybin\",\n+    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210536-524a89f5",
    "createdAt": "2025-10-16T21:05:36.034Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:05:33"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210425-092f4def",
    "createdAt": "2025-10-16T21:04:25.208Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:04:21"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210204-b30f4dee",
    "createdAt": "2025-10-16T21:02:04.651Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:02:01"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210000-f6e22140",
    "createdAt": "2025-10-16T21:00:00.495Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:57"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205923-297a11ac",
    "createdAt": "2025-10-16T20:59:23.332Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:20"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205842-8929e224",
    "createdAt": "2025-10-16T20:58:42.976Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:39"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205804-77914f41",
    "createdAt": "2025-10-16T20:58:04.237Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:00"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-204349-778df3a1",
    "createdAt": "2025-10-16T20:43:49.406Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:43:45"
    },
    "articles": [
      {
        "id": 59,
        "title": "Mescaline",
        "slug": "mescaline"
      },
      {
        "id": 60,
        "title": "5-MeO-DMT",
        "slug": "5-meo-dmt"
      },
      {
        "id": 73,
        "title": "4-HO-MET",
        "slug": "4-ho-met"
      },
      {
        "id": 79,
        "title": "EA-3167",
        "slug": "ea-3167"
      },
      {
        "id": 82,
        "title": "25I-NBOMe",
        "slug": "25i-nbome"
      },
      {
        "id": 102,
        "title": "4-AcO-DMT",
        "slug": "4-aco-dmt"
      },
      {
        "id": 106,
        "title": "Canket",
        "slug": "canket"
      },
      {
        "id": 107,
        "title": "FXE",
        "slug": "fxe"
      },
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 139,
        "title": "DOM",
        "slug": "dom"
      },
      {
        "id": 280,
        "title": "DOB",
        "slug": "dob"
      },
      {
        "id": 158,
        "title": "PMA",
        "slug": "pma"
      },
      {
        "id": 181,
        "title": "DiPT",
        "slug": "dipt"
      },
      {
        "id": 189,
        "title": "DXM Polistirex",
        "slug": "dxm-polistirex"
      },
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 196,
        "title": "Ibogaine",
        "slug": "ibogaine"
      },
      {
        "id": 199,
        "title": "Yopo",
        "slug": "yopo"
      },
      {
        "id": 200,
        "title": "Penis Envy",
        "slug": "penis-envy"
      },
      {
        "id": 205,
        "title": "Bromo-DragonFLY",
        "slug": "bromo-dragonfly"
      },
      {
        "id": 206,
        "title": "Kratom",
        "slug": "kratom"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 222,
        "title": "DOET",
        "slug": "doet"
      },
      {
        "id": 80,
        "title": "3-Quinuclidinyl benzilate",
        "slug": "3-quinuclidinyl-benzilate"
      },
      {
        "id": 346,
        "title": "Tilmetamine",
        "slug": "tilmetamine"
      },
      {
        "id": 239,
        "title": "2C-N",
        "slug": "2c-n"
      },
      {
        "id": 515,
        "title": "25T-2-NBOMe",
        "slug": "25t-2-nbome"
      },
      {
        "id": 263,
        "title": "DOC",
        "slug": "doc"
      },
      {
        "id": 266,
        "title": "TMA",
        "slug": "tma"
      },
      {
        "id": 264,
        "title": "2C-F",
        "slug": "2c-f"
      },
      {
        "id": 351,
        "title": "2-Chloroephenidine",
        "slug": "2-chloroephenidine"
      },
      {
        "id": 368,
        "title": "3,4-MD-PCP",
        "slug": "3-4-md-pcp"
      },
      {
        "id": 49,
        "title": "ALEPH",
        "slug": "aleph"
      },
      {
        "id": 268,
        "title": "ALEPH-2",
        "slug": "aleph-2"
      },
      {
        "id": 138,
        "title": "AMT",
        "slug": "amt"
      },
      {
        "id": 273,
        "title": "2C-P",
        "slug": "2c-p"
      },
      {
        "id": 276,
        "title": "3-HO-PCP",
        "slug": "3-ho-pcp"
      },
      {
        "id": 281,
        "title": "2C-EF",
        "slug": "2c-ef"
      },
      {
        "id": 285,
        "title": "DMT",
        "slug": "dmt"
      },
      {
        "id": 289,
        "title": "O-PCE",
        "slug": "o-pce"
      },
      {
        "id": 290,
        "title": "DMXE",
        "slug": "dmxe"
      },
      {
        "id": 257,
        "title": "DOEF",
        "slug": "doef"
      },
      {
        "id": 292,
        "title": "25CN-NBOH",
        "slug": "25cn-nboh"
      },
      {
        "id": 293,
        "title": "HXE",
        "slug": "hxe"
      },
      {
        "id": 295,
        "title": "2C-D",
        "slug": "2c-d"
      },
      {
        "id": 311,
        "title": "Cannabis",
        "slug": "cannabis"
      },
      {
        "id": 156,
        "title": "4-Methylthioamphetamine",
        "slug": "4-methylthioamphetamine"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      },
      {
        "id": 326,
        "title": "DPT",
        "slug": "dpt"
      },
      {
        "id": 329,
        "title": "4-HO-PiPT",
        "slug": "4-ho-pipt"
      },
      {
        "id": 508,
        "title": "4-MeO-MiPT",
        "slug": "4-meo-mipt"
      },
      {
        "id": 338,
        "title": "4-HO-McPT",
        "slug": "4-ho-mcpt"
      },
      {
        "id": 392,
        "title": "2C-T-21",
        "slug": "2c-t-21"
      },
      {
        "id": 182,
        "title": "Sernyl",
        "slug": "sernyl"
      },
      {
        "id": 44,
        "title": "Dextromethorphan",
        "slug": "dextromethorphan"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      },
      {
        "id": 353,
        "title": "Ephenidine",
        "slug": "ephenidine"
      },
      {
        "id": 359,
        "title": "3-HO-PCE",
        "slug": "3-ho-pce"
      },
      {
        "id": 371,
        "title": "5-MeO-DPT",
        "slug": "5-meo-dpt"
      },
      {
        "id": 375,
        "title": "1B-LSD",
        "slug": "1b-lsd"
      },
      {
        "id": 401,
        "title": "2C-iP",
        "slug": "2c-ip"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      },
      {
        "id": 412,
        "title": "AL-LAD",
        "slug": "al-lad"
      },
      {
        "id": 425,
        "title": "5-MeO-DiBF",
        "slug": "5-meo-dibf"
      },
      {
        "id": 460,
        "title": "Scopolamine",
        "slug": "scopolamine"
      },
      {
        "id": 485,
        "title": "LSZ",
        "slug": "lsz"
      },
      {
        "id": 424,
        "title": "2-Me-DMT",
        "slug": "2-me-dmt"
      },
      {
        "id": 507,
        "title": "25P-NBOMe",
        "slug": "25p-nbome"
      },
      {
        "id": 518,
        "title": "2C-T-4-NBOMe",
        "slug": "2c-t-4-nbome"
      },
      {
        "id": 519,
        "title": "2C-T-7-NBOMe",
        "slug": "2c-t-7-nbome"
      },
      {
        "id": 531,
        "title": "25H-NBOMe",
        "slug": "25h-nbome"
      },
      {
        "id": 526,
        "title": "25I-NBMD",
        "slug": "25i-nbmd"
      },
      {
        "id": 528,
        "title": "25I-NBF",
        "slug": "25i-nbf"
      },
      {
        "id": 529,
        "title": "25I-NBOH",
        "slug": "25i-nboh"
      },
      {
        "id": 534,
        "title": "25C-NB3OMe",
        "slug": "25c-nb3ome"
      },
      {
        "id": 538,
        "title": "2-MeO-Ketamine",
        "slug": "2-meo-ketamine"
      },
      {
        "id": 539,
        "title": "2-MeO-DMT",
        "slug": "2-meo-dmt"
      },
      {
        "id": 540,
        "title": "2C-T-7",
        "slug": "2c-t-7"
      },
      {
        "id": 543,
        "title": "2C-B-FLY-NBOMe",
        "slug": "2c-b-fly-nbome"
      },
      {
        "id": 552,
        "title": "DCK",
        "slug": "dck"
      },
      {
        "id": 560,
        "title": "2-TFMXP",
        "slug": "2-tfmxp"
      },
      {
        "id": 570,
        "title": "4F-MDMB-BINACA",
        "slug": "4f-mdmb-binaca"
      },
      {
        "id": 583,
        "title": "AM-694",
        "slug": "am-694"
      },
      {
        "id": 584,
        "title": "ADBICA",
        "slug": "adbica"
      },
      {
        "id": 589,
        "title": "AMB-CHMICA",
        "slug": "amb-chmica"
      },
      {
        "id": 590,
        "title": "AMB-FUBINACA",
        "slug": "amb-fubinaca"
      },
      {
        "id": 594,
        "title": "CBNA",
        "slug": "cbna"
      },
      {
        "id": 597,
        "title": "Bufotenin",
        "slug": "bufotenin"
      },
      {
        "id": 599,
        "title": "Atropine",
        "slug": "atropine"
      },
      {
        "id": 600,
        "title": "AM-1248",
        "slug": "am-1248"
      },
      {
        "id": 605,
        "title": "25T-NBOMe",
        "slug": "25t-nbome"
      },
      {
        "id": 607,
        "title": "ADB-PINACA",
        "slug": "adb-pinaca"
      },
      {
        "id": 608,
        "title": "ADB-PINACA isomer 2",
        "slug": "adb-pinaca-isomer-2"
      },
      {
        "id": 609,
        "title": "AM-2201",
        "slug": "am-2201"
      },
      {
        "id": 611,
        "title": "BDCK",
        "slug": "bdck"
      },
      {
        "id": 616,
        "title": "AKB-57",
        "slug": "akb-57"
      },
      {
        "id": 622,
        "title": "4-MXP",
        "slug": "4-mxp"
      }
    ],
    "markdown": "# Mescaline · #59\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DMT · #60\n\n-      \"a-typical hallucinogen\",\n\n# 4-HO-MET · #73\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# EA-3167 · #79\n\n-      \"a-typical hallucinogen\",\n\n# 25I-NBOMe · #82\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-AcO-DMT · #102\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Canket · #106\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# FXE · #107\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# MAL · #270\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-BZ · #514\n\n-      \"a-typical hallucinogen\",\n\n# DOM · #139\n\n-      \"a-typical hallucinogen\",\n\n# DOB · #280\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# PMA · #158\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DiPT · #181\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DXM Polistirex · #189\n\n-      \"a-typical hallucinogen\",\n\n# LSD · #191\n\n-      \"a-typical hallucinogen\",\n\n# Ibogaine · #196\n\n-      \"a-typical hallucinogen\",\n\n# Yopo · #199\n\n-      \"a-typical hallucinogen\",\n\n# Penis Envy · #200\n\n-      \"a-typical hallucinogen\",\n\n# Bromo-DragonFLY · #205\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Kratom · #206\n\n-      \"a-typical hallucinogen\",\n\n# Amanita Muscaria · #201\n\n-      \"a-typical hallucinogen\",\n\n# Ibotenic acid · #215\n\n-      \"gabaergic\",\n-      \"A-typical hallucinogen\"\n+      \"gabaergic\"\n\n# DOET · #222\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 3-Quinuclidinyl benzilate · #80\n\n-      \"a-typical hallucinogen\",\n\n# Tilmetamine · #346\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-N · #239\n\n-      \"a-typical hallucinogen\",\n\n# 25T-2-NBOMe · #515\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOC · #263\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# TMA · #266\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-F · #264\n\n-      \"a-typical hallucinogen\",\n\n# 2-Chloroephenidine · #351\n\n-      \"a-typical hallucinogen\",\n\n# 3,4-MD-PCP · #368\n\n-      \"a-typical hallucinogen\",\n\n# ALEPH · #49\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# ALEPH-2 · #268\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AMT · #138\n\n-      \"a-typical hallucinogen\",\n\n# 2C-P · #273\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCP · #276\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-EF · #281\n\n-      \"a-typical hallucinogen\",\n\n# DMT · #285\n\n-      \"a-typical hallucinogen\",\n\n# O-PCE · #289\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# DMXE · #290\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOEF · #257\n\n-      \"a-typical hallucinogen\",\n\n# 25CN-NBOH · #292\n\n-      \"a-typical hallucinogen\",\n\n# HXE · #293\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-D · #295\n\n-      \"a-typical hallucinogen\",\n\n# Cannabis · #311\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# 4-Methylthioamphetamine · #156\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-C · #321\n\n-      \"a-typical hallucinogen\",\n\n# DPT · #326\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-PiPT · #329\n\n-      \"a-typical hallucinogen\",\n\n# 4-MeO-MiPT · #508\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-McPT · #338\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-21 · #392\n\n-      \"a-typical hallucinogen\",\n\n# Sernyl · #182\n\n-      \"a-typical hallucinogen\",\n\n# Dextromethorphan · #44\n\n-      \"a-typical hallucinogen\",\n\n# MDA · #62\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Ephenidine · #353\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCE · #359\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DPT · #371\n\n-      \"a-typical hallucinogen\",\n\n# 1B-LSD · #375\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-iP · #401\n\n-      \"a-typical hallucinogen\",\n\n# Salvia · #409\n\n-      \"A-typical hallucinogen\",\n\n# AL-LAD · #412\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 5-MeO-DiBF · #425\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Scopolamine · #460\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# LSZ · #485\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-Me-DMT · #424\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25P-NBOMe · #507\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-4-NBOMe · #518\n\n-      \"a-typical hallucinogen\",\n\n# 2C-T-7-NBOMe · #519\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25H-NBOMe · #531\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBMD · #526\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBF · #528\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBOH · #529\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25C-NB3OMe · #534\n\n-      \"a-typical hallucinogen\",\n\n# 2-MeO-Ketamine · #538\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-MeO-DMT · #539\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-7 · #540\n\n-      \"a-typical hallucinogen\",\n\n# 2C-B-FLY-NBOMe · #543\n\n-      \"a-typical hallucinogen\",\n\n# DCK · #552\n\n-      \"a-typical hallucinogen\",\n\n# 2-TFMXP · #560\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4F-MDMB-BINACA · #570\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# AM-694 · #583\n\n-      \"a-typical hallucinogen\",\n\n# ADBICA · #584\n\n-      \"depressant\",\n-      \"a-typical hallucinogen\"\n+      \"depressant\"\n\n# AMB-CHMICA · #589\n\n-      \"a-typical hallucinogen\",\n\n# AMB-FUBINACA · #590\n\n-      \"a-typical hallucinogen\",\n\n# CBNA · #594\n\n-      \"nootropic\",\n-      \"a-typical hallucinogen\"\n+      \"nootropic\"\n\n# Bufotenin · #597\n\n-      \"a-typical hallucinogen\",\n\n# Atropine · #599\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# AM-1248 · #600\n\n-      \"a-typical hallucinogen\",\n\n# 25T-NBOMe · #605\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# ADB-PINACA · #607\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# ADB-PINACA isomer 2 · #608\n\n-      \"a-typical hallucinogen\",\n\n# AM-2201 · #609\n\n-      \"a-typical hallucinogen\",\n\n# BDCK · #611\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AKB-57 · #616\n\n-      \"a-typical hallucinogen\",\n\n# 4-MXP · #622\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191133-9b6f5ac8",
    "createdAt": "2025-10-16T19:11:33.130Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:11:30"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",\n\n# 2C-C · #321\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191042-5c6a6d64",
    "createdAt": "2025-10-16T19:10:42.055Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:10:39"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-190938-8a5873a8",
    "createdAt": "2025-10-16T19:09:38.185Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:09:35"
    },
    "articles": [],
    "markdown": "No diff details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-083502-09318c26",
    "createdAt": "2025-10-16T08:35:02.514Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 2:35:00 AM"
    },
    "articles": [
      {
        "id": 36,
        "title": "Trazodone",
        "slug": "trazodone"
      },
      {
        "id": 86,
        "title": "Tranylcypromine",
        "slug": "tranylcypromine"
      },
      {
        "id": 144,
        "title": "Phenelzine",
        "slug": "phenelzine"
      },
      {
        "id": 186,
        "title": "Vilazodone",
        "slug": "vilazodone"
      },
      {
        "id": 303,
        "title": "Ondansetron",
        "slug": "ondansetron"
      },
      {
        "id": 302,
        "title": "Moclobemide",
        "slug": "moclobemide"
      },
      {
        "id": 301,
        "title": "Quetiapine",
        "slug": "quetiapine"
      },
      {
        "id": 307,
        "title": "Tianeptine",
        "slug": "tianeptine"
      },
      {
        "id": 374,
        "title": "Lean",
        "slug": "lean"
      },
      {
        "id": 430,
        "title": "Olanzapine",
        "slug": "olanzapine"
      },
      {
        "id": 442,
        "title": "Clobenzorex",
        "slug": "clobenzorex"
      },
      {
        "id": 458,
        "title": "Chlorpheniramine",
        "slug": "chlorpheniramine"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      }
    ],
    "markdown": "# Trazodone · #36\n\n-    \"psychoactive_class\": \"Antidepressant (Serotonin Antagonist and Reuptake Inhibitor, SARI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Tranylcypromine · #86\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Phenelzine · #144\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Vilazodone · #186\n\n-    \"psychoactive_class\": \"Antidepressant (Selective Serotonin Reuptake Inhibitor and 5-HT1A receptor partial agonist)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Ondansetron · #303\n\n-    \"psychoactive_class\": \"Antiemetic (not psychoactive in the traditional sense, but acts on the central nervous system to prevent nausea/vomiting)\",\n+    \"psychoactive_class\": \"Antiemetic\",\n\n# Moclobemide · #302\n\n-    \"psychoactive_class\": \"Antidepressant (Reversible MAO-A inhibitor)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Quetiapine · #301\n\n-    \"psychoactive_class\": \"Atypical antipsychotic\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Tianeptine · #307\n\n-    \"psychoactive_class\": \"Full μ-opioid receptor agonist; atypical antidepressant\",\n+    \"psychoactive_class\": \"Full μ-opioid receptor agonist; Antidepressant (atypical)\",\n\n# Lean · #374\n\n-    \"psychoactive_class\": \"Opioid depressant; antihistamine sedative\",\n+    \"psychoactive_class\": \"Opioid depressant; Antihistamine; Sedative\",\n\n# Olanzapine · #430\n\n-    \"psychoactive_class\": \"Atypical antipsychotic (multi-receptor antagonist)\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Clobenzorex · #442\n\n-    \"psychoactive_class\": \"Catecholaminergic stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n+    \"psychoactive_class\": \"Stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n\n# Chlorpheniramine · #458\n\n-    \"psychoactive_class\": \"Antihistamine (H1 receptor antagonist)\",\n+    \"psychoactive_class\": \"Antihistamine\",\n\n# Ro5-4864 · #530\n\n-    \"psychoactive_class\": \"atypical benzodiazepine; TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n+    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233456-d6536e79",
    "createdAt": "2025-10-14T23:34:56.256Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:34:54 PM"
    },
    "articles": [
      {
        "id": 294,
        "title": "Bromantane",
        "slug": "bromantane"
      }
    ],
    "markdown": "### Bromantane · #294\n\n- `drug_info.psychoactive_class`: \"Stimulant actoprotector; anxiolytic nootropic\" → \"Stimulant actoprotector; anxiolytic; nootropic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233158-373c6f71",
    "createdAt": "2025-10-14T23:31:58.069Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:31:55 PM"
    },
    "articles": [
      {
        "id": 152,
        "title": "Dimenhydrinate",
        "slug": "dimenhydrinate"
      },
      {
        "id": 396,
        "title": "Propranolol",
        "slug": "propranolol"
      },
      {
        "id": 417,
        "title": "Avizafone",
        "slug": "avizafone"
      }
    ],
    "markdown": "### Dimenhydrinate · #152\n\n- `drug_info.psychoactive_class`: \"Deliriant (anticholinergic); Antihistamine; Anti-emetic\" → \"Deliriant; Antihistamine; Anti-emetic\"\n\n### Propranolol · #396\n\n- `drug_info.psychoactive_class`: updated long text (98 characters; starts \"Not typically classified as psychoactive; Antihypertensive; antiarrhy...\") → text (\"Not typically classified as psychoactive; Antihypertensive; antiarrhythmic; anxiolytic\")\n\n### Avizafone · #417\n\n- `drug_info.psychoactive_class`: \"Sedative-hypnotic; anxiolytic (benzodiazepine)\" → \"Sedative-hypnotic; anxiolytic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251013-212828-39bd2cd6",
    "createdAt": "2025-10-13T21:28:28.668Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:28:26"
    },
    "articles": [
      {
        "id": 595,
        "title": "1cP-MiPLA",
        "slug": "1cp-mipla"
      }
    ],
    "markdown": "### 1cP-MiPLA · #595\n\n- `drug_info.dosages.routes_of_administration[0].dose_ranges.heavy`: \"300 µg +\" → \"300 µg +\"\n- `drug_info.dosages.routes_of_administration[1].dose_ranges.heavy`: \"250 µg +\" → \"250 µg +\"\n- `drug_info.categories[1]`: \"a-typical hallucinogen\" → \"research-chemical\"\n- `drug_info.categories[2]`: removed text (\"research-chemical\")",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-212356-370466a5",
    "createdAt": "2025-10-13T21:23:56.596Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:23:53"
    },
    "articles": [],
    "markdown": "No changelog details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-210154-43d82145",
    "createdAt": "2025-10-13T21:01:54.147Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/13/2025, 3:01:52 PM"
    },
    "articles": [
      {
        "id": 33,
        "title": "3-MeO-PCP",
        "slug": "3-meo-pcp"
      }
    ],
    "markdown": "### 3-MeO-PCP · #33\n\n- `drug_info.alternative_name`: added text (\"3-Methoxyphencyclidine\")",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251012-120815-ffa8a8d5",
    "createdAt": "2025-10-12T12:08:15.759Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:08:14 AM"
    },
    "articles": [
      {
        "id": 510,
        "title": "3-Cl-PCP",
        "slug": "3-cl-pcp"
      }
    ],
    "markdown": "### 3-Cl-PCP · #510\n\n- `drug_info.categories[2]`: removed (was `a-typical hallucinogen`)"
  },
  {
    "id": "20251012-120542-f6e605f4",
    "createdAt": "2025-10-12T12:05:42.088Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:05:40 AM"
    },
    "articles": [
      {
        "id": 389,
        "title": "3-MeO-PCMo",
        "slug": "3-meo-pcmo"
      }
    ],
    "markdown": "### 3-MeO-PCMo · #389\n\n- `content`: `# 3-MeO-PCMo\n## Arylcyclohexylamine (morpholine subgroup) | Dissociative NMDA-receptor antagonist with mild monoaminergic activity\n      \nPotency is roughly 1/10 of 3-MeO-PCP but still active in double-digit milligram range; weigh on 0.001 g scale and perform 1-3 mg allergy test. Virtually no clinical history: all human data are anecdotal. Reports of confusion, mania and prolonged delirium at heavy doses. Limited reagent-test data; use full panel to rule out NBOMe / opioid adulterants. Crystal often hygroscopic – store in airtight, light-protected container with desiccant.` → ``"
  }
]